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ABSTRACT 
 
Eph receptor tyrosine kinases and their ligands ephrins are involved in many physiological 
processes, including tissue homeostasis, vascularisation and development. They are also 
involved in promoting angiogenesis and metastasis in many cancers, including breast, colon 
and lung. Upon interaction with EphB receptors, ephrinB ligands signal through SH2- and 
PDZ-interacting cytoplasmic adaptors. To date, little is known on PDZ-mediated ephrinB 
signalling. The aim of our study was to determine the role of PDZ domain-containing proteins 
in modulating ephrinB2 signalling and trafficking pathways in the context of epithelial breast 
cancer cells, with a specific focus on the scaffolding protein syntenin-1. We also endeavoured 
to determine whether the ephrinB2 – syntenin-1 axis affects breast cancer tumourigenesis. 
Our findings demonstrate that syntenin-1 modulates ephrinB2 internalization upon receptor-
induced stimulation and that this affects ephrinB signalling. Furthermore, we found that 
phospho-Tyr330 on ephrinB2 increases binding to the PDZ domain-containing proteins 
syntenin-1 and PAR3. Finally, we report that ephrinB2 drives MCF7 colony growth in 3D 
cultures and that syntenin-1 is involved in boundary formation between ephrinB2 and EphB4 
expressing cells. These findings describe, for the first time, the role of syntenin-1 in ephrinB2 
signalling and the functional relevance of the ephrinB2 – syntenin-1 axis in epithelial breast 
cancer pathways.  
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1.1  Eph receptors and ephrin ligands 
 
1.1.1  The Eph superfamily of tyrosine kinase receptors and 
  their ligands ephrins 
 
Eph receptors are the largest known superfamily of receptor tyrosine kinases in humans 
and their cognate ligands are called ephrins. Both receptors and ligands are involved in 
various physiological and pathological processes in many cell types and different organs 
(Pasquale 2008). In cancer, different Eph and ephrin expression patterns have been found to 
play important roles in tumour development and progression (Pasquale 2010). There are 14 
members of the Eph receptors superfamily which are subdivided into A and B sub-families, 
depending on the type of ephrin ligands they bind to. EphrinA ligands are anchored to the 
plasma membrane via a glycosyl-phosphatidyl-inositol tail (GPI-linked), while ephrinB 
ligands possess a single transmembrane region. Nine EphA receptors bind to five ephrinA 
ligands and five EphB receptors bind to three ephrinB ligands, although some promiscuity 
between the two classes of receptors and ligands has also been observed (Kullander and Klein 
2002; Gauthier and Robbins 2003; Pasquale 2008). The high diversity of these proteins is due 
to recent gene duplication events, as Eph receptor genes can be found in gene clusters on 
chromosomes 1, 3 and 7 (Kullander and Klein 2002). 
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1.1.1.1 Structural characteristics of Eph receptors and ephrin ligands 
 
The structural domains which characterize all Eph receptors include: 1) an extracellular 
moiety consisting of an immunoglobulin-like globular domain with ligand-interacting 
functions (LBD) followed by a cysteine-rich region (CRD), containing a Sushi domain tightly 
packed to an EGF like module, and two fibronectin type III repeats; 2) a single 
transmembrane region containing two conserved tyrosine residues; 3) an intracellular kinase 
domain followed by a sterile alpha motif (SAM), which participates in the formation of 
heterodimers, and a “postsynaptic density protein, disc large, zona occludens” (PDZ) binding 
motif (PBM) (figure 1.1) (Kullander and Klein 2002; Janes, Nievergall et al. 2012). The 
extracellular domain is also characterized by a high affinity binding site for ephrin ligands and 
two low affinity binding sites which facilitate clustering of multiple-Eph-ephrin complexes 
(Pasquale 2008). 
Both ephrinA and ephrinB ligands have an 
extracellular domain consisting of a high affinity 
receptor binding loop. EphrinB ligands possess a 
transmembrane region and an intracellular moiety 
containing 5-6 tyrosine residues and a C-terminal 
PDZ binding motif, while ephrinA ligands are 
anchored to the plasma membrane via a GPI-link 
(Andres and Ziemiecki 2003). The C-terminal tail 
of ephrinB ligands adopts a well-packed β-hairpin 
structure between amino acids 301 and 322 in a non 
phosphorylated state. Upon protein phosphorylation 
Figure 1.1: structure of Eph receptors and 
ephrin ligands (Janes, Nievergall et al. 2012). 
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on tyrosines 304, 311 or 316, the β-hairpin structure is lost (Song 2003). 
 
 
1.1.1.2 Eph – ephrin interaction mechanisms 
 
Prior to cell contact, ephrin ligands are present on the cell surface as homodimers, while 
Eph receptors remain mostly separate and display minimal kinase activity when not 
stimulated (Himanen, Saha et al. 2007). During cell-cell 
contact, Eph receptors interact with ephrin ligand 
homodimers present on neighbouring cells (figure 1.2). 
The initial recognition and binding of ephrin ligands to 
Eph receptors involve a hydrophobic cavity of the Eph 
LBD where a long ephrin loop penetrates and drives the 
formation of the complex (Nikolov, Xu et al. 2013). This 
interaction subsequently induces the formation of 
circular tetrameric structures held together by lower 
affinity binding events in which each ephrin is bound to 
two Eph receptors and vice-versa (Himanen, 
Yermekbayeva et al. 2010; Seiradake, Harlos et al. 2010). From a structural perspective, the 
binding domain of ephrinB ligands has a β-barrel conformation and can form cis-
homodimers. Moreover, the surface exposed G-H loop and the G β-strand of the extracellular 
domain are necessary for the initial trans-heterodimerization with EphB receptors, while the 
C-D loop participates in the formation of trans-heterotetramers between two receptors and 
two ligands (Blits-Huizinga, Nelersa et al. 2004). Eph receptors are also able to bind together 
Figure 1.2: interaction mechanism 
between Eph receptors and ephrin 
ligands (Andres and Ziemiecki 2003) 
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upon ephrin-induced clustering via their extracellular domains in order to form higher order 
multimers (Nikolov, Xu et al. 2013). Only membrane-bound or artificially clustered 
ligands/receptors can activate the cognate receptor/ligand signalling, whilst non-clustered 
soluble ligands/receptors act as antagonists (Janes, Nievergall et al. 2012). The clustering of 
two Eph molecules is sufficient to activate the receptors. Similarly, clustering of two ephrin 
ligands is also required to trigger reverse signalling (Poliakov, Cotrina et al. 2004). It has also 
been hypothesized that interactions with PDZ domain-containing proteins might help 
oligomerization events of Eph receptors and ephrinB ligands (Bruckner, Pablo Labrador et al. 
1999; Lin, Gish et al. 1999). Although dimerization of Eph receptors and ephrin ligands is 
necessary to trigger a biological response, multimerization strongly increases and sometimes 
even alters the signalling pathways involved (figure 1.3) (Blits-Huizinga, Nelersa et al. 2004). 
In fact, recent reports suggest that the switch between Eph/ephrin induced cell adhesion or 
cell repulsion is determined by the degree of Eph/ephrin clustering (Lackmann and Boyd 
2008). 
 Eph receptors and 
ephrin ligands are capable 
of interacting in trans 
and/or in cis (figure 1.4). 
Various studies have 
suggested that Eph-ephrin 
trans interactions generate 
an activating biological 
response, whilst cis 
interactions inhibit this 
Figure 1.3: formation of Eph-ephrin multimeric complexes upon receptor 
– ligand interaction (Blits-Huizinga, Nelersa et al. 2004).  
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response (Arvanitis and Davy 2008). While co-expression of Eph receptors and ephrin ligands 
is likely to result in formation of cis complexes, it is also possible that they segregate in 
different membrane microdomains, thereby decreasing cis interactions (Noren and Pasquale 
2007).  
Lastly, Eph receptors and ephrin ligands have also been shown to interact in cis with 
other cell surface receptors, such as FGF, PDGF, VEGF and ErbB receptors (Arvanitis and 
Davy 2008; Pasquale 2008; Pitulescu and Adams 2010; Vermeer, Bell et al. 2012; Vermeer, 
Colbert et al. 2013). Intriguingly, Eph receptors are also able to form heterodimers with other 
Eph receptors which share the same ephrin ligand, as recently reviewed by (Janes, Nievergall 
et al. 2012). For example, EphB1 and EphB4 form complexes with kinase-dead EphB6, 
resulting in its trans-phosphorylation (Truitt, Freywald et al. 2010), whilst EphA3 and EphA4 
co-localize in COS-7 cells upon stimulation with ephrinA5 (Marquardt, Shirasaki et al. 2005). 
   
    
Figure 1.4: Eph-ephrin interaction can occur in cis or in trans (Arvanitis 
and Davy 2008). 
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1.1.2  Physiological Functions 
 
The Eph superfamily of tyrosine kinase receptors and their ephrin ligands are widely 
expressed in the majority of organs and tissues. Expression gradients of Eph receptors and 
ephrin ligands in different cell types determine tissue assembly and control cell movement 
through cell repulsion and adhesion (Poliakov, Cotrina et al. 2004). Importantly, coordinated 
spatial and temporal expression of Eph receptors and ephrin ligands control development, 
tissue homeostasis, formation of tissue boundaries and tissue patterning, assembly of neuronal 
circuits and the remodelling of blood vessels and organ size. At the cellular level, Eph 
receptor signalling has been shown to control cell morphology, adhesion, migration and 
invasion by modifying the actin cytoskeleton and the activity of various types of adhesion 
molecules, such as integrins, claudins and cadherins (Pasquale 2010; Nievergall, Lackmann et 
al. 2012). 
 
 
1.1.2.1 Eph – ephrin interaction can mediate cell adhesion or repulsion 
 
Eph receptors and ephrin ligands tightly control the formation of boundaries between 
neighbouring cells of different tissues. The equilibrium between expression levels of Eph 
receptors on one side and ephrin ligands on the other determines whether Eph expressing cells 
will adhere or retract from ephrin expressing cells (Daar 2012). For example, when cell 
adhesion is triggered, activation of ephrinA ligands induces β1-integrin interaction with 
laminin (Huai and Drescher 2001) and caveola-mediated cell adhesion to fibronectin (Davy, 
Gale et al. 1999). EphrinB ligands can regulate cell repulsion by impairing tight junctions 
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assembly (Daar 2012). A study conducted in Xenopus embryos found that ephrinB1 competes 
with the small GTPase Cdc42 for association with PAR6, thus disrupting the 
PAR6/aPKC/Cdc42 complex which is responsible for the formation of cell-cell junctions 
(Lee, Nishanian et al. 2008). However, the same group also found that phosphorylation of 
ephrinB1 upon interaction with EphB receptors causes dissociation of PAR6 from the ligand 
and, consequentially, promotes tight junction assembly and cell-cell adhesion (Lee, Nishanian 
et al. 2008). In the case of cell repulsion, when Eph receptors and ephrin ligands interact, both 
proteins trigger independent signalling cascades. Eph receptor phosphorylation induced by 
ephrin interaction activates ROCK and Cdc42, which regulate cell morphology and trigger 
rounding and repulsion of Eph expressing cells from ephrin expressing cells (Groeger and 
Nobes 2007; Lee and Daar 2009; Daar 2012). When ephrinB ligands are phosphorylated they 
interact with the scaffolding protein Dishevelled which activates ROCK-mediated cell 
retraction (Tanaka, Kamo et al. 2003). Also, ephrinA and EphA interaction can activate the 
metalloproteinase ADAM10 which is responsible for shedding the ligand’s extracellular 
region and allowing cell detachment (Janes, Wimmer-Kleikamp et al. 2009). Finally, EphB4 
can inhibit integrin-mediated cell adhesion independently of ephrinB2 interaction (Pitulescu 
and Adams 2010). A diagram of ephrinA and ephrinB reverse signalling pathways which 
affect cell adhesion and movement is illustrated in figure 1.5.  
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1.1.2.2 The role of Eph/ephrin signalling in vascularisation 
 
Various studies have shown that during embryogenesis the ephrinB2 ligand becomes 
exclusively expressed in embryonic arteries, while the EphB4 receptor in embryonic veins 
(Andres and Ziemiecki 2003; Gauthier and Robbins 2003). Later studies have determined that 
while the EphB4 receptor is sufficient to determine venous and arterial differentiation, 
ephrinB2 ligand expression in the surrounding tissue might serve to direct vessel sprouting 
(Poliakov, Cotrina et al. 2004). In fact, both receptor and ligand expression are fundamental 
for embryonic survival past day 11 in mice, as the absence of either one of these proteins 
disrupts angiogenesis and leads to an incomplete vascular system (Blits-Huizinga, Nelersa et 
Figure 1.5: reverse signalling pathways induced by ephrinA and ephrinB ligands in cell adhesion and 
movement. EphrinB-mediated signalling is divided into non-SH2/PDZ dependent and SH2/PDZ dependent 
pathways (Daar 2012). 
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al. 2004). Knock out of the ephrinB2 or EphB4 gene in mice produces a phenotype which 
displays arteriovenous malformations (Krebs, Starling et al. 2010). Interestingly, during 
embryogenesis only the extracellular portion of the ephrinB2 ligand is necessary, by acting as 
an activator for EphB4 signalling. EphrinB2 reverse signalling becomes vital only after birth 
during neonatal survival (Cowan, Yokoyama et al. 2004). In the retina, higher 
phosphorylation of ephrinB ligands in the developing retinal vasculature of newborn mice 
was observed when compared to adult retinas. Moreover, phosphorylation of ephrinB ligands 
in vascular cells is involved in wound healing, probably serving as a marker for angiogenic 
vessels (Salvucci, Maric et al. 2009). 
Eph receptors and ephrin ligands also regulate vascular remodelling and vessel 
sprouting in adulthood. As reviewed by (Salvucci and Tosato 2012), various studies have 
reported EphB/ephrinB signalling as a major modulator of angiogenesis during the menstrual 
cycle, pregnancy, skeletal bone growth and wound repair. During adulthood, the ephrinB2 
ligand is still expressed in arteries, subsets of microvessels at sites of neovascularisation and 
within tumour vasculature, while the EphB4 receptor is still expressed in veins (Merlos-
Suarez and Batlle 2008). Both receptor and ligand mediate communication signals between 
the arterial and venous endothelia: the expression of the EphB4 receptor attenuates 
endothelial cell growth and inhibits vascular network formation, while ephrinB2 ligand 
expression stimulates these processes (Andres and Ziemiecki 2003).  
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1.1.2.3 Other roles of Eph/ephrin signalling in development 
 
The complementary and mutually exclusive expression patterns of Eph receptors and 
ephrin ligands during embryogenesis is fundamental in the formation of spatial boundaries 
and tissue morphogenesis (Gauthier and Robbins 2003). During the early stages of 
development Eph receptors and ephrin ligands are involved in cell segregation and 
positioning; cell migration, axon guidance and topographic mapping; and skeletal 
morphogenesis (Klein 2012). For instance, EphB/ephrinB interactions control cell positioning 
and segregation along the crypt-villus axis of the small intestine (Batlle and Wilkinson 2012). 
In the developing neural system, Eph/ephrin signalling controls axonal pathfinding of lateral 
and medial motor column neurons and the formation of topographic maps (Klein 2012). 
During somitogenesis and heart development, mesenchymal-to-epithelial transition (MET) 
and endothelial-to-mesenchymal transition (EndoMT) are essential for cell-cell 
communication in establishing boundaries between endothelial/epithelial and mesenchymal 
tissues and cell identity. Eph/ephrin signalling is involved in this process and is able to control 
both MET and EndoMT (Nievergall, Lackmann et al. 2012). 
 
 
1.1.2.4 Eph – ephrin interaction is fundamental in mammary gland  
  development 
 
Eph receptors and ephrin ligands also play a fundamental role during mammary gland 
development and the oestrus cycle in women. The mammary gland is composed of the 
ectodermal parenchyma, formed by the secretory epithelium and the contractile 
Introduction 
~ 12 ~ 
 
myoepithelium, and the mesodermal adipose stroma within which the parenchyma develops. 
During puberty, the epithelium elongates forming a ductal network within the surrounding 
stroma. This process is induced by oestrogen and depends on hormones and epithelial – 
stroma interactions. The expression of the EphB4 receptor and the ephrinB2 ligand is tightly 
controlled by oestrogen during the mammary development and especially the oestrus cycle. 
EphrinB2 expression is confined to the epithelial cells, while EphB4 is present in both 
myoepithelial and epithelial cells, although it is only expressed in the latter during the 
proliferative phase of mammary gland development (Munarini, Jager et al. 2002). In the 
mature mammary gland, the EphB4 receptor is specifically localized to myoepithelial cells of 
alveolar and ductal structures. Receptor and ligand levels are then up-regulated in their 
respective cell types during the oestrogen driven part of the oestrus cycle, concomitant with 
cell proliferation, and then their expression is decreased in the progesterone driven part. 
Studies in ovariectomized mice have shown that expression of the EphB4 receptor and the 
ephrinB2 ligand could be restored to normal levels after oestrogen injections (Nikolova, 
Djonov et al. 1998). Although the responsive element of the transcription factor activated by 
oestrogen is present in the EphB4 receptor and ephrinB2 ligand genes, the levels of mRNA 
remain unaffected in the presence or absence of the hormone. Thus, the effect of oestrogen on 
receptor and ligand levels is likely to be indirect (Nikolova, Djonov et al. 1998; Andres and 
Ziemiecki 2003; Merlos-Suarez and Batlle 2008). The equilibrium between expressed 
ephrinB2 and EphB4 is vital for the correct development of the mammary gland. In mice, 
over-expression of EphB4 causes disrupted proliferation of the ductal epithelium and 
diminished branching of the ducts during pregnancy-related mammary development, while 
after pregnancy it caused delayed post-lactation apoptosis (Munarini, Jager et al. 2002). 
EphrinB2 signalling is also necessary for a correct development of the mammary gland. A 
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study by (Kaenel, Antonijevic et al. 2012) showed that epithelial mammary cells expressing a 
mutant form of the ephrinB2 ligand, where the cytoplasmic tail had been truncated, formed 
overgrown ducts which seemed to have an impaired contact inhibition phenotype. These ducts 
displayed multilayered organization and lacked an internal lumen. Cells expressing this 
ephrinB2 mutant were also less differentiated, retained some proliferation capability and 
lower apoptosis activity and they exhibited aberrant polarization. 
 
 
1.1.2.5 Eph/ephrin signalling drives cellular segregation during cell  
 differentiation in the intestine’s villi 
 
In the intestine, Eph receptors and ephrin ligands control the segregation of 
differentiating cells moving from the stem cell compartment towards the epithelium of the 
villi (Batlle and Wilkinson 2012). This process is driven by a gradual change in Eph and 
ephrin expression pattern. In the crypts, undifferentiated cells gradually lose EphB receptors 
expression whilst acquiring ephrinB ligands expression, which causes cells to differentiate 
and migrate towards the epithelium surface in the villi (Poliakov, Cotrina et al. 2004). The 
Wnt signalling pathway is responsible for the induction of EphB2 and EphB3 receptors and 
the repression of ephrinB1 and ephrinB2 ligands in the proliferative stem cell compartment in 
the crypts (Merlos-Suarez and Batlle 2008; Genander and Frisen 2010; Pitulescu and Adams 
2010). The balance between receptor and ligand expression regulated by the β-catenin/Tcf 
pathway demarcates the undifferentiated cell population from the differentiating one (Andres 
and Ziemiecki 2003). Disruption of the EphB/ephrinB signalling pathway in embryonic and 
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adult intestine disturbs cell positioning and inhibits cell proliferation (Batlle, Henderson et al. 
2002). 
 
 
1.1.2.6 Involvement of Eph receptors and ephrin ligands in other tissue 
 homeostasis processes 
 
Given their important functions in cell morphology, adhesion and invasion, it is not 
surprising that Eph receptors and ephrin ligands are also involved in many other physiological 
processes. For example, Eph/ephrin signalling axes regulate synaptic formation and plasticity 
and the development of the nervous system by controlling axon guidance and patterning of 
neuronal connections. In this case, ephrin ligands control axonal pathfinding by acting as 
repulsive cues to Eph receptor bearing axons (Gauthier and Robbins 2003). Also, in neuronal 
stem/progenitor cells, Eph/ephrin signalling is important during development and adulthood 
for the maintenance and self-renewal of the stem cell niche (Genander and Frisen 2010). 
Eph/ephrin signalling also controls cell segregation during differentiation in the hair 
follicle and epidermis. In this context, ephrinA and ephrinB ligands are able to negatively 
regulate proliferation of progenitor cells in the hair follicle of adult mice, although it is still 
unclear whether this is mediated by ephrin-induced reverse signalling or Eph-driven forward 
signalling (Genander, Holmberg et al. 2010; Lin, Wang et al. 2012). 
Recent studies have reported the expression of Eph and ephrin proteins in bone cells. 
Although little is known about the role of these proteins in skeletal development, Eph/ephrin 
signalling is thought to mediate communication between osteocytes and osteoclasts or 
osteoblasts in response to various stimuli. Moreover, the EphB4 – ephrinB2 axis might be 
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responsible for the formation of new capillaries in the bone. Skeletal malformations have also 
been attributed to the disruption of Eph/ephrin signalling, as mutations in the EFNB1 gene are 
associated with craniofrontonasal syndrome (CFNS) (Matsuo and Otaki 2012). 
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1.1.3  Eph/ephrin signalling 
 
Eph receptors and ephrin ligands trigger two different signalling cascades. On receptor 
– ligand contact and subsequent clustering, Eph receptors are activated and phosphorylate 
specific tyrosines on their cytoplasmic tail via their kinase domain. This creates phospho-
docking sites for Src Homology type-2 (SH2) domain-containing proteins and triggers so 
called “forward” signalling. Activated Eph receptors also mediate other types of signalling 
through protein-protein interactions via the SAM and PDZ-binding motifs (Kullander and 
Klein 2002; Noren, Lu et al. 2004). Key components of Eph forward signalling are the Rho 
family of GTPases (RhoA, CDC42, Rac), which are involved in the regulation of the actin 
cytoskeleton, cell movement and adhesion (Klein 2009). Phosphorylated Eph receptors 
associate and activate a number of Rho GEFs, including Vav2, Tiam, Kalirin and Intersectin 
(Cowan, Shao et al. 2005; Klein 2009; Salvucci and Tosato 2012). Although Eph receptors 
are also involved in other signalling pathways, details of these will be omitted unless directly 
affecting ephrin-triggered signalling, given that the focus of this study is on ephrinB-induced 
reverse signalling. 
Ephrin ligands can also trigger signalling pathways, called “reverse” signalling, when 
interacting with Eph receptors or, as in the case of ephrinB ligands, through lateral 
interactions with other tyrosine kinase receptors (Gauthier and Robbins 2003; Pasquale 2008).  
Given the many physiological functions in which Eph receptors and ephrin ligands are 
involved in, it is not surprising that Eph/ephrin signalling produces various downstream 
effects. One of the main targets for Eph/ephrin signalling axes is the actin cytoskeleton. 
(Marston, Dickinson et al. 2003) observed that lamellipodia and filopodia only assemble in 
EphB4 receptor expressing cells and that the phosphorylated receptor co-localizes with 
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lamella and the tips of filopodia, suggesting that EphB4 receptor activation stimulates their 
formation. Also, Eph receptors can activate RhoA and inhibit Cdc42 and Rac kinases, shifting 
cytoskeleton dynamics towards increased contraction and reduced extension (Salvucci and 
Tosato 2012). Moreover, the Abelson family of non-cytoplasmic tyrosine kinases Abl and 
Arg (Abl related gene) can bind both phosphorylated and non-phosphorylated EphB2 and 
these interactions seem to play a critical role in actin cytoskeleton regulation during Eph-
mediated axon pathfinding (Kullander and Klein 2002). Similarly, ephrinB ligands regulate 
the Rho family of GTPases and the phosphorylated tyrosines on their cytoplasmic tail act as 
docking sites for the Grb4 adaptor protein. Importantly, Grb4 can activate various proteins 
able to modulate cytoskeleton dynamics, such as Axin, CAP, Dynamin, FAK and paxillin 
(Cowan and Henkemeyer 2001).  
E-cadherin plays an important role in the regulation of cell adhesion through Eph/ephrin 
signalling. More specifically, ectopic expression of E-cadherin in breast cancer cells, which 
lack endogenous E-cadherin, increased EphA2 phosphorylation and caused decreased cell 
adhesion to the extracellular matrix (Zantek, Azimi et al. 1999). Conversely, in colorectal 
cancer cells, stimulation of EphB3 expressing cells caused cell clustering and redistribution of 
E-cadherin to the cell membrane. Furthermore, down-regulation of E-cadherin impaired Eph-
induced cell clustering and sorting (Cortina, Palomo-Ponce et al. 2007). Interestingly, this 
mechanism does not apply to heterotypic contacts between EphB3 expressing cells and 
ephrinB1 expressing cells. A subsequent study from the same group reported that 
EphB3/ephrinB1 signalling induces cell segregation between EphB3 and ephrinB1 expressing 
MDCK cells by inhibiting E-cadherin-mediated cell adhesion at heterotypic contacts. In this 
process, ephrinB1-induced activation of EphB3 stimulates ADAM10 activity, which, in turn, 
targets E-cadherin at sites of EphB3-ephrinB1 interaction (Solanas, Cortina et al. 2011). Thus, 
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through the modulation of E-cadherin activity, EphB receptors seem to possess the ability to 
increase adhesion between homotypic cell populations and form cell boundaries at sites of 
heterotypic contacts. However, the molecular mechanism underlying this process seems to 
differ depending on the type of EphB receptors and ephrinB ligands involved. A recent study 
by (Fagotto, Rohani et al. 2013) conducted on Xenopus laevis described a different 
mechanism of Eph/ephrin-induced formation of spatial boundaries between the notochord and 
the presomitic mesoderm tissues. The authors observed high expression levels of EphB4 in 
the presomitic mesoderm and high levels of ephrinB2 in the notochord. Disruption of 
EphB4/ephrinB2 signalling prevented the formation of spatial boundaries between these 
tissues. As E-cadherin clustering is enhanced upon inhibition of EphB4/ephrinB2 signalling 
and causes adhesion between heterotypic contacting cells, the authors concluded that 
EphB4/ephrinB2 signalling is responsible for the inhibition of E-cadherin clustering and for 
tissue separation by controlling myosin activity. 
Studies have shown that Eph receptors and ephrin ligands can directly interact with 
claudins in cis and increase paracellular permeability by reducing claudin-4 integration in 
tight junctions. Interestingly, claudin-4 interaction with ephrinB1 on the extracellular domain 
caused ligand phosphorylation, which in turn affected intercellular adhesion (Tanaka, Kamata 
et al. 2005).  
In neuronal cells of the central nervous system, EphB – ephrinB interactions are 
responsible for growth-cone collapse and axon pathfinding. Ephrin ligands also have a role in 
positionally selective synaptogenesis between motor neurons and muscle fibres (Klein 2001), 
while ephrinB2 PDZ-mediated reverse signalling upon EphB interaction is responsible for the 
recruitment of presynaptic machinery during the development of presynaptic and postsynaptic 
compartments (McClelland, Sheffler-Collins et al. 2009). Interestingly, the role of ephrinB 
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ligands in modulating physiological functions in the nervous system is mainly linked to 
phosphorylation-dependent reverse signalling (Bush and Soriano 2012). For example, 
mutation of all five tyrosines in mouse ephrinB2 resulted in defects in hippocampal long term 
potentiation (LTP) (Bouzioukh, Wilkinson et al. 2007), and postnatal pruning of mossy fibre 
axons was attributed to the phosphorylation-dependent reverse signalling initiated by 
ephrinB3 (Xu and Henkemeyer 2009). 
Apart from affecting cell adhesion and repulsion, Eph/ephrin signalling can also 
modulate gene expression by cross-activating other receptors or via the JAK-STAT and the 
MAPK pathways (Poliakov, Cotrina et al. 2004). In fact, studies have shown that Eph 
activation reduces ERK activity thus inhibiting mitogenic signals and enhancing cytoskeleton 
modifications. Eph receptors are also able to induce or suppress integrin activity depending on 
the cellular context (Kullander and Klein 2002). For example, EphB2-dependent inhibition of 
cell adhesion involves phosphorylation and inactivation of R-Ras, which in turn suppress 
integrin-ECM interaction (Zou, Wang et al. 1999). By contrast, EphB1 signalling was found 
to enhance αVβ1 integrin-mediated cell adhesion in transfected human kidney cells (Huynh-
Do, Stein et al. 1999). 
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1.1.4  EphrinB ligands 
 
The three types of ephrinB ligands (ephrinB1, ephrinB2 and ephrinB3) are highly 
homologous, contain 333 to 346 amino acids in humans and their 33 aa C-terminal 
cytoplasmic tails are 95% identical. They are the main players in the Eph/ephrin reverse 
signalling pathway. The C-terminal region of these three proteins contains 5-6 conserved 
tyrosine residues, a polyproline stretch and a PDZ binding motif at the C-terminus (Gauthier 
and Robbins 2003). Referring to the human ephrinB2 ligand, the tyrosine residues are located 
at positions 304, 311, 316, 330 and 331. Interestingly, the ephrinB1 ligand has an additional 
tyrosine residue at position 313 (see table 1.1 for ephrinB cytoplasmic tail sequences and 
positions of tyrosine residues). EphrinB2 residues 311, 316 and 330 are phosphorylated 
during EphB receptor binding and serve as docking sites for SH2 domain-containing proteins, 
while the PDZ-binding motif acts as an independent binding site for PDZ domain-containing 
proteins. A study by (Kalo, Yu et al. 2001) on chicken ephrinB1, found that EphB receptor 
binding causes ligand phosphorylation on tyrosines at sites 312, 317 and 331 (corresponding 
to tyrosine residues 311, 316 and 330 in human ephrinB2, see table 1.1). In particular, they 
observed that tyrosine 331 in chicken ephrinB1 is highly phosphorylated upon receptor 
interaction, while tyrosines 312 and 317 are phosphorylated to a lesser degree. In human 
ephrinB2, tyrosines 330 and 331 are located within the last four amino acids of the C-terminal 
region, which corresponds to the PDZ binding motif. Using carboxyl-terminal peptides of 
ephrinB ligands, (Lin, Gish et al. 1999) reported that tyrosine phosphorylation at the -3 
position impairs PDZ mediated binding of an adaptor protein syntenin-1, but not FAP1 
(PTPL1), a PDZ domain-containing tyrosine phosphatase. Indeed, phosphorylation of 
tyrosines within the PDZ binding motif sequence is known to regulate PDZ mediated binding 
Introduction 
~ 21 ~ 
 
in certain cases, as reviewed by (Ivarsson 2012). However, SH2 mediated signalling and PDZ 
mediated signalling are generally thought to be independent from each other, as the structural 
conformation of the last 33 amino acids of the C-terminal region of ephrinB ligands allows 
for both SH2 and PDZ interactions to occur simultaneously (Su, Xu et al. 2004). As the topic 
of SH2 versus PDZ binding is pivotal to the aims of this study, we will expand on it in greater 
detail later on in the introduction. 
 
Protein Species Sequence of C-terminal 36 aa (Tyr highlighted) aa positions 
ephrinB1 Homo sapiens 
NNYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 
  313     317             324        329                          343-344 
311-346 
ephrinB2 Homo sapiens 
SVFCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 
               304             311        316                           330-331 
298-333 
ephrinB3 Homo sapiens 
PPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 
               311              318        323                         337-338 
305-340 
ephrinB1 Gallus gallus 
NNYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 
      301    305             312        317                          331-332 
299-334 
ephrinB1 Xenopus laevis 
NNYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 
      296    300             307        312                          326-327 
294-329 
 
Table 1.1: protein sequences of the C-terminal region of human ephrinB1, ephrinB2 and ephrinB3 (Homo 
sapiens); chicken ephrinB1 (Gallus gallus); and Xenopus ephrinB1 (Xenopus laevis). Tyrosine residues are 
highlighted and their positions within the wild type sequence are included. Information source: NCBI protein 
library. 
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1.1.4.1 EphrinB ligands’ activation through phosphorylation 
 
Upon EphB receptor interaction, ephrinB ligands are phosphorylated by Src family 
kinases (Palmer, Zimmer et al. 2002). This, however, is not necessary for ephrinB ligand 
phosphorylation by other tyrosine kinase receptors, such as FGF, PDGF, VEGF and ErbB 
receptors (Arvanitis and Davy 2008; Pasquale 2008; Pitulescu and Adams 2010; Vermeer, 
Colbert et al. 2013). Both ephrinB ligands and Src kinases are recruited to lipid rafts upon 
EphB receptor binding and clustering (Palmer, Zimmer et al. 2002). It has been reported that 
EphB/ephrinB binding causes cleavage of the ligand’s extracellular domain by Matrix 
Metallo-Proteinases (MMP) and association with presenilin-1 (PS1). PS1 subsequently 
recruits γ-secretase which cleaves the C-terminal region of ephrinB to generate two 
cytoplasmic terminal fragments (CTF1 and CTF2). CTF2 is able to bind to PAG/Cbp, which 
is part of a tripartite complex with C-src kinase (Csk) inhibitor and Src (figure 1.6). This 
allows the detachment of Csk inhibitor from Src, thus allowing Src to auto-phosphorylate and 
become active. CTF2 is also able to bind directly to activated Src and further enhance its 
activity. As a result of PS1 – γ-secretase cleavage, the cytoplasmic domain of ephrinB1 can 
also translocate to the nucleus and enhance Zhx2 transcriptional activity to maintain neural 
progenitor state (Georgakopoulos, Litterst et al. 2006; Tomita, Tanaka et al. 2006; Wu, Qiu et 
al. 2009). Once Src is activated, it phosphorylates tyrosine residues on the C-terminal tail of 
ephrinB ligands which have not yet made contact with EphB receptors. This prevents γ-
secretase from cleaving the ligand and creates SH2 docking sites for SH2 domain-containing 
proteins, such as Grb4 and STAT3 (Georgakopoulos, Litterst et al. 2006; Georgakopoulos, Xu 
et al. 2011). Studies have shown that after 2-5 minutes from EphB – ephrinB interaction, 
ephrinB ligands co-localize with Src family kinases, which reach their peak of 
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phosphorylation/activation within 10 minutes, together with ephrinB ligand phosphorylation. 
30 minutes after the removal of EphB, PTP-BL (PTPL1), a PDZ domain-containing 
phosphatase, interacts with ephrinB ligands and reduces its level of phosphorylation thus 
terminating reverse signalling (Palmer, Zimmer et al. 2002). Another mechanism of signal 
termination involves ligand endocytosis and degradation: as (Foo, Turner et al. 2006) reported 
that prolonged ephrinB2 stimulation with EphB4/Fc caused complete depletion and 
degradation of the ligand. 
 
Figure 1.6: Src-mediated ephrinB2 phosphorylation mechanism as described by (Georgakopoulos, Xu et al. 
2011). 
 
  
Introduction 
~ 24 ~ 
 
1.1.4.2    EphrinB ligand signalling via Grb4 adaptor protein 
 
Grb4 is an adaptor protein containing a single SH2 domain and three SH3 domains. 
When ephrinB ligands are phosphorylated, Grb4 binds to specific phospho-tyrosines via its 
SH2 domain and serves as a docking protein for SH3-binding domain-containing proteins 
(figure 1.7) (Andres and Ziemiecki 2003; Gauthier and Robbins 2003). In human ephrinB2, 
the 22 amino acids sequence in position 301-322, which contains 3 of the 5 conserved 
tyrosine residues, is fundamental for Grb4 binding (Cowan and Henkemeyer 2001; Su, Xu et 
al. 2004). In fact, phosphorylation of tyrosine residues at sites 311 and 316 increase protein 
structure flexibility. This facilitates phosphorylation of tyrosine site 304, generating the SH2-
binding motif to which Grb4 binds (Song 2003; Su, Xu et al. 2004). A similar study by 
(Bong, Park et al. 2004) on Xenopus ephrinB1, reached the same conclusion and added that 
phosphorylation on Tyr300 (which the authors refer to as Tyr298 and which corresponds to 
Tyr304 in human ephrinB2) is 
induced by FGFR1 activation. 
Once bound to the cytoplasmic 
tail of ephrinB ligands, Grb4 acts 
as a scaffolding platform via its 
three SH3 domains, which are 
bound by various cytoskeletal 
regulating proteins, such as Abi-
1,Axin, CAP, Dynamin, 
hnRNPK, Pak1, PINCH, 
DOCK180, Cbl and Abl tyrosine 
Figure 1.7: summary of proposed ephrinB pathways triggered 
through Grb4 binding (Cowan and Henkemeyer 2001). 
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kinase (figure 1.7). These proteins can then modulate cell adhesion and actin dynamics 
(inducing the loss of polymerized F-actin structures) and cause disassembly of focal 
adhesions (Cowan and Henkemeyer 2002; Kullander and Klein 2002). Also, Grb4 binding to 
phosphorylated ephrinB ligands has been shown to activate focal adhesion kinase (FAK), 
which induces cell rounding (Cowan and Henkemeyer 2001), through activation of the G 
protein-coupled receptor kinase-interacting protein (GIT) 1 (Segura, Essmann et al. 2007). 
 
 
1.1.4.3 EphrinB ligands promote gene expression through STAT3   
 
Another protein that binds to the phosphorylated C-terminal tail of ephrinB ligands via 
its SH2-binding motif is the transcription factor STAT3. In Xenopus ephrinB1, the tyrosine 
residue which serves as a docking site for this protein is located at position 312 (which the 
authors refer to as Tyr310 and which corresponds to Tyr316 in human ephrinB2). Although 
STAT3 is able to bind to any of the three phosphorylated ephrinB ligands, phosphorylation of 
tyrosine in position 296 (referred to as 294 by the authors and exclusive only to ephrinB1) of 
Xenopus ephrinB1 strongly enhances its binding to phospho-Tyr312 (referred to as 310 by the 
authors) (Bong, Lee et al. 2007). When the ligand is phosphorylated either through EphB 
interaction or by FGF receptor-mediated activation, STAT3 binds to phospho-Tyr312 
(referred to as 310 by the authors) via its SH2 domain and is phosphorylated/activated by 
Jak2, which was found to interact with the C-terminal tail of non-phosphorylated Xenopus 
ephrinB1 (Bong, Lee et al. 2007). The transcription factor then separates from the ephrinB 
ligand, forms homodimers with other phosphorylated STAT3 proteins and translocates to the 
nucleus, where it induces gene expression of proteins involved in migration, survival, 
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apoptosis and modulation of inflammation (Bong, Lee et al. 2007). A study by (Salvucci, 
Maric et al. 2009) using human umbilical vein endothelial cells (HUVEC) and mesenchymal 
stem cells (MSC) (both expressing the ephrinB2 ligand and the EphB4 receptor on the cell 
surface) cultured in Matrigel-based 3D cultures, underlined the importance of Src and Jak2 
kinases in the ephrinB reverse signalling pathway. In fact, silencing of the ephrinB2 ligand in 
this model prevented the formation of cord-like structures and this event could be mimicked 
by using Src and Jak2 inhibitors, thus highlighting the importance of these proteins during 
ephrinB reverse signalling events. 
 
 
1.1.4.4 EphrinB ligands signal via Dishevelled 
 
Activation of ephrinB ligands through phosphorylation of their tyrosine residues 
induces RhoA activation via Dishevelled and c-Jun N-terminal kinase (JNK) activation, 
which leads to cell rounding and detachment (Kullander and Klein 2002).  
Dishevelled is a cytoplasmic protein containing a DIX, a PDZ and a DEP domain. It 
binds to SH3 domains of Grb4-bound proteins and by doing so is involved in ephrinB ligand 
signalling. Upon ephrinB phosphorylation, Grb4 binds to the SH2 docking sites of the ligand, 
allowing Dishevelled to bind to its SH3 domains and to recruit RhoA and ROCK, which 
mediate cell retraction. Interestingly, Dishevelled is also able to bind ephrinB ligands in non-
phosphorylated conditions. This interaction, however, is not PDZ domain-dependent, but 
relies on the protein’s DEP domain (Lee, Bong et al. 2006). Moreover, when ephrinB ligands 
are phosphorylated, Dishevelled is phosphorylated as well, although the functional meaning 
of this event is still unclear (Tanaka, Kamo et al. 2003). It could either be induced by ephrinB 
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ligand phosphorylation together with SH2 domain-containing proteins or by phosphorylation 
independent activation of JNK (Xu, Lai et al. 2003). In the retina, knock down of Dishevelled 
prevented ephrinB1 expressing retinal progenitor cells from dispersing to the eye field. The 
same phenotype was observed upon knock down of ephrinB1, which could be rescued by 
over-expression of Dishevelled (Lee, Bong et al. 2006). A later study from the same group 
reported that FGFR-induced phosphorylation of Xenopus ephrinB1 on Tyr326 and 327 (which 
correspond to Tyr330 and 331 in human ephrinB2; referred to as Tyr324 and 325 by the 
authors) disrupted ephrinB1 – Dishevelled interaction, thus modulating progenitor cell 
movement (Lee, Mood et al. 2009). 
 
 
1.1.4.5 PDZ-mediated signalling in ephrinB ligands 
 
EphrinB ligands contain a PDZ binding motif at the C-terminus of their cytoplasmic 
tail, which is formed by the last four C-terminal amino acids. This motif is fundamental to the 
physiological role of ephrinB ligands. Moreover, PDZ-derived signalling through interacting 
PDZ domain-containing proteins is often independent of Eph – ephrin interaction and 
SH2/phospho-tyrosine mediated signalling (Pasquale 2008). Many PDZ domain-containing 
proteins have been found to interact with the PDZ binding motif of ephrinB ligands, such as 
PTPL1 (FAP1), GRIP1, GRIP2, PDZ-RGS3, PICK1, PAR3 and syntenin-1 (figure 1.8). It has 
been hypothesized that some of these proteins might be able to facilitate assembly of ephrinB 
ligands in supramolecular signalling complexes and modulate their activation by cluster 
formation (Lin, Gish et al. 1999; Cowan and Henkemeyer 2002; Kullander and Klein 2002; 
Gauthier and Robbins 2003). An early study by (Lin, Gish et al. 1999) reported that ephrinB1 
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tyrosine phosphorylation at position -2, which is located within the PDZ binding motif of 
ephrinB ligands, impairs PDZ mediated-binding of syntenin-1. However, phosphorylation of 
tyrosine at position -3 does not influence PDZ binding. The same study also reported that 
FAP1 binding to ephrinB ligands remains unaffected by phosphorylation of either tyrosine at 
position -2 or -3. Another study has shown that PDZ binding of PDZ-RGS3 is not affected by 
any phosphorylation events of tyrosine residues present within the last C-terminal 33 amino 
acids of ephrinB ligands (Su, Xu et al. 2004). In a similar way, GRIP1 and GRIP2 binding to 
ephrinB2 is not affected by tyrosine phosphorylation on the cytoplasmic tail, but is enhanced 
upon phosphorylation of serine at position -8 (Essmann, Martinez et al. 2008). These reports 
suggest that ephrinB ligand phosphorylation modulates PDZ mediated-binding of specific 
PDZ domain-containing proteins. Indeed, modulation of PDZ binding via phosphorylation of 
tyrosine, serine and threonine residues located within the PDZ binding motif sequence, or in 
close proximity to it, has been reported in many other protein-protein interactions (Ivarsson 
2012). 
The importance of the PDZ binding motif in ephrinB ligands under physiological 
conditions was highlighted by in vivo experiments (Bush and Soriano 2012). In a study by 
(Makinen, Adams et al. 2005), the authors reported that mice expressing a truncated form of 
the ephrinB2 ligand, lacking the C-terminus region, showed lymphatic vascular malformation 
and died in embryonic stage, while mice expressing a version of the ligand which was 
mutated at tyrosine phospho-sites survived. This suggests that the PDZ binding motif of the 
ephrinB2 ligand is fundamental for lymphatic vascular formation, but probably not for blood 
vascular remodelling. 
Another study also highlighted the importance of PDZ-mediated reverse signalling of 
ephrinB1 in normal axon guidance during formation of the corpus callosum. Phosphorylation-
Introduction 
~ 29 ~ 
 
mediated reverse signalling does not play a role in this process or impairs PDZ-mediated 
signalling (Bush and Soriano 2009).  
At the cellular level, the PDZ binding motif is critical for modulating cell contraction 
and membrane blebbing in ephrinB2 ligand expressing cells even in the absence of EphB4 
receptor interaction. This is necessary to promote increased cell mobility and migration, 
which are Grb4 and Rac dependent. This observation proves that PDZ-mediated signalling 
can happen independently of ephrinB stimulation by EphB receptors and is able to regulate 
different aspects of ephrinB ligands functions (Bochenek, Dickinson et al. 2010).  
 
  
Figure 1.8: PDZ domain-containing proteins which interact with ephrinB ligands (Cowan and 
Henkemeyer 2002). 
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1.1.4.6 EphrinB ligands signal through various PDZ domain-containing 
  proteins 
 
FAP1 (PTPL1) is a PDZ domain-containing tyrosine phosphatase and binds to ephrinB 
ligands via its fifth PDZ domain (Lin, Gish et al. 1999). Currently, it is the only phosphatase 
known to de-phosphorylate ephrinB ligands (Gauthier and Robbins 2003). Recently it has 
been described as a tumour suppressor, as its decreased expression in breast cancer correlates 
with poor overall patient survival rate (Vermeer, Bell et al. 2012). Studies have shown that 
PTPL1 co-localizes with ephrinB ligands and Src family kinases in lipid rafts and when it 
binds to the PDZ domain of ephrinB ligands it can de-phosphorylate both the ligand and Src 
kinases (Palmer, Zimmer et al. 2002). 
In neuronal cells, syntenin-1 acts as a homodimerized scaffolding protein and binds to 
the PDZ binding motif of ephrinB ligands, possibly forming complexes necessary during 
maturation of presynaptic specializations (Cowan and Henkemeyer 2002). Recent data has 
emphasized the importance of syntenin-1 in EphB-dependent development of presynaptic and 
postsynaptic compartments via ephrinB1 and ephrinB2 ligands (McClelland, Sheffler-Collins 
et al. 2009). Moreover, syntenin-1 binding to ephrinB3 is required during ephrinB3-driven 
dendrite pruning and synapses formation upon EphB receptor stimulation (Xu, Sun et al. 
2011). 
PDZ-RGS3 is a regulatory protein which acts as a GTPase-activating protein (GAP) for 
the α-subunits of trimeric G proteins. When it binds to ephrinB ligands via its PDZ domain it 
can neutralize C-X-C chemokine receptor type-4 (CXCR4) attraction to stromal cell-derived 
factor-1 (SDF-1), thus allowing inward migration of cerebellular granule cells (Cowan and 
Henkemeyer 2002). Interestingly, a study by (Makinen, Adams et al. 2005) found that PDZ-
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RGS3 localization in lymphatic vessel endothelium was disturbed in ephrinB2
∆V/∆V
 mutant 
mice and suggested that the ephrinB2 – PDZ-RGS3 axis might be involved in cell migration 
during remodelling of the lymphatic vasculature. A more recent study in HUVEC cells also 
found that ephrinB2-induced cell motility, independently of stimulation by EphB receptors, 
requires the PDZ-mediated interaction between the ligand and PDZ-RGS3 (Bochenek, 
Dickinson et al. 2010). Finally, an in vivo study on the role of PDZ-RGS3 in maintaining self-
renewal processes in neuronal progenitor cells, found that loss of PDZ-RGS3 mimicked the 
loss of ephrinB1 and caused progenitor cells to differentiate (Qiu, Wang et al. 2010). 
Therefore, the authors concluded that the ephrinB1 – PDZ-RGS3 axis might be essential in 
the maintenance of neuronal progenitor cells. 
GRIP proteins are multi PDZ domain-containing scaffolding proteins which have the 
postulated role of clustering other proteins containing PDZ binding motifs together. GRIP is 
able to bind EphB2 and EphA7 receptors and ephrinB ligands through its PDZ domains 6 and 
7. It is also able to bind AMPA receptors via its 4
th
 and 5
th
 PDZ domain, thus allowing GRIP 
to act as a bridge between ephrinB ligands and AMPA receptors (Torres, Firestein et al. 
1998). Early studies reported that ephrinB ligands are able to recruit GRIP proteins to lipid 
rafts via PDZ-mediated interaction (Bruckner, Pablo Labrador et al. 1999). More recently, 
EphB2-driven ephrinB2 phosphorylation on Ser325 has been identified as a positive switch 
for PDZ-mediated GRIP binding, which in turn regulates AMPA receptors turnover at post-
synaptic sites (Essmann, Martinez et al. 2008).  
PICK1 contains a single PDZ domain and mediates clustering of ephrinB ligands, albeit 
not when EphB2 is co-expressed in the same cell. Given its ability to interact with PKC, it has 
been postulated that this protein might functionally couple ephrinB ligands with other 
signalling cascades (Torres, Firestein et al. 1998). In neurons, ephrinB3 has been shown to 
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regulate dendrite pruning and synapses formation upon EphB receptor stimulation via PDZ-
mediated binding to PICK1 (Xu, Sun et al. 2011). 
Through the PDZ binding motif, ephrinB ligands also play a role in organizing 
cytoskeletal complexes that are involved in establishing or maintaining cell polarity via PAR3 
activity. This protein binds to ephrinB ligands via its second or third PDZ domain and forms 
ternary complexes with atypical protein kinase C (aPKC) and PAR6. These complexes, after 
binding and activating Cdc42 and Rac1, regulate asymmetrical cell division and establish and 
maintain cell polarity (Cowan and Henkemeyer 2002). Association of ephrinB1 with PAR6 
can also modulate cell-cell adhesion and paracellular permeability through the formation of 
tight junctions. EphrinB1 competes with Cdc42 for association with PAR6, which 
constitutively binds aPKC. Upon ephrinB1 phosphorylation caused by EphB receptors in 
trans or FGF receptors and claudins in cis, PAR6 dissociates from ephrinB1 and associates 
with Cdc42. This causes activation of aPKC, which induces the formation of tight junctions 
(Lee, Nishanian et al. 2008). 
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1.1.4.7 EphB/ephrinB endocytosis pathway 
 
The endocytic process triggered by receptor/ligand interaction involves the whole 
EphB/ephrinB complex, which can be internalized either in the EphB receptor or the ephrinB 
ligand expressing cell. This particular type of endocytosis is called trans-endocytosis 
(illustrated in figure 1.9). However, while in EphB receptor expressing cells the kinase 
domain is required for complex endocytosis, internalization of the complex into ephrinB-
expressing cells may not be dependent on ligand phosphorylation or PDZ-mediated reverse 
signalling (Pitulescu and Adams 2010). The internalization of the EphB/ephrinB complex 
starts 10 minutes after cell contact. During the initial stages of trans-endocytosis, the 
receptor/ligand complex is mostly internalized in ephrinB ligand expressing cells. After 60 
minutes from cell contact, this process is reversed, and most of the internalized complex can 
be observed within EphB receptor expressing cells (Zimmer, Palmer et al. 2003). 
Interestingly, stimulation of ephrinB2 expressing cells with an EphB4/Fc chimeric protein for 
time periods longer than 2 hours caused a total depletion of ephrinB2 from the cell surface for 
up to 24 hours, while 
stimulation for 1 hour did 
not. This suggests that 
ephrinB expressing cells 
might be able to terminate 
reverse signalling through 
ligand internalization and 
degradation (Foo, Turner et 
Figure 1.9: trans-endocytosis of the EphB/ephrinB complex can occur in 
either the EphB or ephrinB expressing cell (Pitulescu and Adams 2010). 
Introduction 
~ 34 ~ 
 
al. 2006). Truncation of the cytoplasmic tail of EphB receptors causes trans-endocytosis to be 
directed only towards ephrinB ligand expressing cells, while truncation of the cytoplasmic tail 
of the ligand inverts this process and allows internalization to occur only into the receptor 
expressing cell. Interestingly, truncation of the cytoplasmic tail of both receptor and ligand 
simultaneously completely abolishes the trans-endocytosis process and results in strong cell 
adhesion (Zimmer, Palmer et al. 2003). Various studies have revealed that trans-endocytosis 
does not follow a canonical endocytic pathway, as the vesicles containing the receptor/ligand 
complex do not co-localize with any known endocytic markers, including clathrin and 
caveolin. Instead, it is thought that the mechanism driving this process resembles 
phagocytosis or macro-pinocytosis. In fact, activation of Rho GTPases and actin 
polymerization are needed during trans-endocytosis. In this respect, Cdc42 has been shown to 
promote the formation of filopodia and dendritic spines, and Rho-A to regulate actin 
dynamics, cell contractility and phagocytosis (Marston, Dickinson et al. 2003; Zimmer, 
Palmer et al. 2003; Groeger and Nobes 2007; Pitulescu and Adams 2010). In spite of this, it 
has been suggested that trans-endocytosis of the EphB/ephrinB complexes into ephrinB-
expressing cells may, in fact, involve clathrin. In this regard, ephrinB ligands do have three 
conserved YXXɸ sequences (with X representing any aminoacid and ɸ a hydrophobic 
aminoacid) within the terminal 33 amino acids of their cytoplasmic tails, which might serve 
as target sequences for clathrin-dependent endocytosis adaptor proteins (AP) (Traub 2003; 
Edeling, Smith et al. 2006). In one study, internalized vesicles containing the EphB/ephrinB 
complex co-localized with the endocytic marker for early endosomes EEA1 and blocking 
dynamin or lowering potassium concentration inhibited ephrinB1 internalization upon EphB1 
stimulation (Parker, Roberts et al. 2004). Eph receptors were also found to concentrate in 
caveolae enriched regions on the cell membrane and EphB1 was reported to associate with 
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caveolin-1. This suggests that Eph signalling might be able to control both the early and late 
phases of clathrin-mediated endocytosis (Vihanto, Vindis et al. 2006). In this regard, EphB 
receptors have also been reported to inhibit the late phases of clathrin-mediated endocytosis 
by inducing phosphorylation of synaptojanin-1, thus inhibiting its association with endophilin 
and impairing clathrin un-coating (Irie, Okuno et al. 2005). 
After internalization of the EphB/ephrinB complex, EphB receptors maintain their 
phosphorylation status and possibly their signalling activity until they are processed for 
degradation (Zimmer, Palmer et al. 2003; Pitulescu and Adams 2010). Trans-endocytosis of 
the receptor/ligand complex allows the contacting cells to retract from one another. At this 
point EphB receptor expressing cells round up and then re-spread. Interestingly, 
receptor/ligand internalization within EphB receptor expressing cells is not necessary for cell 
retraction, but is fundamental for cell re-spreading. This process takes place even in the 
constant presence of ephrinB2/Fc chimeric protein, suggesting that active ephrinB/EphB 
complex is critical for re-spreading in EphB receptor expressing cells (Groeger and Nobes 
2007). 
 
 
1.1.4.8 EphB/ephrinB processing by proteolytic cleavage 
 
Proteolytic cleavage can also be triggered by Eph/ephrin interaction. This process 
involves both EphB receptors and ephrinB ligands. After binding to ephrinB2, the EphB2 
receptor is cleaved by MMP-2 and MMP-9 at two sites of the protein, producing two soluble 
fragments: an extracellular long fragment and an intracellular fragment. Interestingly, only 
one of the two cleavage sites of EphB2 is conserved in EphB3 and EphB1, suggesting that 
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Eph receptors can be processed differently. Moreover, MMP mediated EphB2 receptor 
cleavage induced by ephrinB2 ligand interaction is necessary for cell repulsion events and 
EphB2 receptor phosphorylation and activation. In fact, in the absence of MMP cleavage, the 
EphB2 receptor is rapidly de-phosphorylated, which suggests that MMP mediated cleavage 
can regulate duration of EphB2-dependent signalling (Lin, Sloniowski et al. 2008).  
Proteolytic cleavage also affects ephrinB ligands. Binding of the EphB2 receptor to 
ephrinB1 stimulates secretion of MMP-8 through PDZ-mediated reverse signalling and 
activation of Arf1. MMP-8 then cleaves the extracellular domain of the ephrinB1 ligand, 
producing a 35 kDa soluble fragment which retains the ability to inhibit motility of EphB2 
receptor expressing cells. Moreover, ephrinB1 ligand extracellular cleavage acts as a negative 
feedback event for future EphB2 – ephrinB1 interactions (Tanaka, Sasaki et al. 2007). Other 
reported proteolytic cleavage events include ephrinB ligands cleavage by PS1 and γ-secretase 
(described in section 1.1.4.1), ADAM10 and γ-secretase cleavage of EphB receptors upon 
ephrinB ligand interaction (Arvanitis and Davy 2008) and also human rhomboid 
intramembrane serine protease (RHBDL2) cleavage of ephrinB3 ligands at the 
transmembrane domain when bound to EphB receptors (Tanaka, Sasaki et al. 2007). 
 
 
1.1.4.9 Cross-talk between ephrinB ligands and tyrosine kinase receptors 
 
EphrinB ligands were shown to interact with other tyrosine kinase receptors, such as 
PDGF, FGF, VEGF and ErbB receptors (Kullander and Klein 2002; Poliakov, Cotrina et al. 
2004; Arvanitis and Davy 2008; Pasquale 2008; Pitulescu and Adams 2010; Vermeer, Colbert 
et al. 2013). EphrinB1 is able to physically interact with FGF receptors and is phosphorylated 
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on tyrosine as a consequence. Specifically, the aminoacid sequence between position 302 and 
308 as well as tyrosine phosphorylation on residues 305 and 310 in Xenopus ephrinB1 are 
required for its association with FGF receptors. Moreover, ligand-induced stimulation of FGF 
receptors leads to endogenous tyrosine phosphorylation of ephrinB1. This phosphorylation 
event depends on the FGF receptor kinase domain and is independent from Src kinase 
activation (Chong, Park et al. 2000). A later study from the same group also reported that 
FGF-dependent phosphorylation of Xenopus ephrinB1 triggers Grb4-mediated reverse 
signalling (see section 1.1.4.2) (Bong, Park et al. 2004). Conversely, ephrinB ligands can be 
involved in regulation of cellular responses to FGFs. Specifically, ephrinB2 was linked to 
FGF receptor signalling through syndecans. Stimulation of ephrinB2 causes expression and 
shedding of syndecan-1 from the membrane, which then forms complexes with FGF receptors 
and inhibits its activity (Yuan, Hong et al. 2004). 
EphrinB ligands are functionally linked with VEGF receptor signalling and this has a 
fundamental role in the formation of new vessels and angiogenesis. EphrinB2 is expressed in 
endothelial cells together with VEGFR-2 and VEGFR-3. Upon VEGF stimulation, ephrinB2 
is activated and co-localizes with VEGF receptors. In turn, ephrinB2 reverse signalling 
activates VEGF receptors and mediates their internalization, which triggers activation of 
ERK1/2 and Akt signalling pathways (Germain and Eichmann 2010; Sawamiphak, Seidel et 
al. 2010). In ephrinB2 knock-out mice, VEGFR-3 activation by VEGF-C is impaired, causing 
down-regulation of Rac1, Akt and ERK1/2 activation (Wang, Nakayama et al. 2010). The 
PDZ binding motif of ephrinB2 is essential for its association with VEGF receptors. 
Moreover, activation and internalization of these receptors are driven by PDZ-mediated 
reverse signalling (figure 1.10). On the other hand, tyrosine phosphorylation of the 
cytoplasmic tail of ephrinB2 is not required (Germain and Eichmann 2010; Pitulescu and 
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Adams 2010; Sawamiphak, Seidel et al. 2010; Wang, Nakayama et al. 2010). In a more recent 
study, (Nakayama, Nakayama et al. 2013) reported that ephrinB2-induced internalization of 
VEGFR-2 and VEGFR-3 is mediated by PAR3 and the clathrin-associated sorting protein 
disabled-2 (Dab2) in a clathrin-dependent manner. More specifically, PAR3 recruits Dab2 to 
VEGFR-2, VEGFR-3 / ephrinB2 complexes via PDZ interactions with the PDZ binding motif 
of ephrinB2, thus mediating internalization of the protein complex. Interestingly, VEGF 
stimulation of VEGF receptor positive endothelial cells also induced aPKC phosphorylation, 
which in turn prevented VEGF receptor internalization in a seemingly negative feedback loop. 
Other tyrosine kinase receptors, such as PDGF receptors and tie-2 receptor, can also 
associate and phosphorylate ephrinB ligands in cis upon activation (Palmer, Zimmer et al. 
2002; Bong, Park et al. 2004). For example, in hepatic stellate cells PDGF signalling through 
ephrinB2 regulates cell motility and vascular coverage in the liver (Das, Shergill et al. 2010).  
Figure 1.10: VEGF receptor internalization is mediated by PDZ-mediated ephrinB2 reverse signalling 
(Germain and Eichmann 2010). 
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Finally, ephrinB1 associates with ErbB2 and ErbB1 by directly interacting through their 
transmembrane domains. Moreover, ephrinB1 – ErbB1,2 complexes co-localize at cell-to-cell 
junctions (Vermeer, Colbert et al. 2013). High levels of ErbB2 are concomitant with high 
levels of ephrinB1 phosphorylation and consequent increase in ERK1/2 activation (Vermeer, 
Bell et al. 2012; Vermeer, Colbert et al. 2013).  
 
 
Introduction 
~ 40 ~ 
 
1.1.5  EphB receptors and ephrinB ligands are involved in  
  cancer progression 
 
Within the vast field of cancer research, significant attention has been focused on 
angiogenesis and metastasis, the former being fundamental for tumour growth and the latter 
for malignant disease progression. Given their role in modulating cell migration, adhesion and 
repulsion, it is not surprising that Eph tyrosine kinase receptors and their cognate ephrin 
ligands are considered to be pivotal proteins in cancer angiogenesis and metastasis. Indeed, 
Eph receptors and/or ephrin ligands are de-regulated in most types of cancer cells (Pasquale 
2008; Genander and Frisen 2010; Nievergall, Lackmann et al. 2012). Moreover, de-regulation 
of Eph/ephrin signalling promotes the development of aggressive metastatic tumours (Lee and 
Daar 2009). In support of this, recent studies have reported that gene inactivation by CpG 
hyper-methylation in the promoter region of various Eph receptors and ephrin ligands is 
linked with increased aggressiveness of several types of tumours, including colorectal, 
prostate and breast cancer (Arvanitis and Davy 2012). Various studies have also found a 
strong correlation between higher expression levels of many Eph/ephrin family members and 
increased invasiveness of a number of aggressive tumours (Liu, Jung et al. 2004; Campbell 
and Robbins 2008).  
Data collected from many studies has proven that only in exceptional cases does 
Eph/ephrin protein up-regulation increase the cell proliferation rate. Rather, the involvement 
of Eph/ephrin signalling axes in tumourigenesis is likely to be linked with regulation of cell-
ECM and cell-cell adhesion or repulsion, both of which increase cell motility and metastasis. 
Usually, high expression levels of Eph receptors and low levels of ephrin ligands facilitate 
tumour growth and metastasis, as seen in breast, colon, liver and prostate carcinomas (Mosch, 
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Reissenweber et al. 2010). In other cases, such as uterine cancer, high co-expression of the 
EphB4 receptor and ephrinB2 ligand was found to enhance proliferation, migration and 
invasion of tumour cells, and this correlated with grade and stage of the tumour and poor 
prognosis for patients (Alam, Fujimoto et al. 2007). In malignant glioblastomas, ephrinB2 and 
ephrinB1 ligands are over-expressed and highly phosphorylated, which also correlates with 
poor prognosis and overall survival of patients (Nakada, Anderson et al. 2010). Although 
many members of the Eph/ephrin superfamily are up-regulated in cancer, some advanced 
forms of tumour show down-regulated levels of these proteins. It has been hypothesized that 
initial Eph receptor up-regulation could subsequently be switched off through hyper-
methylation of its gene promoter region (Brantley-Sieders 2012). Table 1.2 lists all reported 
cases of abnormal expression of EphB and ephrinB proteins in various different types of 
cancer. 
Other reports have shown that tumour associated cytokines and growth factors, such as 
tumour necrosis factor-α (TNFα) and vascular endothelial growth factor A (VEGFA), as well 
as stress conditions such as cyclic stretch and hypoxia, up-regulate various Eph receptors and 
ephrin ligands. Mutations within the tyrosine kinase and the ephrin binding domains of Eph 
receptor genes have also been identified in human gastric, prostate and colorectal tumours and 
melanoma. Other cancer associated genetic changes involve loss of heterozygosity (Pasquale 
2010). Because phosphorylated Eph receptors suppress tumour cell growth by inhibiting 
oncogenic pathways, such as h-Ras-ERK, PI3K-Akt and Abl-Crk pathways, it is feasible that 
these mutations might indirectly promote tumour growth. In fact, up-regulation of Eph 
receptors leads to their reduced activation. This suggests that the pro-oncogenic effect of Eph 
receptors over-expression depends on their role as activators of ephrinB reverse signalling 
(Pasquale 2010). 
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Within the B subclass of the Eph receptor and ephrin ligand superfamily, EphB4 and 
EphB2 receptors and ephrinB2 and ephrinB1 ligands are the most studied in cancer 
progression. These proteins are over-expressed in highly invasive and metastatic tumours and 
their expression levels correlate with clinical stage and histological grade of many cancers 
(Campbell and Robbins 2008). EphB2 receptor expression, for example, was found to 
negatively associate with overall survival of breast cancer patients, while EphB4 receptor 
protein levels increased with clinical stage and histological grade of the tumour (Wu, Suo et 
al. 2004). EphB4 receptor and ephrinB2 ligand expression levels are modulated by different 
signalling pathways. In more than half of known breast cancers and tumour cell lines, the 
Table 1.2: expression profile of EphB receptors and ephrinB ligands in human epithelial malignancies 
(Brantley-Sieders 2012). 
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EphB4 receptor is up-regulated by JNK, Akt and Wnt pathways and also by oestrogen-
controlled gene expression and gene amplification. Interestingly, the Wnt pathway can down-
regulate the ephrinB2 ligand in the same cancers and cell lines (Noren and Pasquale 2007). 
Only in a few cases has EphB/ephrinB signalling been linked with an increase in cell 
proliferation. In a study by (Steinle, Meininger et al. 2002), stimulation of EphB4 receptor 
with ephrinB2/Fc soluble ligand caused a 38% increase in endothelial cell proliferation. The 
same stimulation also caused a 63% increase in migration and both of these effects could be 
inhibited by using ERK1/2 or Akt inhibitors, which suggests that cell proliferation and 
migration might be linked in this particular case. A recent study by (Vermeer, Colbert et al. 
2013) has also revealed that ephrinB1 association with ErbB1 or ErbB2 induces ERK1/2 
phosphorylation, thus promoting cell proliferation and survival. 
  
 
1.1.5.1 EphB receptors and ephrinB ligands induce cancer angiogenesis 
 
Hypoxia is a common stress condition in cancer tissues and it can influence many 
aspects of cell survival and gene expression. For example, it can up-regulate HIF-1α, a protein 
which plays a pivotal role in cancer angiogenesis. Interestingly, it has also been shown to 
reduce EphB4 receptor levels and promote ephrinB2 ligand expression indirectly through 
VEGFR up-regulation in the tumour-associated endothelium (Bochenek, Dickinson et al. 
2010; Mosch, Reissenweber et al. 2010). Indeed, ephrinB2 is up-regulated in both 
physiological and pathological angiogenesis (Wang, Nakayama et al. 2010). Increase in 
ephrinB ligand expression has widely been associated with increased tumour angiogenesis 
(Kandouz 2012). For instance, high levels of ephrinB1 in hepatocellular carcinoma (HCC) 
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tissues increase tumour vessel number in vivo (Sawai, Tamura et al. 2003). In malignant 
melanoma, increased expression of ephrinB2 correlates with higher tumour vascularisation 
(Vogt, Stolz et al. 1998). Furthermore, ephrinB2 mRNA levels were found to be higher in 
metastatic melanoma cell lines rather than in the primary isogenic counterpart (Liu, Jung et al. 
2004). EphrinB2 is also involved in the modulation of mammary gland vascularisation 
(Haldimann, Custer et al. 2009), which will be described in more detail further on in this 
chapter. 
At the molecular level, VEGF-triggered changes in expression of EphB4 and ephrinB2 
involve the Delta-Notch signalling pathway. The ultimate effect of this process is to turn 
venous endothelial cells into arterial cells, thus enhancing angiogenesis (Hainaud, Contreres 
et al. 2006). Conversely, activation of ephrinB2 induces VEGFR-2 internalization and 
activation, thereby controlling tip cell filopodial extension and vascular sprouting, which 
initiate angiogenesis (Sawamiphak, Seidel et al. 2010). Also, ephrinB2 activates JNK and 
PI3K pathways, which both stimulate protease release into the extracellular matrix and cause 
its degradation. This facilitates endothelial invasion of cells to the surrounding tissue and 
forms new vessels within the growing tumour (Noren, Lu et al. 2004). The EphB4 receptor, 
which is expressed in the majority of the tumour tissue, also plays an important role in the 
angiogenic process by acting as a positive cue for endothelial ephrinB2 ligand expressing 
cells (Merlos-Suarez and Batlle 2008). In fact, deletion of either the EphB4 receptor or the 
ephrinB2 ligand in these interacting cells produces an identical phenotype and ultimately 
inhibits tumour growth (Hainaud, Contreres et al. 2006). 
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1.1.5.2 The role of EphB receptors and ephrinB ligands in cancer  
  metastasis 
 
EphrinB ligands also play an important role in regulating tumour metastasis (Kandouz 
2012). For example, elevated ephrinB2 expression in oesophageal squamous carcinomas 
induces metastatic progression (Tachibana, Tonomoto et al. 2007). In migrating and invading 
glioma cells, ephrinB2 and ephrinB3 were over-expressed and highly phosphorylated 
(Nakada, Drake et al. 2006; Nakada, Anderson et al. 2010). 
Various studies have reported that the ephrinB2 – EphB4 axis is responsible for 
inducing or suppressing cancer metastasis depending on the tumour type. In melanoma cells, 
ephrinB2-mediated activation of EphB4 increases cell migration via RhoA activation (Yang, 
Pasquale et al. 2006). By contrast, ephrinB2-stimulated EphB4 inhibits motility and invasion 
of breast cancer cells via a pathway which involves Abl family tyrosine kinases and Crk 
(Noren, Foos et al. 2006). EphrinB2 reverse signalling is also involved in regulating cancer 
metastasis. Over-expression of a mutant form of ephrinB2 with a truncated cytoplasmic tail 
promotes metastasis of mammary tumours and results in a tumour phenotype presenting a 
majority of cells with stem/progenitor characteristic (Kaenel, Antonijevic et al. 2012). The 
ability of ephrinB2 to reverse signal is fundamental to keep EphB4 activated and regulate its 
expression by causing its internalization and degradation after receptor/ligand interaction. If 
reverse signalling is defective, EphB4 expression on neighbouring cells increases and this 
event ultimately may promote metastasis (Harburg and Hinck 2011). In other cases, ephrinB 
ligand reverse signalling can also cause cancer cell migration and invasion by promoting Src 
and Rac1 activation (Pasquale 2010). In human brain glioblastoma tumours, ephrinB2 
phosphorylation induced cellular migration and invasion in the glioblastoma cell line U251 
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(Nakada, Anderson et al. 2010). Additionally, ephrinB2 up-regulation has been shown to 
enhance integrin-mediated attachment, while ephrinB1 up-regulation induces MMP-8 
secretion, which promotes invasion, and STAT3 activation, which is involved in cancer 
progression (Tanaka, Sasaki et al. 2007; Pasquale 2010). 
 
 
1.1.5.3 Breast cancer and the EphB4/ephrinB2 model in mammary gland 
carcinoma 
 
Breast cancer is the most common cancer in women. In 2008-2010 in the UK, the rate 
of breast cancer incidence in women was 126 per 100,000, more than three times higher than 
the second most common cancer in women, which is lung cancer (40 per 100,000 women). 
With an estimated survival rate of ~80%, breast cancer maintained a mortality rate of 26 per 
100,000 women in 2008-2010, making it the second most deadly type of cancer in women 
after lung cancer (Office of National Statistics) (http://www.ons.gov.uk/ons/rel/cancer-
unit/cancer-incidence-and-mortality/2008-2010/stb-cancer-incidence-and-mortality-in-the-
united-kindom--2008-2010.html). 
From a pathological perspective, breast cancer can be subdivided in several entities with 
distinct clinical behaviour. Based on gene expression profiling, breast cancer is commonly 
classified in the following five classes: luminal A, luminal B, normal breast-like, HER2-
positive and basal-like (Geyer, Marchio et al. 2009). However, recent genome-wide 
expression profiling was able to identify two new subtypes, namely luminal C and claudin-
low classes (Kittaneh and Gluck 2011). The luminal A subtype represent 40% of all breast 
cancers and are characterized by over-expression of oestrogen receptor (ER) and under-
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expression of HER2 and proliferation-related genes. It is usually associated with favourable 
prognosis (Kittaneh and Gluck 2011). Luminal B breast tumours have a lower expression of 
ER-related genes, variable HER2 expression and higher expression of proliferation-related 
genes. They represent 20% of breast cancers and are associated with higher risk of relapse 
(Kittaneh, Montero et al. 2013). The luminal C intrinsic subtype is distinguished by luminal A 
and B subtypes by the high expression of a cluster of genes of presently unknown function 
which is also present in basal-like and HER2-enriched subtypes (Sorlie, Perou et al. 2001). 
The HER2-positive subtype represents 20-30% of all breast cancers and is characterized by 
over-expression of HER2 and, usually, under-expression of ER and PR. The prognosis for this 
subtype of breast cancer is often poorer compared to the luminal A subtype (Sorlie, Tibshirani 
et al. 2003). The basal-like subtype represents 15% of breast cancers and its name is derived 
from shared gene expression patterns with normal basal epithelial cells. Basal-like tumours 
are often ER-negative, PR-negative and HER2-negative and thus are commonly referred to as 
“triple-negative” breast cancers. They frequently contain BRCA1 mutations and are 
particularly resistant to chemotherapy (Bayraktar and Gluck 2013). The recently recognized 
claudin-low subtype is characterized by over-expression of genes associated with epithelial-
to-mesenchymal (EMT) transition. The majority of these tumours have no expression of 
luminal differentiation markers and are ER, PR and HER2 negative (Prat, Parker et al. 2010). 
Finally, the normal breast-like subtype resembles normal breast tissue with relatively high 
expression of adipose and other non-epithelial cell type genes and low expression levels of 
luminal epithelial cell genes (Rakha, Reis-Filho et al. 2008). 
EphA2 and EphB4 receptors are often over-expressed in breast cancer and correlate 
with cancer progression, while over-expression of EphA4, EphA7 and EphB6 also correlates 
with reduced overall patient survival. Specifically, it was found that EphA2, EphA4, EphA7, 
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EphB4 and EphB6 are highly expressed in human invasive ductal carcinoma (Brantley-
Sieders, Jiang et al. 2011). Clinical data on breast cancer progression has shown that ephrinB2 
expression is lost in 75% of breast cancers sampled, while EphB4 is over-expressed in 65% of 
breast cancers. In most cases, the EphB4 receptor was found in up to 58% of the tumour 
tissue, while ephrinB2 ligand expression is confined to endothelial vascular cells (Kumar, 
Singh et al. 2006). Interestingly, although EphB/ephrinB signalling has been linked to ER, 
HER2 and claudin pathways, no functional correlation between expression levels of these 
proteins has been observed, or indeed investigated, in the context of breast cancer. Based on 
the many studies which have investigated the role of Eph and ephrin proteins in breast cancer, 
it appears that Eph/ephrin expression does not directly correlate with the presence/absence of 
a specific marker (ie ER, PR, HER2, claudin) (Brantley-Sieders, Jiang et al. 2011; Brantley-
Sieders 2012). However, the co-expression of Eph/ephrin proteins with one or more of these 
markers produces an effect on the malignancy of the tumour and patient prognosis (Brantley-
Sieders, Jiang et al. 2011). To the best of our knowledge, a study directly addressing the 
correlation between Eph/ephrin expression and known breast cancer markers has not yet been 
conducted. 
During mammary gland carcinogenesis, ephrinB2 expression diminishes in epithelial 
cells at early stages, while EphB4 expression gradually shifts from myoepithelial cells to 
epithelial cells, following tumour progression. However, once the carcinogenesis process 
reaches its final stages, EphB4 expression is lost or can only be found in anaplastic cells 
interspersed in the tumour mass. This observation suggests that EphB4 functions as a tumour 
suppressor (Nikolova, Djonov et al. 1998). Thus it has been suggested that, during the early 
stages of tumour cell proliferation, EphB4 acts as a tumour suppressor by limiting tumour 
expansion. However, further during tumour development, ephrinB2 expression is lost and 
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EphB4 activity interrupted, allowing the tumour to expand and invade the surrounding tissue 
(Garber 2010). 
Specifically, EphB4 over-expression in epithelial breast cancer cells promotes tumour 
progression and metastasis by acting as a cue for ephrinB2 expressing cells and thus 
enhancing tumour vascularisation. However, ligand-induced EphB4 activity is associated with 
tumour suppression, as it inhibits cell proliferation, motility and invasion (Noren, Foos et al. 
2006). At a molecular level, EphB4 phosphorylation creates SH2 phospho-sites on the 
cytoplasmic tail of the receptor which are bound by Abl and Crk contemporarily. Abl then 
phosphorylates Crk, thus inactivating it and impeding its binding to Cas. This event inhibits 
cell migration, by blocking MMP-2 production, and survival, while promoting apoptosis 
(Noren, Foos et al. 2006). However, by interacting with ephrinB ligands, EphB receptors 
stimulate their oncogenic activity (Pasquale 2010). Therefore, the equilibrium between EphB4 
and ephrinB2 protein levels is crucial to determine the receptor’s function as a tumour 
promoter or suppressor. In the case of low levels of ephrinB2 and high levels of EphB4, the 
latter’s activation will be relatively low. At the same time, EphB4 will strongly activate the 
ephrinB2 reverse signalling pathway, thus promoting angiogenesis by acting as a cue for 
endothelial invading cells. In the opposite case of high levels of ephrinB2 and low levels of 
EphB4, the latter will be strongly activated and function as a tumour suppressor by inhibiting 
cell growth (Noren and Pasquale 2007). Interestingly, ephrinB ligands might also be involved 
in stimulating cell proliferation and survival in breast cancer cell lines by associating with 
ErbB receptors (Vermeer, Bell et al. 2012). In this pathway, ephrinB1 interaction with ErbB1 
or ErbB2 was found to induce high levels of ERK1/2 phosphorylation in HNSCC cells 
(Vermeer, Colbert et al. 2013). 
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In support of these findings, studies have shown that EphB4 kinase activity inhibits cell 
proliferation of human breast cancer cells MDA-MB-435 in tumour xenografts. Instead, over-
expression of an EphB4 kinase deficient mutant in the same model produced faster growing 
and highly metastatic tumours in vivo by activating the ephrinB2 reverse signalling pathway 
in endothelial cells and thus enhancing angiogenesis (Noren, Lu et al. 2004). However, both 
over-expression of the EphB4 receptor in the mammary epithelium of xenograft models 
(Brantley-Sieders, Jiang et al. 2011) and over-expression of ephrinB2 in a NeuT transgenic 
animal model (Haldimann, Custer et al. 2009) accelerated tumour onset and lung metastasis, 
suggesting that strong imbalances towards higher EphB4 or ephrinB2 expression are both 
capable of promoting tumour progression.  
 
 
1.1.5.4 EphB receptors and ephrinB ligands targeted therapies 
 
The importance of Eph/ephrin superfamily members in cancer angiogenesis and 
metastasis has spurred the research for new cancer therapies which target these proteins. 
Antibodies and antagonistic peptides targeting Eph receptors, as well as function-blocking 
soluble Eph receptors, have been widely tested to inhibit ephrin ligand stimulation. Recently, 
anti-Eph/ephrin therapies using EphB4 receptor and ephrinB2 ligand monomers, monoclonal 
antibodies and RNA interference oligonucleotides have been developed (Mosch, 
Reissenweber et al. 2010). In a study by (Krasnoperov, Kumar et al. 2010), anti-EphB4 
monoclonal antibodies were found to inhibit tumour angiogenesis, tumour growth and 
metastasis in mouse xenografts.  
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Given the strong evidence brought forward by many studies regarding the inhibition of 
cancer growth, angiogenesis and metastasis by disrupting Eph/ephrin signalling, many 
research groups have focused their attention on developing small peptides able to bind the 
extracellular domain of Eph receptors in order to disrupt interaction with the cognate ephrin 
ligands. Other similar approaches include the generation of peptides able to disrupt clustering 
of Eph receptors and interaction with other cell membrane receptor tyrosine kinases. As 
reviewed by (Noberini, Lamberto et al. 2012), in the last decade many inhibitory peptides 
have been generated for EphB receptors, including EphB1, EphB2 and EphB4. Recently, 
newly generated molecules which act as peptidomimetics to selectively inhibit the protein-
protein interface between EphB4 and ephrinB2 have also been developed (Duggineni, Mitra 
et al. 2013). EphrinB2 reverse signalling has also been targeted by using a chimeric protein 
consisting of the soluble extracellular domain of EphB4 fused to human serum albumin. By 
impairing ephrinB2 clustering and activation, this molecule is able to inhibit growth factors-
induced migration and invasion of Kaposi sarcoma cells in vitro, while in vivo it increased 
hypoxia and reduced pericyte recruitment and vessel density and perfusion (Scehnet, Ley et 
al. 2009). Similarly, tumour growth and intra-tumoural microvessel density are reduced in 
melanoma cells expressing a soluble monomeric form of the EphB4 receptor (Martiny-Baron, 
Korff et al. 2004). EphrinB1 reverse signalling has been targeted in scirrhous gastric cancer: 
by using a synthetic peptide consisting of the 15 C-terminal amino acids of ephrinB1 fused to 
HIV-TAT, ephrinB1 interaction with Dishevelled was disrupted, thus blocking RhoA 
activation and MMP secretion. Ultimately, this diminished tumour cell migration and cancer 
metastasis (Tanaka, Kamata et al. 2010). In the near future, these short synthetic peptides and 
peptidomimetics bode well for the development of new targeted anti-cancer therapies. 
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The kinase domain of Eph receptors has also been targeted using various small 
molecule inhibitors. For instance, NVP-BHG712, which inhibits EphB4 kinase activity, 
suppressed VEGF-driven vessel formation and angiogenesis (Martiny-Baron, Holzer et al. 
2010). In pilot studies, the use of siRNA against EphB4 resulted in inhibition of malignant 
cell behaviour. Moreover, recombinant Eph receptors and ephrin ligands are also considered 
as cancer targeting agents for specific drug delivery or to activate the T-cell immune response 
(Pasquale 2010). 
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1.2  Syntenin-1 
 
1.2.1  The PDZ domain-containing protein syntenin-1 
 
Syntenin-1 is a PDZ domain-containing protein initially identified as a binding partner 
of syndecan-1 with hypothesized scaffolding function (Grootjans, Zimmermann et al. 1997). 
In a separate study, syntenin-1 was also identified as melanoma differentiation-associated 
gene 9 (mda9) in SV-40 immortalized 
human melanocytes and human 
melanoma cells treated with 
recombinant IFN-γ (Lin, Jiang et al. 
1998). It contains 298 amino acids and 
is composed of the N-terminal domain 
(NTD), two PDZ domains and the C-
terminal domain (CTD). The NTD is 
113 amino acids long and contains three 
LYPXL sequences (where X is any 
aminoacid) centred at position 5, 47 and 
51. The first of these sequences has 
been identified as a ubiquitin binding 
motif (Rajesh, Bago et al. 2011). The 
PDZ1 and PDZ2 domains are 80 to 100 
amino acids long each and comprise of 
Table 1.3: interacting partners of syntenin-1 (Beekman 
and Coffer 2008). 
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six β-sheets and two α-helices. The short CTD is only 24 amino acids long. The PDZ 
domains, which carry out most of the protein’s functions, bind multiple PDZ binding motif 
sequences (Beekman and Coffer 2008). A list of reported proteins which interact with 
syntenin-1 can be found in table 1.3. The name “syntenin” was coined after preliminary 
evidence showed that this protein could interact with the COOH-terminal domain of all four 
syndecans (Sarkar, Boukerche et al. 2008). Syntenin-1 is widely expressed in all adult tissues 
(Grootjans, Zimmermann et al. 1997; Lin, Jiang et al. 1998; Zimmermann, Tomatis et al. 
2001) and is particularly abundant in the skin, spinal cord, heart and lung during foetal 
development of mouse embryos (Jeon, Das et al. 2013). Based on database entries, a 
homologous protein of syntenin-1 was identified and named syntenin-2. This protein shares 
70% identity of the PDZ domains of syntenin-1 and is expressed as isoform α or isoform β. 
Syntenin-2β lacks 85 amino acids at the N-terminus compared to isoform α. Syntenin-2 is also 
capable of PDZ-mediated binding, but does not share all the same partners with syntenin-1. 
Interestingly, the two proteins were found to form heterodimers as well as homodimers 
(Koroll, Rathjen et al. 2001). 
 
 
1.2.1.1 Syntenin-1’s localization 
 
PDZ domain-containing proteins are often localized on the cytoplasmic side of the 
plasma membrane and are restricted to specific subcellular compartments. In epithelial cells, 
syntenin-1 is located at areas of cell-cell contacts where it co-localizes with F-actin, 
syndecans, E-cadherin, β-catenin and α-catenin. In fibroblasts, syntenin-1 localizes at focal 
adhesions and stress fibres (Zimmermann, Tomatis et al. 2001). Phosphatidyl-Inositol 4,5-
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bisphosphate (PIP2) and phospholipase Cδ assist its anchorage to the plasma membrane 
(Zimmermann, Meerschaert et al. 2002). Syntenin-1 is also localized in the endoplasmic 
reticulum, intermediate compartment, cis-Golgi and apical endosomes (Fernandez-Larrea, 
Merlos-Suarez et al. 1999).  
 
 
1.2.1.2 Characteristics of syntenin-1’s PDZ domains 
 
Syntenin-1 contains two PDZ domains very similar in sequence, which vary in binding 
affinity to different PDZ binding motifs on different target proteins. However, in most cases 
both PDZ domains cooperate in binding to PDZ binding sequences (Grootjans, Reekmans et 
al. 2000). For example, the PDZ-mediated interaction of syntenin-1 with syndecans and 
neurexins is strengthened upon binding of both PDZ domains to the same PDZ binding 
sequence, although individually the PDZ2 domain has a higher affinity than the PDZ1 
domain. When the PDZ2 domain of syntenin-1 interacts with the PDZ binding motif 
sequence, PDZ1 is able to bind to the same sequence in a non-conventional manner 
(Grembecka, Cierpicki et al. 2006). This study confirms previous reports that the cytoplasmic 
sequence of ephrinB ligands does not detectably associate with syntenin-1’s PDZ1 domain 
and only weakly with PDZ2 when tested separately (Lin, Gish et al. 1999) and that strong 
interaction was only detected when both PDZ domains were present (Song, Vranken et al. 
2002). The selectivity of the PDZ interaction is mediated by the side chains of amino acids P0 
and P-2 of the target protein. There are three known types of PDZ binding sequences which 
have been reported and to which syntenin-1 can bind: class I sequences contain a X[S/T]Xɸ 
motif at amino acids P-3P-2P-1P0 of the PDZ-binding motif (where ɸ represents a hydrophobic 
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side chain and X any side chain); class II sequences contain a XɸXɸ motif at amino acids P-
3P-2P-1P0; class III sequences contain a X[D/E]Xɸ motif at amino acids P-3P-2P-1P0 (Ivarsson 
2012). Additionally, syntenin-1 is capable of low-to-medium affinity degenerative binding to 
unconventional PDZ-binding motifs (Kang, Cooper et al. 2003; Grembecka, Cierpicki et al. 
2006). At the structural level, Val209, Gly210 and Phe211 in the PDZ2 domain form the 
binding pocket for the C-terminal P0 aminoacid of the target protein, while Phe213 interacts 
with aminoacid P-2. Interestingly, a glutamic acid in position P-3 of the target protein  contacts 
Arg128 of the PDZ1 domain of the neighbouring syntenin-1 protein, which is part of the 
head-to-tail homodimer, and stabilizes the PDZ interaction (Grembecka, Cierpicki et al. 
2006). 
It has been suggested that the PDZ1 domain can have a chaperone-like function by 
stabilising folding of the PDZ2 domain. (Boukerche, Aissaoui et al. 2010). This mode of 
regulation seems to be important for interaction of syntenin-1 PDZ2 domain with c-Src 
(Boukerche, Su et al. 2008).  
Phosphorylation of Ser/Thr/Tyr residues located in close proximity or within the PDZ-
binding motif is known to modulate PDZ-mediated binding (Ivarsson 2012). For example, 
tyrosine phosphorylation at position -1 of syndecan-1 disrupts its association with syntenin-1 
(Sulka, Lortat-Jacob et al. 2009), while phosphorylation of serine at position -9 of ephrinB 
ligands increases binding to GRIP proteins (Essmann, Martinez et al. 2008). Interestingly, 
interaction of ephrinB ligands with other PDZ domain-containing proteins remains unaffected 
by phosphorylation events. For example, tyrosine phosphorylation at position -2 and/or -3 of 
ephrinB ligands does not alter association with the PDZ domain-containing phosphatase 
FAP1 (PTPL1) (Lin, Gish et al. 1999). In the case of syntenin-1 interaction with ephrinB 
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ligands, phosphorylation of tyrosine at position -2, but not -3, was found to impair PDZ-
mediated binding of syntenin-1 (Lin, Gish et al. 1999). 
 
 
1.2.1.3 Syntenin-1’s CTD and NTD functions 
 
Apart from PDZ domains, the NTD and CTD also play an important role in syntenin-1 
functions. The NTD, for example, controls localization of the protein to the plasma 
membrane; it is necessary for homo- and hetero-dimerization; and can interact with 
transcription factors Sox4 and Eukaryotic translation Initiation Factor 4A (EIF4A). Also, the 
NTD contains various tyrosine residues which can be phosphorylated by Src kinases and act 
as docking sites for zeta-chain-associated protein 70 (ZAP-70) and Src kinases (Beekman and 
Coffer 2008). Recently, a study on syntenin-1 interaction with ubiquitylated proteins has 
uncovered the importance of the NTD for syntenin-1 binding to ubiquitin molecules. More 
specifically, the L
4
YPXL
8
 domain proved to be indispensable in this context (Rajesh, Bago et 
al. 2011). Also, the three LYPXL domains present in the NTD and centred at positions 5, 47 
and 51, were found to be necessary for the interaction with ALIX during syndecan-lead cargo 
recruitment to exosomal compartments (Baietti, Zhang et al. 2012).  
A role for the NTD and CTD in modulating syntenin-1 targeting to the plasma 
membrane was proposed by (Wawrzyniak, Vermeiren et al. 2012). In this study, the authors 
reported that phosphorylation of Tyr56, which is located in the NTD, decreased syntenin-1 
localization at the plasma membrane, while the negative charges of residues K280/R281 at the 
CTD increased cell membrane localization. The shorter CTD is also required for CD63 high 
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affinity interaction with syntenin-1 while the NTD is involved in shifting CD63 clathrin-
dependent to clathrin-independent endocytosis (Latysheva, Muratov et al. 2006). 
 
 
1.2.1.4 Syntenin-1 mediates protein trafficking and recycling 
 
Syntenin-1 interacts with many different proteins located at the cell surface and by 
doing so is able to modulate both trafficking and recycling processes of its targets (Beekman 
and Coffer 2008). An extensive study by (Zimmermann, Zhang et al. 2005) reported that 
syntenin-1 modulates syndecan recycling dynamics via interaction with PI(4,5)P2 through 
Rab11 and Arf6 positive endosomal compartments. Furthermore, cell membrane receptors 
associated with syndecans (e.g. FGF receptors) might be recycled together with the syntenin-1 
– syndecan complex. Interestingly, syndecan-4 phosphorylation at Ser183 disrupts association 
with syntenin-1, thus suggesting that phosphorylation could play a critical role in modulating 
syndecan recycling via syntenin-1 (Koo, Jung et al. 2006). A recent study by (Baietti, Zhang 
et al. 2012) has also reported the formation of a syndecans – syntenin-1 – ALIX tripartite 
complex in connection with cargo recruitment to exosomal compartments. The authors 
demonstrated that clustering of syndecan cargo, such as FGF receptors, induces recruitment of 
syntenin-1 – ALIX. The syndecan – syntenin-1 – ALIX complex is then able to recruit 
syndecan cargo to specific CD63 positive budding exosomes and actively supports budding 
processes and the production of exosomes.  
Alternatively, syntenin-1 can also inhibit protein internalization by retaining the target 
on the plasma membrane. Deletion of the C-terminal valine of Notch-associated Delta1 ligand 
as well as syntenin-1 depletion via siRNA caused decreased presence of Delta1 on the cell 
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surface (Estrach, Legg et al. 2007). Similarly, syntenin-1 interaction with tetraspanin CD63 
impairs its internalization (Latysheva, Muratov et al. 2006), possibly by competing with the 
clathrin-dependent endocytosis-associated protein AP2 and shifting CD63 internalization to a 
clathrin-independent endocytosis pathway (Janvier and Bonifacino 2005). 
Syntenin-1 is also involved in protein trafficking to the cell surface, as mutation of the 
C-terminal valine of proTGFα was shown to disrupt association with syntenin-1 and cause 
proTGFα’s retention in the endoplasmic reticulum (Fernandez-Larrea, Merlos-Suarez et al. 
1999). 
 
 
1.2.1.5 Syntenin-1 plays various roles as a scaffolding protein 
 
Given its ability to bind many different target proteins, syntenin-1 is known to have a 
crucial role as a scaffolding protein, taking part in many different pathways and processes. In 
neurons, syntenin-1 localizes at sites of synapse formation and growth cones. Interactions 
between syntenin-1 and adhesion molecules, such as SynCAM, neurexin and neurofascin, as 
well as cytoplasmic proteins, such as Sch-1 and PICK1, may contribute to synaptic structure 
formation. Association of syntenin-1 with glutamate receptors GluR5 and GluR6 might be 
important to induce membrane protrusions during brain development (Beekman and Coffer 
2008). A detailed study by (McClelland, Sheffler-Collins et al. 2009) reported that syntenin-1 
interaction with ephrinB ligands is necessary for the recruitment of pre-synaptic machinery 
during the EphB/ephrinB driven development of presynaptic and postsynaptic compartments 
in neurons. 
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Syntenin-1 was initially found to interact with ephrinB ligands by (Lin, Gish et al. 
1999). Since then, there has been much speculation on the possible significance of this 
interaction. It has been widely hypothesized that syntenin-1 might facilitate ephrinB 
clustering, given its role as a scaffolding protein (Cowan and Henkemeyer 2002). However, a 
study by (Grembecka, Cierpicki et al. 2006) reported that from a structural perspective it is 
more probable that preferential binding occurs after ephrinB multimerization. 
 Other syntenin-1 functions involve Interleukin-5 (IL-5) mediated activation of Sox4, by 
acting as a bridge between the transcription factor and the IL-5 receptor α (Sarkar, Boukerche 
et al. 2004).  A recent study by (Beekman, Vervoort et al. 2012) has also reported that 
syntenin-1 interaction with the C-terminus of Sox4 causes syntenin-1 relocation to the 
nucleus, where it stabilizes Sox4 expression by inhibiting proteasomal-driven degradation of 
the transcription factor. Syntenin-1 is also a component of cell adhesion sites, microfilaments 
and apical early endosomes and may directly or indirectly affect Rho family GTPases activity 
(Koo, Lee et al. 2002).   
Recently, a study by (Rajesh, Bago et al. 2011) has reported that syntenin-1 may play a 
pivotal role in ubiquitin-dependent sorting of its transmembrane cargo. Syntenin-1 is able to 
bind mono-ubiquitin through a non conventional pocket which includes amino acids 71-74 on 
the ubiquitin molecule with residues 8-12 providing a stabilizing interaction. The L
4
YPXL
8
 
sequence in syntenin-1 is fundamental for ubiquitin binding. Furthermore, syntenin-1’s ability 
to bind ubiquitin is controlled by Ulk1 kinase, which can phosphorylate syntenin-1 at Ser6, 
thus inhibiting ubiquitin binding. The authors speculate that syntenin-1 plays a role in sorting 
of ubiquitylated proteins in endocytic vesicles with Ulk1 kinase regulating this trafficking 
pathway. 
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1.2.1.6 Syntenin-1’s role as a modulator of FAK/Src signalling 
 
One of the well described roles of syntenin-1 as a scaffolding protein is linked to FAK 
and c-Src pathway activation upon cell adhesion to fibronectin. This event induces syntenin-1 
expression and PKCα phosphorylation and subsequent activation of c-Src and FAK. At the 
molecular level, cell adhesion to fibronectin leads to PIP2-bound syntenin-1 association with 
syndecan-4 and PKCα. The latter then binds PIP2, thus inducing PKCα auto-phosphorylation 
and activation, which is accompanied by FAK phosphorylation and syntenin-1 expression 
through a positive feedback loop. FAK is recruited to phospho-PKCα sites where it becomes 
activated and associates with c-Src, causing its phosphorylation and activation. The outcome 
of phosphorylation of these two kinases is the activation of p38, JNK, ERK and nuclear factor 
NF-ᶄB pathways. In this process syntenin-1 acts as a scaffolding protein by recruiting and 
holding into complex PKCα, FAK and c-Src, allowing these kinases to interact and activate 
each other. A simplified diagram of this pathway is illustrated in figure 1.11. Down-regulation 
of either syntenin-1 or 
PKCα causes the other to 
decrease in expression 
levels, which suggests that 
these two proteins are 
interdependent of each other 
and necessary for 
fibronectin-dependent 
activation of FAK and c-Src 
(Hwangbo, Kim et al. 2010). Figure 1.11: model of signalling pathway regulated by syntenin-1 
through its interaction with c-Src (Boukerche, Su et al. 2008). 
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The same group also found that syntenin-1 modulates collagen-1-induced stimuli by 
recruiting the integrin-linked kinase (ILK)-PINCH1-α-parvin (IPP) complex to integrin β1-
associated signalling platform, leading to Akt, Rac1 and ERK1/2 activation (Hwangbo, Park 
et al. 2011).  
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1.2.2  Syntenin-1 promotes cancer metastasis and   
  angiogenesis 
 
Syntenin-1 is over-expressed in many highly metastatic tumours. It was initially 
identified as a melanoma differentiation-associated gene (mda9) by (Lin, Jiang et al. 1998). In 
human melanoma cells, syntenin-1 contributes to the activation of FAK and c-Src kinases 
upon cell interaction with fibronectin, which in turn cause activation of JNK, p38 and NF-ᶄB 
pathways, thus promoting anchorage-independent growth and metastasis (Beekman and 
Coffer 2008; Boukerche, Su et al. 2008). This pathway can be inhibited by the metastasis 
suppressor Raf kinase inhibitor protein (RKIP), which physically interacts with syntenin-1 
and prevents its association with FAK and c-Src kinases (Das, Bhutia et al. 2012). Syntenin-
1-mediated activation of c-Src kinases also induces EGF receptor activation in uroepithelial 
cells, thus increasing their proliferation and invasion properties (Dasgupta, Menezes et al. 
2013). Also, syntenin-1 activation of NF-ᶄB through FAK phosphorylation induces activation 
of pro-MMP-2, which is 
then secreted and 
induces migration and 
invasion by increasing 
degradation of ECM 
proteins (Boukerche, Su 
et al. 2008; Sarkar, 
Boukerche et al. 2008; 
Boukerche, Aissaoui et 
Figure 1.12: signalling pathways activated by syntenin-1 to increase 
migration, invasion and metastasis (Sarkar, Boukerche et al. 2008). 
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al. 2010). The PDZ2 domain of syntenin-1 plays a fundamental role in this process by binding 
to c-Src and thus recruiting it in FAK/Src complexes. In fact, mutations within the PDZ2 
domain completely abolish syntenin-1’s effect on migration and metastasis in general 
(Boukerche, Aissaoui et al. 2010). Syntenin-1 can also indirectly activate the PI3K-Akt and 
the ERK1/2 pathways, which are involved in invasion processes, as illustrated in figure 1.12 
(Sarkar, Boukerche et al. 2008).  
Syntenin-1-dependent activation of the PI3K-Akt pathway in human melanoma cells 
has recently been linked to increased angiogenesis. As previously described, fibronectin-
induced activation of FAK and c-Src kinases is modulated by syntenin-1 and triggers the 
PI3K-Akt pathway. Activated Akt causes HIF-1α translocation to the nucleus, which induces 
insulin growth factor-binding protein-2 (IGFBP-2) expression. After secretion, IGFBP-2 
interacts with αVβ3 integrin on 
endothelial cells, causing 
activation of the PI3K-Akt 
pathway and subsequent 
generation of the pro-angiogenic 
factor VEGF-A (see figure 1.13). 
Thus, syntenin-1 plays an 
important role in inducing 
angiogenesis in human melanoma 
(Das, Bhutia et al. 2013). 
  
Figure 1.13: hypothetical model of syntenin-1 induction of 
angiogenesis (Das, Bhutia et al. 2013). 
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1.2.2.1 Syntenin-1’s role in breast cancer 
 
Studies on MCF7 breast carcinoma cells have observed that syntenin-1 over-expression 
increased their migration and invasion properties (Koo, Lee et al. 2002; Sarkar, Boukerche et 
al. 2008). Recently, high syntenin-1 expression levels have been linked with tumour size, 
lymph node status and recurrence in breast cancer. Syntenin-1 was found to correlate with 
patient overall survival and disease free survival, acting as an independent prognostic factor 
for these values. The same study reported that over-expression of syntenin-1 increased cell 
migration of MDA-MB-231 breast cancer cells in vitro and proliferation in vivo. The authors 
linked these processes to syntenin-1-induced over-expression of integrin β1 and subsequent 
increase in ERK1/2 activity, which lead to cell migration and angiogenesis. These findings 
were supported by the observation of increased metastasis to lungs and tumour growth in 
orthotopic xenograft tumour models in nude mice. However, syntenin-1 over-expression did 
not increase MMP expression, suggesting that only cell migration and not invasion is induced 
in this model (Yang, Hong et al. 2013). Although this study could not find any correlation 
between the expression levels of syntenin-1 and oestrogen receptors (ER), progesterone 
receptors (PR) or human epidermal growth factor receptor 2 (Her-2), a report by (Qian, Li et 
al. 2013) identified a negative correlation between syntenin-1 expression and ER positivity in 
a large panel of breast cancer cell lines. Moreover, stimulation of ER positive MCF7 cells 
with 17-β estradiol down-regulated syntenin-1 expression. In this study, syntenin-1 was also 
found to increase cell proliferation by promoting cyclin E expression in ER negative breast 
cancer cell lines, thus providing ER negative tumours with an alternative means to promote 
tumour growth. 
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1.3  Hypothesis and research objectives 
 
Eph tyrosine kinase receptors and ephrin ligands are involved in various stages of 
embryogenesis, organ development and tissue homeostasis. Furthermore, increasing evidence 
has shown that these proteins play an important role in cancer progression. Although Eph 
forward signalling has been widely studied, less is known on ephrin reverse signalling and, 
particularly, PDZ-dependent signalling.  
One of the best characterized PDZ domain-containing partners of ephrinB ligands is 
syntenin-1, a scaffolding protein known for its ability to modulate trafficking of membrane 
proteins and facilitate the formation of signalling complexes.   Whilst the significance of the 
ephrinB – syntenin-1 interaction is still largely unknown, there is a certain degree of overlap 
between ephrinB and syntenin-1 pathways. Endocytosis of ephrinB ligands is fundamental for 
EphB/ephrinB-induced repulsion between contacting cells and can also be triggered to 
terminate ephrinB reverse signalling upon prolonged stimulation with EphB receptors. The 
molecular mechanisms underlying this process are still not completely understood and widely 
debated. Previous work from our group has reported that syntenin-1 binds to CD63 via PDZ-
mediated interaction and modulates its internalization. Therefore, syntenin-1 might also be 
capable of modulating ephrinB internalization. Finally, both ephrinB ligands and syntenin-1 
have been shown to affect progression in breast, colon, pancreatic and ovarian cancers.  
The overall aim of this study was to understand how the ephrinB – syntenin-1 complex 
may function in the context of breast cancer. Specific aims of our study were as follows: 
1. to examine the contribution of syntenin-1 to ephrinB2 signalling pathways; 
2. to establish the role of syntenin-1 in trafficking of ephrinB2; 
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3. to analyse the functional consequences of disrupting the ephrinB2 – syntenin-1 axis in 
the context of breast cancer epithelial cells. 
 
  
 
 
 
 
MATERIALS AND METHODS 
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2.1  Cell culture and cell lines 
 
2.1.1  Cell lines 
 
Origin and characteristics of all cell lines used in this study are listed in table 2.1 below. 
MCF7, T47D and HEK293T cells were from Cancer Research UK, while MCF7 TetOn 
tetracycline inducible cells were purchased from Clontech. Information on growth culture 
medium and supplements used for each cell line is listed in Appendix 1. Appendix 3 contains 
recipes of all solutions used in this study. 
 
Cell line Tissue Type ER Tumour 
MCF7 Breast Epithelial Positive Adenocarcinoma 
T47D Breast Epithelial Positive Ductal carcinoma 
MCF7 TetOn Breast Epithelial Positive Adenocarcinoma 
HEK293T Embryonic Kidney Epithelial Negative NA 
 
Table 2.1: list of cell lines used in this study. 
 
 
2.1.2  Cell maintenance 
 
MCF7 and HEK293T cells were routinely grown in T25 and T75 flasks (Corning) in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Calf Serum 
(FCS) and penicillin/streptomycin antibiotics. Stably transfected MCF7 cells were grown in 
supplemented DMEM medium containing 1 µg/ml Puromycin. T47D cells were grown in 
Roswell Park Memorial Institute (RPMI) medium with 10% FCS supplemented with 
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penicillin/streptomycin. MCF7 tetracycline inducible cell lines (MCF7 TetOn) were 
maintained in DMEM medium supplemented with 10% tetracycline-free FCS, 
penicillin/streptomycin and 100 µg/ml Geneticin. Stably transfected MCF7 TetOn cells were 
grown in the above medium supplemented with 100 µg/ml Zeocin. Stably transfected MCF7 
TetOn cells transduced with lentiviruses were grown in the presence of 100 µg/ml Zeocin and 
1 µg/ml puromycin. All cell lines were maintained in a 37°C, 5% CO2 incubator (Galaxy R 
CO2 Incubators, RS Biotech) to ensure optimal growth. When passaging cells, growth 
medium was discarded and cells were washed with warm 1x Phosphate Buffer Saline (PBS). 
Cells were subsequently detached from plastic by incubating with 0.05% Trypsin-EDTA 
solution at 37°C for 3-5 minutes. Floating cells were re-suspended in 5 ml of complete growth 
medium and centrifuged at 400 g for 3 minutes. The cell pellet was suspended in complete 
growth medium and cells were seeded at required density. 
 
 
2.1.3  Freezing and Thawing Procedures 
 
After reaching 80% confluency, cells were washed, detached and centrifuged as 
described in section 2.1.2. The cell pellet was then suspended in 1 ml of freezing medium and 
transferred into a 1 ml CryoTube
TM
 vial (Nunc). Vials were wrapped in paper towels and 
placed at -80°C for 24 hours before being transferred to liquid nitrogen for long-term storage. 
When thawing cells from liquid nitrogen, frozen vials were briefly incubated at 37°C in 
a water bath until completely thawed and then transferred to 4 ml of warm complete medium. 
Cells were subsequently centrifuged at 400 g for 3 minutes and cell pellet was gently 
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suspended in complete growth medium. Cells were seeded in T25 flasks and growth medium 
was changed on the next day to remove floating cell debris.  
 
 
2.1.4  Transfection of eukaryotic cells using FuGene® 6  
  reagent 
 
Following manufacturer’s recommendations, cells were split 16-24 hours before 
planned transfection and plated in 35 mm or 60 mm Petri dishes (Corning) in order to achieve 
50-80% confluency on the day of transfection. Ratio of FuGene® 6 transfection reagent 
(Roche) to plasmid DNA quantity was maintained at 3:1 (3 µl of reagent to 1 µg of plasmid) 
for all transfections. Quantities used for different plating conditions can be found in table 2.2. 
Before use, FuGene® 6 transfection reagent was incubated at room temperature for 5 minutes 
and then added to serum-free medium and incubated at room temperature for additional 5 
minutes. Plasmid DNA was thawed, vortexed for a few seconds and spun down in a mini 
centrifuge before being added to FuGene® 6 reagent-containing medium. The transfection 
mixture was then delicately mixed by tapping and incubated for 25 minutes at room 
temperature to allow lipid-DNA complexes to form. The FuGene® 6 reagent-DNA solution 
was added directly to the growth medium and gently mixed to allow even distribution of 
lipid-DNA complexes. Cells were subsequently placed in the incubator (37°C, 5% CO2) for 
24-48 hours before being used. Co-transfections were conducted maintaining a 1:1 ratio of 
plasmid DNA. A ratio of 3:1 was used when wanting to achieve antibiotic resistance: 3 parts 
of gene-containing plasmid to 1 part of antibiotic resistance-containing plasmid. A list of 
plasmids used in this study is shown in table 2.3 at the end of section 2.1.9. 
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Container Surface Area 
(cm
2
) 
FuGene® 6 
(µl) 
DNA (µg) Serum Free 
Medium (µl) 
Total Volume 
of Medium (ml) 
35 mm 8 3.0 – 9.0 1.0 – 2.0 100 2.0 
60 mm 21 6.0 – 20.0 2.0 – 4.5 200 4.0 – 6.0 
100 mm 55 17.0 – 51.0 5.6 – 11.0 600 10.0 
 
Table 2.2: quantities and volumes of DNA, FuGene® 6 transfection reagent and growth medium used for each 
culture dish in this study following manufacturer’s guidelines. 
 
 
2.1.5  Transfection of eukaryotic cells using FuGene® 6  
  reagent for lentivirus production 
 
Following the same procedure as described in paragraph 2.1.4, HEK293T cells were 
plated on 6 or 10 cm dish (Corning) the day before in order to obtain 70-80% confluency on 
day of transfection. Cells were co-transfected with three plasmids including the lentiviral-
based plasmid of interest, psPAX2 and pMD2.G at a ratio of 2:2:1, respectively. The 
lentiviral-based plasmid contained the gene of interest, while the psPAX2 and pMD2.G 
plasmids encoded the proteins necessary for the production of lentivirus particles. After 24 
hours the antibiotics-free medium was replaced with complete growth medium. Lentiviral 
supernatant was harvested at 48 and 72 hours after transfection and cells were supplemented 
with fresh complete growth medium. The culture supernatant was centrifuged at 400 g for 5 
minutes to remove cell debris, filtered using 0.22 µm filters (Millipore) and kept at 4°C for 
short term storage if not used immediately. For long term storage, lentiviral supernatant was 
frozen at -80°C. Cells for lentiviral infection were plated on T25 or T75 flasks 16-24 hours 
before planned infection in order to reach 30-50% confluency on the day of infection. Growth 
medium was replaced with lentiviral supernatant supplemented with sterile Polybrene (8 
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µg/ml) and placed in the incubator (37°C, 5% CO2) for 24 hours. Cells were re-infected on 
the following day with fresh lentiviral supernatant (supplemented with Polybrene) and 
incubated for further 24 hours. The supernatant was subsequently replaced with fresh 
complete growth medium and cells were used for further analysis as required. 
 
 
2.1.6  Generation of stable ephrinB2 expressing MCF7 cells 
 
As described in section 2.1.4, MCF7 cells were co-transfected with pCDNA3.1(-)-
ephrinB2-Flag and pCDNA3.1(-)-puro plasmids at a ratio of 3:1 respectively. The former 
endoced N-terminus Flag tagged human ephrinB2 wild type cDNA, while the latter encoded 
for puromycin resistance. Growth medium was changed 24 hours after transfection and at 48 
hours cells were lifted and seeded on a T75 flask. Puromycin was subsequently added to the 
growth medium at a final concentration of 1 µg/ml in order to select cells for antibiotic 
resistance. After selection (2-3 weeks time), cells were stained with anti-Flag mAb and sorted 
for positive expression using Fluorescent Activated Cell Sorting (FACS) as described in 
section 2.3.2. The resulting cell line was called MCF7-ephrinB2. 
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2.1.7  Generation of tetracycline inducible MCF7 cells  
  expressing ephrinB2, ephrinB2/G and ephrinB2/∆V  
 
As described in section 2.1.4, MCF7 TetOn cells were co-transfected with pBI-
ephrinB2-Flag constructs (pBI-ephrinB2-Flag, pBI-ephrinB2/G-Flag, pBI-ephrinB2/∆V-Flag) 
and pZeoSV at a ratio of 3:1, respectively. Growth medium was changed 24 hours after 
transfection and at 48 hours cells were lifted and seeded on a T75 flask. Zeocin was then 
added to the medium at the initial concentration of 400 µg/ml for 3-4 days. Growth medium 
was subsequently changed and Zeocin concentration was reduced to 100 µg/ml. After further 
selection (3-4 weeks), cells were stained with anti-Flag mAb and sorted for positive 
expression using FACS as described in section 2.3.2. The resulting cell lines were called 
MCF7 Tet-ephrinB2, MCF7 Tet-ephrinB2/G and MCF7 Tet-ephrinB2/∆V. 
Tetracycline inducible cell lines were routinely stimulated with 1 µg/ml doxycycline, 
according to manufacturer’s guidelines (Clontech), for 48 hours to ensure maximum protein 
expression. Unless otherwise specified, all MCF7 tetracycline inducible cell lines were 
stimulated in this manner 24 hours after plating for any experiment. 
 
 
2.1.8  Generation of syntenin-1 knock down tetracycline  
  inducible ephrinB2 expressing MCF7 cells 
 
MCF7 Tet-ephrinB2 cells were infected with lentiviral particles derived after 
transfection with pLKO.1-puro plasmid encoding shRNA which targets syntenin-1 (purchased 
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from Sigma). A list of tested shRNA sequences targeted against styntenin-1 is shown in 
Appendix 2. pLKO.1-puro plasmid encoding shRNA (5) was used to infect cells, which were 
then selected in growth medium containing 1 µg/ml puromycin. After selection (2-3 weeks), 
syntenin-1 expression was analyzed by Western blotting (WB) to assess the level of syntenin-
1 knock down.  
 
 
2.1.9  Generation of RFP expressing MCF7 tetracycline  
  inducible cell lines and GFP expressing T47D cells 
 
MCF7 TetOn cell lines were transfected with the pBabe-RFP plasmid, using FuGene6® 
transfection reagent (protocol described in section 2.1.4). RFP-expressing cells were selected 
using 1 µg/ml puromycin. T47D cells were infected with lentiviral particles encoding GFP 
(pVLTHM vector), as described in section 2.1.5. FACS analysis was then performed to select 
the T47D cell population expressing GFP (section 2.3.2). All plasmids used in this study are 
listed in table 2.3. 
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Plasmid Gene encoded Resistance Source 
pCDNA3.1(-) empty puromycin provided by F. 
Berditchevski 
pCDNA3.1(-)-ephrinB2-
Flag 
human ephrinB2-Flag NA provided by F. 
Berditchevski 
pZeoSV empty Zeocin Invitrogen 
pBI empty NA provided by F. 
Berditchevski 
pBI-ephrinB2-Flag human ephrinB2-Flag NA made in-house 
pBI-ephrinB2/G-Flag human ephrinB2/G-Flag NA made in-house 
pBI-ephrinB2/∆V-Flag human ephrinB2/∆V-Flag NA made in-house 
pLKO.1-shSyntenin-1 shRNA against syntenin-1 puromycin Sigma 
psPAX2 lentivirus packaging NA Addgene 
pMD2.G lentivirus envelop NA Addgene 
pCMV2-PTPL1-Flag human PTPL1-Flag NA provided by F. 
Berditchevski 
p-EGFP-PICK1-myc human PICK1-myc NA provided by F. 
Berditchevski 
GRIP1-myc human GRIP1-myc NA provided by F. 
Berditchevski 
GRIP2-myc human GRIP2-myc NA provided by F. 
Berditchevski 
PAR3-Flag human PAR3-Flag NA provided by F. 
Berditchevski 
pCDNA3.1(-)-RGS3-myc human PDZ-RGS3-myc NA provided by G. 
Willars 
pVLTHM Green Fluorescent Protein NA Addgene 
pBabe-RFP Red Fluorescent Protein puromycin provided by F. 
Berditchevski 
 
Table 2.3: list of plasmids used in this study. 
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2.1.10 3D cultures in collagen 
 
The day before embedding cells in 3D collagen, cells were detached from tissue culture 
dish and re-plated as described in section 2.1.2. Collagen Type I was reconstituted from 
powder solution by leaving O/N on a rotating platform in 0.1 M acetic acid at a concentration 
of 1.6 mg/ml and was always kept on ice when used. On the day of experiment, cells were 
detached and counted using a Burker chamber (Marienfeld). 100 µl of collagen were diluted 
with 110 µl of complete growth medium and neutralized with 10 µl of 1M NaOH. 10
4
 cells in 
100 µl of growth medium were then added to the collagen mixture (ratio of 1:2 (v/v)) and 
mixed thoroughly. Collagen mixture containing cells (40-50 µl containing ~1.5*10
3
 cells) was 
then plated in an 8-well chamber glass slide (Labtek) and incubated at 37°C, 5% CO2 for 20-
30 minutes to allow collagen to solidify. Subsequently, 400 µl of complete growth medium 
was carefully added to each well and the slide was returned to an incubator for long-term 
culture. Growing medium was changed every 4-5 days by replacing 200 µl of growth 
medium. During culturing, cells in selected wells were stimulated with the EphB4/Fc chimera 
molecule (R&D) every two days. Prior to use, EphB4/Fc (100 µg/ml) was pre-clustered with 
anti-human Fc IgG antibody (2.5 mg/ml) at a ratio of 10:1 (v/v) for 1 hour at 4ºC, as 
described in the study by (Palmer, Zimmer et al. 2002). EphB4/Fc was added directly to the 
growth medium at a final concentration of 5 µg/ ml. 
 
 
  
Materials and Methods 
~ 78 ~ 
 
2.1.11 3D cultures in 2% Matrigel 
 
The day before embedding in 3D Matrigel, cells were detached from the tissue culture 
dish and re-plated as described in section 2.1.2. Frozen Matrigel aliquots were left to thaw on 
ice in a cold room until ready to use and were kept on ice during the preparation of cells. On 
the day of the experiment, the wells of the 8-well chamber glass slide (Labtek) was coated 
with a mixture composed of 50% MG (v/v) in complete growth medium (40 µl/well) and 
placed in incubator at 37°C for 20-30 minutes to allow MG to solidify. In the meantime, cells 
were detached and counted using a Burker chamber (Marienfeld). In order to obtain a 
concentration of 10
4
 cells/ml. Cell suspension was added to 4% MG in complete growth 
medium at a ratio of 1:1 (v/v) and mixed thoroughly. Cell suspension containing ~10
3
 cells 
2% MG (v/v) was then added to wells (400 µl/well) and the slide was placed in the incubator 
for long-term culture. Growing medium was changed every 4-5 days by replacing 200 µl of 
growth medium. As described in section 2.1.10, EphB4/Fc was added to the growth medium 
every two days to selected wells at a final concentration of 5 µg/ ml. 
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2.2  Molecular biology techniques 
 
2.2.1  Sub-cloning of ephrinB2 from pCDNA3.1(-) to pBI  
  plasmid 
 
The pCDNA3.1(-)-ephrinB2-Flag plasmid was provided by Dr Fedor Berditchevski. 
This plasmid was generated by inserting the ephrinB2 cDNA, obtained by reverse 
transcription PCR of ephrinB2 RNA extracted from mammary epithelial cells (HB2), in a 
pCDNA3.1(-) empty vector. A Flag sequence (DYKDDDDK) was added at the N-terminus of 
the protein, after the leader peptide sequence.  
The ephrinB2-Flag was PCR amplified using the pCDNA3.1(-)-ephrinB2-Flag plasmid 
as a template and primers which included sites for recognition by PstI endonuclease (forward 
primer) and SalI endonuclease (reverse primer). A full list of primer sequences used in this 
study is shown in Appendix 2. PCR was conducted using High Fidelity TAQ Polymerase 
(Roche) following manufacturer’s guidelines. The 50 µl PCR mix was prepared in a Dome 
Cap 200 µl PCR tube (Appleton Woods) and contained 1x polymerase buffer, 1 nmole of 
each primer, 50 ng of template DNA, 0.4 mM of dNTP mix (0.1 mM of each NTP) and 2.5 
units of DNA polymerase, all in d H2O. The tubes were placed in a GeneAmp PCR system 
2700 thermal cycler (Applied Biosystems) which was programmed with the following 
settings: initial DNA denaturation of 5 minutes at 95ºC; then 35 cycles of 95ºC for 30 seconds 
(denaturation), 56ºC for 30 seconds (annealing), 72ºC for 1 minute (elongation); and a final 
elongation interval of 7 minutes at 72ºC. 
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These two restriction sites were present on the MCS of the pBI plasmid and allowed us 
to insert the ephrinB2-Flac cDNA fragment into it. After sub-cloning, large copy numbers of 
the pBI-ephrinB2-Flag plasmid were produced via transformation of 5-alpha I
q
 competent E. 
coli cells (NEB) and maxi-prep plasmid DNA purification. Finally, the concentration and 
purity of the plasmid were measured and the plasmid was diluted to a 1 mg/ml concentration 
in dH2O. 
 
 
2.2.1.1 Agarose gel electrophoresis and DNA gel extraction 
 
Amplified PCR fragments were separated and purified from backbone vector using 
agarose gel electrophoresis. Agarose gels were prepared by mixing 1% agarose (w/v) and 5 µl 
of Syber Safe DNA dye in 100 ml of TAE buffer; heating the mixture at 100ºC until the slurry 
had completely dissolved; and then pouring it in a gel casting chamber and allowing it to set. 
The gel was subsequently placed in a horizontal mini DNA tank (Geneflow) and completely 
immersed in 1x TAE buffer. 5 µl of PCR products supplemented with 1 µl of 5x DNA gel 
loading dye (Qiagen) were then loaded in each well of the gel, with one well used to load a 1 
Kb DNA size marker (Fermentas). The samples were separated by electrophoresis at 100 
Volts for 1 hour. 
DNA fragments were visualized under UV light and the ephrinB2-Flag fragment was 
excised from the gel using a scalpel and was placed in a 1.5 ml tube. The Qiagen DNA gel 
extraction kit was used to extract the ephrinB2-Flag fragment from the gel according to 
manufacturer’s protocol. Efficiency of purification was assessed by loading 1/10 of the 
purified ephrinB2-Flag on 1% agarose gel as described above. 
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2.2.1.2 DNA digestion using restriction enzymes 
 
The ephrinB2-Flag PCR fragment and the pBI vector DNA were digested with SalI and 
PstI endonucleases (Roche) over night at 37ºC according to manufacturer’s protocol. The 
digestion was set up in 50 µl of d H2O containing 1x buffer H (Roche) and 10 units of each 
endonuclease. The digested ephrinB2-Flag fragment and pBI empty vector were resolved in 
1% agarose gel at 100 Volts for 1 hour as previously described. Both the digested pBI 
plasmid and ephrinB2-Flag fragment were purified from the gel as previously described. 
 
 
2.2.1.3 DNA ligation and bacterial transformation 
 
The ligation mix was 25 µl in volume and contained 1x T4 ligation buffer (NEB), 200 
units of T4 ligase (NEB), 3 µl of digested pBI plasmid (~1.5 µg) and 19 µl of digested 
ephrinB2-Flag fragment. The ligation was carried out over-night at room temperature. 
Half of the ligation reaction was used for transformation and transferred to a 1.5 ml tube 
containing 18 µl of 5-alpha I
q
 competent E. coli cells (NEB). Transformation procedure was 
conducted according to manufacturer’s protocol. Transformation mix was kept on ice for 30 
minutes; heated at 42ºC in a water bath for 45 seconds; and then placed back on ice for 5 
minutes. The mix was subsequently supplemented with 250 µl of 2% Lysogeny Broth (LB) 
and placed on an orbital shaker for 1 hour at 37ºC. 50 µl of the transformation mix were then 
aseptically streaked on a 10cm LB agar plate containing 100 µg/ml ampicillin. The plate was 
incubated over-night at 37ºC. 
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2.2.1.4 Mini-prep DNA purification and DNA sequencing 
 
5 clones were picked from the agar plate and transferred to 5 ml of LB supplemented 
with 100 µg/ml ampicillin. The tubes were then incubated over-night on a shaker at 37ºC. 
Bacterial cells were pelleted at 5000 g for 5 minutes and DNA was purified using a Qiagen 
mini-prep kit, following manufacturer’s protocol. An aliquot of purified plasmid was digested 
with PstI and SalI for 2 hours (as described in section 2.2.1.2) and resolved in a 1% agarose 
gel at 100 Volts for 1 hour (as described in section 2.2.1.1). 
Plasmids containing an insert of the expected size were sequenced using a capillary 
sequencer ABI 3730 (Functional Genomics facility, Biosciences building, University of 
Birmingham). The following mixture was prepared for sequencing in a final volume of 20 µl: 
3.2 pmoles of pBI MCS2 forward primer, 3.2 pmoles of ephrinB2 internal forward primer, 
300 ng of pBI-ephrinB2 plasmid DNA and 1x BigDye Reaction Mixture (BDRM). The 
sequences were matched against the ephrinB2-Flag cDNA sequence used as a template for 
PCR.  
 
 
2.2.1.5 Maxi-scale DNA purification 
 
A small volume (200 µl) of bacterial used for DNA mini-scale purification suspension 
was added to 400 ml of LB supplemented with 100 µg/ml ampicillin and incubated on a 
heated shaker at 37ºC over-night. The next day, bacterial cells were pelleted at 5000 g for 5 
minutes and the plasmid DNA was purified using a Qiagen maxi-prep kit following 
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manufacturer’s protocol. The plasmid DNA was finally diluted in dH2O at a final 
concentration of 1 mg/ml.  
 
 
2.2.2  Generation of ephrinB2/G and ephrinB2/∆V mutants  
 
Quick Change Mutagenesis approach was used to generate the ephrinB2/G and 
ephrinB2/ΔV mutants. The following PCR mix was prepared in a final volume of 50 µl: 1x 
Pfu polymerase buffer (Fermentas), 50 ng of plasmid DNA, 1 nmole of each primer, 1 mM of 
dNTP mix (0.25 mM of each dNTP) and 2.5 units of Pfu polymerase enzyme (Fermentas). 
The PCR was carried out in the thermal cycler which was programmed with the following 
settings: initial DNA denaturation of 5 minutes at 95ºC; then 18 cycles of 95ºC for 30 seconds 
(denaturation), 56ºC for 60 seconds (annealing),72ºC for 12 minutes (elongation); and a final 
elongation interval of 7 minutes at 72ºC. 10 units of DPN1 (Roche) were then added to the 
PCR mix and incubated at 37ºC for 1 hour to digest the template pBI-ephrinB2-Flag plasmid 
DNA. The PCR mix was subsequently transferred in a 1.5 ml tube and supplemented with 2 
volumes of 100% ethanol and 4 µl of 5 M NaCl (final NaCl concentration of 0.13 M). The 
tube was placed at -80ºC for 3 hours to allow plasmid DNA precipitation. DNA was then 
pelleted via centrifugation at 12,000 g for 30 minutes in a mini-centrifuge and the supernatant 
was discarded. The DNA was washed with 500 µl of 70% ethanol and pelleted at 12,000 g for 
15 minutes. Supernatant was removed and the DNA pellet was left to dry at room temperature 
and successively diluted in 7 µl of dH2O. 
Following the same procedures described in the previous sections, the newly generated 
pBI-ephrinB2/G-Flag and pBI-ephrinB2/ΔV-Flag plasmids were transformed in bacterial 
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competent cells and plated on agar plates containing ampicillin. 5 clones for each plasmid 
were then picked, amplified in 5 ml of LB, digested with SalI and PstI endonucleases and 
resolved in a 1% agarose gel in order to verify that no recombination events had occurred 
during PCR. The plasmids were then sequenced as described in section 2.2.1.4 and purified 
on large scale as described in section 2.2.1.5. 
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2.3  Cell biology techniques 
 
2.3.1  Flow cytometry analysis 
 
Cells were detached using enzyme-free cell dissociation buffer (Invitrogen) and counted 
using a Burker chamber. Cells were then centrifuged at 400 g for 3 minutes and re-suspended 
in ice-cold PBS at 3-5x10
5
/50 µl. All the following steps were conducted on ice. 50 µl of 1% 
BSA/PBS per well were aliquoted to a 96-well U-bottom plate (Iwaki, Japan) and left on ice 
for 20 minutes to block unspecific binding of antibodies to plastic. Blocking buffer was then 
replaced with primary antibody diluted in 1% BSA/PBS (150 µl/well). Cells were added to 
the antibodies and incubated for 1 hour on ice. After centrifugation (400 g for 3 minutes), 
cells were washed twice in ice-cold PBS (175 µl/well). Cells were then re-suspended in 
appropriate fluorochrome-labeled secondary antibody diluted in 1% BSA/PBS (150 µl/well). 
Cells were incubated for 1 hour on ice in the dark and then washed with ice-cold PBS twice, 
as above. Cells were re-suspended in 250 µl of ice-cold PBS per sample and transferred into 
flow cytometry tubes (BD Falcon) containing 250 µl of ice-cold 2% paraformaldehyde. 
Samples were kept in the dark at 4°C prior to analyses on a Beckman Coulter Epics XL or BD 
Accuri C6 flow cytometer. Primary and secondary antibodies used in this study are listed in 
table 2.4 at the end of section 2.4.5.4. 
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2.3.2  Fluorescence Activated Cell Sorting (FACS) 
 
The day before the planned cell sorting experiment, cells were split using trypsin in 
order to avoid the formation of cell clamps on the day of sorting. All the following procedures 
were conducted under sterile conditions. Cells were detached using enzyme-free dissociation 
buffer and pelleted by centrifugation at 400 g for 3 minutes at 4°C. Cells were then re-
suspended in 1.5 ml of sterile filtered ice-cold complete growth medium containing primary 
antibody and incubated on ice for 1 hour. Cells were then centrifuged at 400 g for 3 minutes at 
4°C and washed twice with 2 ml of ice-cold complete growth medium. Cells were 
subsequently re-suspended in 1.5 ml of sterile filtered ice-cold complete growth medium 
containing appropriate fluorochrome-labeled secondary antibody and incubated on ice in the 
dark for 1 hour. Cells were washed twice with ice-cold complete growth medium as described 
above. After final centrifugation at 400 g for 3 minutes at 4°C, cells were re-suspended in 2 
ml of ice-cold complete growth medium. Cell suspension was passed through Cell Trics 
filters (Partec) to remove cell clamps and transferred in sterile FACS tubes (BD Falcon). Two 
collecting tubes containing 2 ml of ice-cold complete growth medium were prepared in order 
to separate negative and positive cell populations. Cells were sorted using a Beckman Coulter 
MoFlo Legacy FACS machine. After sorting, cells were centrifuged at 400 g for 3 minutes, 
re-suspended in complete growth medium containing double quantity of 
penicillin/streptomycin antibiotics and plated on Petri dish. Cells were kept in incubator 
(37°C, 5% CO2) for 24-48 hours before growth medium was replaced with normal complete 
growth medium. 
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2.3.3  Immunofluorescence staining 
 
Cells were plated on ethanol-sterilized 16 mm round glass cover-slips (VWR) placed in 
a 12-well plate (Corning). When cells reached required density, growth medium was 
discarded and cells were washed twice in PBS. Subsequently, cells were fixed for 20 minutes 
with 2% paraformaldehyde/PBS at room temperature. Fixed cells were then washed three 
times in PBS and permeabilized with 0.1% TritonX-100/PBS for 3 minutes at room 
temperature. After three more washes in PBS, cells were incubated for 1 hour with blocking 
solution containing 20% heat inactivated goat serum in PBS. Cover-slips were subsequently 
placed face-down on a 30 µl drop of primary antibody diluted in blocking solution aliquoted 
on nescofilm (Bando Chemical) which had been previously arranged in a humid chamber. 
Incubation with primary antibody lasted 1 hour. Cover-slips were then placed back in the 12-
well plate and washed three times for 10 minutes with PBS on an orbital shaker at room 
temperature. Incubation with fluorescent secondary antibody diluted 1:200 and subsequent 
washes (under aluminium foil) was performed using the procedure described above. Stained 
coverslips were air-dried and mounted on glass slides using 10 µl of anti-fade fluorescence 
mounting medium containing 0.1 µg/ml Hoechst 33342. Cover-slips were sealed on the edges 
by transparent nail varnish and stored at -20ºC. Immunofluorescence staining was analyzed at 
a ZEISS LSM510 META confocal microscope. 
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2.3.4  Hoechst staining of 3D colonies grown in 2% MG 
 
Colonies grown in 2% Matrigel were carefully washed with 400 µl of PBS and 
subsequently fixed with 400 µl of 3% paraformaldehyde/PBS for 40 minutes at room 
temperature. Colonies were then washed once with PBS as described above and incubated 
with 200 µl of 0.1% TritonX-100/PBS at room temperature for 3-5 minutes. Permeabilizing 
solution was removed and 200 µl of 0.05% TritonX-100/PBS containing 0.1 µg/ml Hoechst 
33342 was added to wells to stain nuclei. Colonies were incubated for 40 minutes at room 
temperature in the dark. The excess of staining solution was removed and colonies were 
washed twice (10 minutes for each wash) with 400 µl of PBS at room temperature. Finally, 
washing solution was replaced with 200 µl of PBS containing 0.02% Sodium Azide (NaN3). 
Cells were left in the dark at 4ºC over night before pictures were taken at a ZEISS LSM510 
META confocal microscope using a 20x objective. 
 
 
2.3.5  Gap-closure assay 
 
Cells were detached and counted in a Burker chamber. Cells were resuspended in 1 ml 
of complete growth medium in a 15 ml tube (Corning) at a concentration of 3*10
5
 cells/ml 
and 70 µl were aliquoted and plated in the chambers of a 35mm µ-Dish culture insert (Ibidi), 
as described in step 2 of figure 2.1. The dish was placed in the incubator at 37ºC, 5% CO2 for 
24 hours and, the next day, cells were stimulated with 1µg/ml doxycycline for further 24 
hours in the incubator. The chamber insert was removed (step 3), leaving a 500 µm wide gap 
between the two cell populations. 2 ml of fresh growth medium containing 1 µg/ml 
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doxycycline was added to the dish (step 4). Cells were returned to the incubator and gap-
closure was observed using a Nikon Eclipse TS100 inverted fluorescence microscope every 
24 hours for 8 days. When RFP and GFP expressing cells were used, the 8 day time-point was 
photographed using red and green filters at the same microscope.  
 
 
Figure 2.1: diagram illustrating a gap-closure assay. 1) Silicon insert formed of two chambers glued to the glass 
bottom of a 35mm dish (Ibidi); 2) 70 µl of cell suspension are added to each chamber of the insert; 3) after cells 
have reached confluency within the chambers, the silicon insert is removed using forceps; 4) cells are covered 
with 2 ml of fresh growth medium and placed in incubator. The 500 µm gap between the two cell populations is 
closed as cells proliferate and migrate outward. 
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2.4  Biochemical methods 
 
2.4.1  Protein extraction for Western blot analysis 
 
Cells were grown in 35 mm or 60 mm Petri dishes until they reach 90% confluency. 
Growth medium was removed from dishes and cells were washed twice with PBS. Depending 
on cell confluency and dish size, 50-200 µl of freshly made Laemmli lysis buffer (without 
bromophenol blue) was added to the dishes and cells were scraped from the surface using 
disposable plastic cell scrapers (Sarsted). Cell lysates were then transferred to 1.5 ml plastic 
tubes (Starlabs), heated at 95°C for 15 minutes and spun down. At this point, samples were 
either frozen at -80°C for long term storage or directly assayed for protein concentration and 
prepared for separation on SDS-PAGE. 
When preparing samples for signalling experiments (section 3.1.2.2), cells were starved 
in serum-free medium for 4 hours and stimulated with the chimeric molecule EphB4/Fc for 
various time intervals prior to lysis. EphB4/Fc was pre-clustered with anti-human Fc IgG 
antibody as described in section 2.1.10 and subsequently added to the growth medium at a 
final concentration of 5 µg/ml.  
When inhibiting Src family kinases in signalling experiments (section 3.1.2.2), the Src 
inhibitor SU6656 (Calbiochem) was added to serum-free medium at a final concentration of 
10 µM, 1 hour prior to stimulation with the EphB4/Fc chimera molecule. The inhibitor was 
left in growth medium throughout the time-course of EphB4/Fc stimulation as described in 
the study by (Palmer, Zimmer et al. 2002). 
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2.4.2  Protein Assay 
 
Frozen cell lysates were left to thaw at room temperature, heated at 95°C for 5 minutes 
and spun down. Samples were assayed in a 96-well flat-bottom plate (BD Falcon) using 
BioRad DC protein assay kit, according to the manufacturer’s protocol (Bio-Rad 
Laboratories). Protein concentration for each sample was determined using Excel Datasheet 
(Windows Office 2007). Protein lysates were diluted with Laemmli buffer to equalize protein 
concentration and supplemented with ¼ volume of 4x Laemmli buffer. If necessary, samples 
were supplemented with 2-β-mercaptoethanol at a final concentration of 5% to keep proteins 
reduced. Once samples were prepared for loading and mixed homogenously, samples were 
heated at 95°C for 5 minutes and loaded on a SDS-PAGE gel or frozen at -80°C for long term 
storage. 
 
 
2.4.3  SDS – PAGE and Immunoblotting 
 
Protein samples were resolved using SDS-polyacrylamide gel electrophoresis (PAGE). 
Proteins were separated using 8 or 10% SDS-PAGE (Appendix 3). If used, frozen samples 
were thawed at room temperature and heated at 95°C for 5 minutes before loading. Proteins 
were resolved at 12 mA using BioRad electrophoretic equipment (power pack, gel tank and 
gel glasses). Pre-stained protein markers (NEB) were used to monitor sample separation. 
Resolved proteins were subsequently transferred to nitrocellulose membrane (VWR) via 
electroblotting at 40 V over-night using BioRad electroblotting equipment (power pack, gel 
tank, blotting sandwich holders and sponges). The membranes were rinsed in PBS-Tween 
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0.1% and then incubated in 5% dry skimmed milk (Marvel) diluted in PBS-Tween to block 
unspecific binding of antibodies. Membranes were incubated with primary antibody over 
night at 4°C on a rotating platform and then washed three times for 10 minutes each with 
PBS-Tween. When blots were developed on film, membranes were incubated with the 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at room 
temperature on an orbital shaker and then washed three times for 10 minutes with PBS-
Tween. Proteins were detected using Enhanced Chemiluminescence Plus reagents (ECL Plus) 
(Biological Industries) followed by autoradiography: films were developed using a Kodak X-
OMAT 1000 developer. All primary antibodies used for immunoblotting are listed in table 2.4 
at the end of section 2.4.5.4. When detecting phospho-proteins, membranes were washed and 
incubated in TBS-Tween 0.1%. 
When developing membranes using the Odyssey CLx infrared imaging system (Licor), 
IRDye 800CW or 680CW secondary antibodies were used. Incubation with these antibodies 
and subsequent washes were performed in the dark. Membranes were then placed on the glass 
panel of the imaging system and infrared fluorescence was recorded.  
 
 
2.4.4  Densitometric analysis on the Odyssey CLx  
 
Densitometric analysis was carried out on the images of Western blots obtained with the 
Odyssey CLx infrared imaging system (Licor). Equal square boxes were drawn around each 
band and the infrared fluorescence absorbance within the boxes was measured. The 
background level for each individual blot was calculated on an area free of bands and 
subtracted from the absorbance readings of the measured bands. These raw absorbance values 
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represented the denistometric value which we used to quantify the levels of protein expression 
in Western blots throughout this study. 
 
 
2.4.5  Pull down and co-immunoprecipitation assays 
 
2.4.5.1 Protein extraction 
 
Cells grown on 35 or 60 mm Petri dishes were washed twice with PBS and 300 or 600 
µl of ice cold 1% TritonX-100 lysis buffer was added (see Appendix 3 for buffer 
composition). All solutions, Petri dishes and samples were kept on ice during procedures. 
Cells were scraped using disposable plastic cell scrapers and cell lysates were transferred to a 
1.5 ml tube and placed at 4ºC on a rotary wheel for 30 minutes to ensure total lysis. Samples 
were then centrifuged at 12,000 g for 10 minutes in a mini-centrifuge (Eppendorf) to remove 
insoluble material. 
When preparing samples for signalling experiments (section 3.2.1.1 and 3.2.1.2), cells 
were starved in serum-free medium for 4 hours and stimulated with the chimeric molecule 
EphB4/Fc for multiple time-points prior to lysis, as described in section 2.4.1. 
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2.4.5.2 Pull down assay 
 
NeutrAvidin
TM
-conjugated agarose beads (50% slurry solution) were transferred to 1.5 
ml tubes (30 µl/tube) and washed twice with 500 µl of ice cold PBS. Two tubes containing 
NeutrAvidin agarose beads were prepared for each sample. In one tube, NeutrAvidin agarose 
beads were incubated with custom made biotin-conjugated peptides in 400 µl of ice cold PBS 
at 4ºC on a rotary wheel for 1 hour and subsequently washed twice with 500 µl of PBS. The 
second tube was kept for pre-clearance of cell lysates.   
Prior to pre-clearance, 45 µl of cell lysate where aliquoted from each sample and 
prepared for WB loading to serve as whole lysate control. Cell lysates were then incubated 
with the NeutrAvidin agarose beads prepared for pre-clearance for 45 minutes at 4ºC on a 
rotary wheel. Subsequently, pre-clearance NeutrAvidin agarose beads were discarded and cell 
lysates were incubated with peptide-conjugated NeutrAvidin beads over-night at 4ºC on a 
rotary wheel.  
The next day, peptide-conjugated NeutrAvidin beads were spun down in a mini-
centrifuge and the supernatant was discarded. The beads where then washed three times with 
ice cold TBS-Tween 0.1%.  
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2.4.5.3 Co-immunoprecipitation assay 
 
Anti-Flag mAb (M2) conjugated to agarose beads was prepared for 
immunoprecipitation as described above (30 µl/sample). Cell lysates were incubated with 
anti-Flag conjugated agarose beads over-night on a rotary wheel at 4ºC. Anti-Flag conjugated 
agarose beads were then washed three times as described above. 
 
 
2.4.5.4 Sample preparation for WB analysis 
 
Each sample was prepared for WB by adding 15 µl of 2x Laemmli buffer containing 
10% 2-β-mercaptoethanol. Samples were then shortly vortexed, spun down in a mini-
centrifuge and boiled at 95ºC for 5 minutes. Whole lysate control samples were prepared for 
WB loading by adding 15 µl of 4x Laemmli buffer and 1.5 µl of 2-β-mercaptoethanol to each 
sample. Samples were either loaded immediately on SDS-PAGE gels or frozen at -80ºC for 
long term storage. When loading samples on SDS-PAGE gels, beads were discarded. 
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Primary antibodies Target antigen 
Target MW 
(kDa) 
Source Supplier 
Catalogue 
number 
anti-Flag pAb Flag sequence - Rabbit Sigma F7425 
anti-Flag M2 mAb Flag sequence - Mouse Sigma F1804 
ephrinB1/2/3 (C-18) 
pAb 
C-terminus of human 
ephrinB1/2/3 
45-55 Rabbit Santa Cruz sc-910 
phospho-ephrinB 
pAb 
human pEphrinB 
(Tyr324/329) 
45-55 Rabbit Cell Signaling 3481 
Src (36D10) mAb C-terminus of human Src 60 Rabbit Cell Signaling 2109 
phospho-Src Family 
pAb 
human pSrc (Tyr416) 60 Rabbit Cell Signaling 2101 
EphB4 
mouse EphB4 
extracellular domain 
120 Goat R&D AF446 
CASK mAb CASK aa353-486 120 Mouse 
BD Transduction 
Laboratories 
610782 
β-actin mAb N-terminus of β-actin 42 Mouse Sigma A5441 
SDCBP (M01) mAb 
(syntenin-1) 
human SDCBP aa 1-101 33 Mouse Abnova 
H0000638
6-M01 
Dvl-2 mAb (30D2) Human Dishevelled-2 90-95 Rabbit Cell Signaling 3224 
anti-myc (A-14) 
C-terminus of human c-
myc 
- Rabbit Santa Cruz sc-789 
anti-GST (B-14) GST protein 26 Mouse Santa Cruz sc-138 
4C5G mouse PI4K - Mouse LGC Standards CRL-2538 
CD81 (M38) human CD81 22-24 Mouse 
hybridoma 
provided by 
- 
 
Table 2.4: list of primary antibodies used in this study. 
 
Secondary antibodies Target antigen Source Supplier Catalogue number 
anti-human Fc IgG human IgG, Fc specific Goat Sigma I2136 
anti-mouse Igs/HRP Mouse IgG, IgA, IgM Goat DakoCytomation P0447 
anti-rabbit Igs/HRP All rabbit Igs Goat DakoCytomation P0448 
anti-goat Igs/HRP All goat Igs Rabbit DakoCytomation P0449 
anti-rabbit IgG/IRDye 
800CW 
Rabbit IgG Goat Licor 926-32211 
anti-mouse IgG/IRDye 
680RD 
Mouse IgG Goat Licor 926-68078 
anti-mouse FITC Mouse IgG Goat Sigma F2012 
Alexa Fluor® 488 
F(ab’)2 anti-mouse 
Mouse IgG Goat Life Techonologies A11017 
 
Table 2.5: list of secondary antibodies used in this study. 
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2.4.6  Biotinylation assay 
 
2.4.6.1 Biotin labelling and internalization 
 
Cells were grown in 60 mm Petri dishes and were 80-90% confluent on the day of the 
experiment. Duplicate plates were prepared for each condition, as each sample required a 
control. All procedures were performed on ice and, when necessary, in a cold room with all 
solutions chilled prior to use. Cells were washed twice in PBS* (PBS supplemented with 1 
mM MgCl2 and 0.5 mM CaCl2). 3 ml of PBS* containing EZ link NHS-SS-Biotin (Thermo 
Scientific) were then added to cells and the dishes were incubated on a rotating platform at 
4ºC for 1 hour. After incubation, biotin solution was removed and remaining free biotin was 
quenched by washing cells three times for 5 minutes with PBS* containing 50 mM glycine 
and 0.5% BSA at 4ºC. Cells were washed twice with PBS* and subsequently incubated at 
37ºC, 5% CO2 for 15 or 60 minutes in pre-warmed complete growth medium containing 
either anti-Fc IgG antibody at a final concentration of 2.5 µg/ml or EphB4/Fc at a final 
concentration of 5 µg/ml, as described in section 2.4.1. 
 
 
2.4.6.2 MESNA treatment and pull down assay 
 
After the incubation period which allowed cell surface proteins to be internalized, cells 
were washed twice with PBS*. Cells on one of the plates were lysed in 1% TritonX-100 lysis 
buffer as described in section 2.4.5.1. Cells on the other plate were successively incubated 
four times with MESNA at 4ºC for 15 minutes on a rotating platform. Cells were 
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subsequently washed twice with PBS** (PBS supplemented with 0.33 mM MgCl2 and 0.9 
mM CaCl2) and incubated with PBS** containing 5 mg/ml iodoacetamide at 4ºC for 15 
minutes to quench residual MESNA. After the incubation, cells were washed three times with 
PBS** and lysed as above. Biotinylated proteins from protein lysates were collected on 
NeutrAvidin-conjugated agarose beads after over-night incubation at 4ºC on a rotary wheel 
(15 µl of agarose beads were used per reaction). Samples were washed three times with TBS-
Tween 0.1% and resolved by SDS-PAGE as described in section 2.4.5.4. Resolved proteins 
were transferred to nitrocellulose membrane and blots were developed using the Odyssey CLx 
infrared imaging system (Licor) as described in section 2.4.3. Densitometric analysis was 
performed using the Odyssey CLx imaging software (Licor). 
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2.4.7  Label-free interaction analysis (Biacore) 
 
Label-free interaction analysis was conducted on a Biacore 3000. Biacore sensor CM5 
chips (GE Healthcare) were coated with streptavidin (GE Healthcare) using EDC/NHS, 
ethanolamine and glycine 0.1 M solutions. Response Units (RU) were then normalized and 
biotin-conjugated peptides were added to the streptavidin-coated chips by means of applying 
a constant flow of HBS-EP solution containing 100 µg/ml of peptide and 1% DMSO. A list of 
peptides used can be found in Appendix 2. Once peptide binding to streptavidin reached 
saturation, the flow was interrupted, the RU were normalized and recombinant full length 
syntenin-1 protein was injected to the flow of HBS-EP solution. As syntenin-1 binding 
reached a saturation plateau, the injection of protein-containing solution was substituted with 
HBS-EP buffer and the constant flow was maintained until syntenin-1 was completely 
removed from peptides. The binding curves, or “sensorgrams”, for each peptide (including the 
negative control peptide NET5) were normalized and presented in a unified graph for 
comparison. 
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3.1   Establishing an epithelial breast cancer model  
  system to study ephrinB2 biology 
 
Normal breast epithelial cells naturally express low levels of the ephrinB2 ligand, while 
myoepithelial cells express the cognate EphB4 receptor. However, during the proliferative 
phase of the mammary gland development epithelial cells temporarily express the EphB4 
receptor as well (Munarini, Jager et al. 2002). The difficulty in finding a suitable cell line in 
which to study ephrinB2 biology derives from the fact that many breast epithelial cancer cells 
acquire the ability to express the EphB4 receptor. In fact, during mammary gland 
carcinogenesis EphB4 receptor expression is shifted from myoepithelial to epithelial cells 
(Nikolova, Djonov et al. 1998). Moreover, in most breast cancers the EphB4 receptor is found 
in 58% of the tumour tissue (Kumar, Singh et al. 2006). 
 
 
3.1.1  Identifying a suitable epithelial breast cancer cell 
 model 
 
As a first step, it was necessary to screen a wide range of epithelial breast cancer cell 
lines to identify cells that don’t express (or express low relative levels of) ephrinB ligands. 
This was fundamental, as our intention was to create a model system in which we could 
establish a stable expression of the ephrinB2 protein or ephrinB2 mutants in an epithelial 
breast cancer cell line.  
Results and Discussion 
~ 102 ~ 
 
We performed Western Blotting (WB) analysis on a panel of 21 breast cancer cell lines 
to assess the endogenous expression levels of ephrinB ligands. Myoepithelial and HB2 cells 
(a non-tumorigenic mammary epithelial cell line which displays luminal phenotype) were also 
included in the screening. WB data shown in figure 3.1 demonstrates that ephrinB ligands are 
heterogeneously expressed within the panel of cell lines tested. Furthermore, the expression 
levels vary considerably, with some cell lines expressing high levels of ephrinB ligands (such 
as MDA-MB-330, CAMA-1, ZR75.1 and SUM149), whilst others expressing smaller 
amounts (such as HB2, MDA-MB-134, MRSV, BT549, DCIS, GI101 and MDA-MB-231). 
We have also found that expression of ephrinB ligands was below the level of detection in 
several cell lines (such as MDA-MB-175, MDA-MB-435, MCF7, T47D, BT474, SKBR3, 
MYO, BT20, CAL51 and MDA-MB-468). As ephrinB ligands are all relatively similar in size 
(ephrinB1 = 346 aa; ephrinB2 = 333 aa; ephrinB3 = 340 aa) and are subject to N-
glycosylation (data not shown), it was difficult to distinguish between them on the blot when 
using pan anti-ephrinB pAb. The lower molecular weight band (between 25 and 30 kDa) is 
probably associated with EphB-induced ligand degradation. 
As the preferential receptor for ephrinB2 is the EphB4 receptor (Pasquale 2008), we 
also analysed endogenous EphB4 levels in these cell lines (figure 3.1). Interestingly, we 
observed that EphB4 was expressed at different levels in nearly all these cell lines, with only 
MDA-MB-134, MCF7 and MDA-MB-157 cells expressing minimal amounts or no protein. 
Within EphB4 expressing cell lines, we noticed that MDA-MB-330, T47D, ZR75.1, BT474, 
SKBR3, ZR75.30, DCIS, GI101 and MDA-MB-468 expressed higher levels of the EphB4 
receptor compared to the remaining cell lines. 
One of the main aims of our study was to understand the significance of the ephrinB2 – 
syntenin-1 axis in the context of epithelial breast cancer. Although syntenin-1 is widely 
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expressed in different cell types and usually abundant in epithelial cells (Beekman and Coffer 
2008), we analysed endogenous syntenin-1 expression levels in the same panel of cell lines 
using WB (figure 3.1). As expected, all cell lines expressed medium to high levels of 
endogenous syntenin-1, apart from MDA-MB-157 cells in which syntenin-1 was barely 
detectable.      
Table 3.1 summarizes the data on expression levels of ephrinB ligands, EphB4 and 
syntenin-1. Based on these data, the MCF7 cell line (lane 7, figure 3.1) stood out as the best 
candidate to use as a model system. Although it expresses lower levels of syntenin-1 
compared to some of the other cell lines, it presents minimal levels of endogenous EphB4 and 
no ephrinB ligands. 
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Figure 3.1: ephrinB, EphB4 and syntenin-1 expression in a panel of breast cell lines.  
A panel of breast cancer cell lines together with myoepithelial and non-tumourigenic HB2 mammary cells was 
tested for EphB4 receptor, ephrinB ligands and syntenin-1 expression using WB. Cell lysates were provided by 
Dr Fedor Berditchevski and protein concentrations were measured and standardized to ensure equal loading on 
SDS-PAGE. Endogenous EphB4 was detected with anti-EphB4 pAb; endogenous ephrinB ligands were detected 
with anti-ephrinB pAb which recognizes the C-terminal tail of all three ephrinB ligands; endogenous syntenin-1 
was detected with anti-syntenin-1 mAb.  
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Table 3.1: general indications on the level of overall expression of EphB4, ephrinB ligands and syntenin-1 
proteins in 23 epithelial mammary cell lines analyzed via WB analysis. Indications refer to the signal strength 
detected by WB: none = no signal detected; minimal = signal barely visible; low-high: relative signal strength, 
with high being the highest signal detected for a specific protein. 
  
Cell line EphB4 expression ephrinB expression syntenin-1 expression WB lane 
HB2 LOW MEDIUM MEDIUM 1 
MDA-MB-134 MINIMAL MEDIUM LOW 2 
MDA-MB-330 MEDIUM HIGH MEDIUM 3 
MDA-MB-175 MEDIUM LOW MEDIUM 4 
MDA-MB-435 LOW MINIMAL LOW 5 
CAMA-1 LOW HIGH MEDIUM 6 
MCF7 LOW NONE LOW 7 
T47D MEDIUM MINIMAL MEDIUM 8 
ZR75.1 HIGH HIGH MEDIUM 9 
BT474 HIGH NONE LOW 10 
SKBR3 HIGH NONE LOW 11 
ZR75.30 MEDIUM LOW MEDIUM 12 
MYO LOW LOW LOW 13 
MRSV MEDIUM MEDIUM MEDIUM 14 
BT20 LOW MINIMAL MEDIUM 15 
BT549 LOW MEDIUM LOW 16 
CAL51 MEDIUM MINIMAL HIGH 17 
DCIS HIGH MEDIUM MEDIUM 18 
GI101 HIGH MEDIUM HIGH 19 
MDA-MB-157 NONE MEDIUM MINIMAL 20 
MDA-MB-231 LOW MEDIUM MEDIUM 21 
MDA-MB-468 HIGH MINIMAL HIGH 22 
SUM149 LOW HIGH LOW 23 
Results and Discussion 
~ 106 ~ 
 
3.1.2 Generation and characterization of MCF7 cells 
expressing wild type ephrinB2 
 
In generating our model system, we decided to establish an MCF7 cell line which 
expressed the wild type ephrinB2 protein containing a Flag sequence at the N-terminus. This 
modification should not alter protein functionality or binding ability to the EphB4 receptor 
and allowed us to use anti-Flag antibodies throughout our study to monitor expression levels 
of transfected ephrinB2 for some of the planned experiments. In order to achieve stable 
protein expression, we stably transfected MCF7 cells with ephrinB2-Flag as described in 
section 2.1.4 of Materials and Methods. Fluorescence-activated Cell Sorting (FACS) using 
anti-Flag antibody was subsequently performed in order to select and separate ephrinB2-Flag 
expressing cells from non-expressing cells, as described in section 2.3.2 of Materials and 
Methods. FACS was performed twice to obtain a homogenous population of MCF7 cells 
expressing high levels of ephrinB2 on the cell surface. From this moment onward, we will 
refer to ephrinB2-Flag expressing MCF7 cells as MCF7-ephrinB2.  
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3.1.2.1 Assessing cell surface expression, overall expression and cell  
  localization of ephrinB2 
 
After having established the MCF7-ephrinB2 cell line, we verified cell surface 
expression levels using flow cytometry; overall expression levels by WB analysis; and protein 
localization within cells using immunofluorescence. The histogram in figure 3.2A illustrates 
mean fluorescence values obtained with flow cytometry performed on MCF7-ephrinB2 and 
MCF7 parental cells using anti-Flag antibody. Figure 3.2B illustrates results of WB with both 
anti-Flag and anti-ephrinB antibodies to detect ephrinB2 overall expression. EphrinB2 
appears as a doublet due to different glycosylation status. We also assessed phosphorylation 
of ephrinB2 using a phospho-specific ephrinB antibody and observed that the basal level of 
phosphorylation was low in MCF7-ephrinB2 cells. In order to determine localization of 
ephrinB2 in MCF7 cells, we carried out immunofluorescence analysis on MCF7-ephrinB2 
cells using anti-Flag antibody. Hoechst 33342 was used to stain the nuclei. Figure 3.2C shows 
that ephrinB2 is mostly detected at the plasma membrane. Taken together, the flow 
cytometry, WB analysis and immunofluorescence prove that ephrinB2 is expressed in MCF7-
ephrinB2 cells and that it is mainly localized on the cell surface. 
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Figure 3.2: the stably transfected MCF7-ephrinB2 cell line shows robust expression and clear localization 
of ephrinB2 on the cell surface.  
MCF7 cells were stably transfected with a plasmid encoding Flag-tagged ephrinB2 wild type and sorted for 
ephrinB2 expression on the cell surface via FACS. A) flow cytometry analysis using anti-flag mAb to detect 
ephrinB2 cell surface expression in parental MCF7 cells and stably transfected MCF7-ephrinB2 cells after 
sorting. The histogram shows the mean fluorescence values measured. B) MCF7-ephrinB2 and MCF7 parental 
cells were lysed in 1x Laemmli buffer and protein samples resolved on SDS-PAGE. EphrinB2 total expression 
was detected with anti-Flag mAb and anti-ephrinB pAb. Phosphorylated ephrinB2 was detected with phospho-
specific anti-ephrinB pAb. β-actin was detected with anti-β-actin mAb as loading control. C) 
immunofluorescence images taken at the confocal microscope of MCF7-ephrinB2 cells fixed with 2% PFA and 
probed with anti-Flag mAb. Hoechst33342 staining was used for nuclear detection.   
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3.1.2.2 Assessing the functionality of ephrinB2 
 
To confirm the functionality of ephrinB2-Flag in MCF7 cells, we stimulated MCF7-
ephrinB2 cells with a soluble EphB4/Fc molecule and examined ephrinB2 and Src 
phosphorylation using WB analysis. In a parallel experiment, we added the Src family kinase 
inhibitor SU6656 to cells 1 hour prior to EphB4/Fc stimulation. This allowed us to determine 
whether ephrinB2 phosphorylation upon EphB4/Fc stimulation is Src dependent. We 
stimulated MCF7-ephrinB2 cells with the EphB4/Fc soluble protein after 4 hours of serum 
deprivation to minimize possible basal phosphorylation of the protein. Taking into 
consideration previous studies on ephrinB2 phosphorylation induced by soluble EphB4 ligand 
(Georgakopoulos, Litterst et al. 2006; Georgakopoulos, Xu et al. 2011), we stimulated cells 
with 5 µg/ml EphB4/Fc chimera pre-clustered with anti-human Fc IgG antibody in order to 
maximize ephrinB2 phosphorylation. In fact, multimerization of ephrinB ligands strongly 
increases signal activation (Blits-Huizinga, Nelersa et al. 2004). 
Figure 3.3A shows the WB analysis of MCF7-ephrinB2 cells stimulated with 
EphB4/Fc. Phosphorylation of Src family kinases is induced at the earliest time-point of 5 
minutes (lane 2) and remains stable up to the final time-point of 240 minutes, where it 
decreases (lane 7). EphrinB2 phosphorylation appears at the 15 minute time-point (lane 3) and 
increases over time, reaching its peak between 60 and 120 minutes (lanes 5 and 6 
respectively). At the 240 minute time-point (lane 7) ephrinB2 phosphorylation diminishes, 
which is consistent with signal termination and protein degradation described previously 
(Pasquale 2008). Indeed, ephrinB2 overall expression levels also decreased at the longer time-
points (120 and 240 minutes, lanes 6 and 7, respectively). As expected, Src overall expression 
levels remained unchanged. 
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Figure 3.3B illustrates the effect of Src inhibitor on EphB4-induced phosphorylation of 
ephrinB2 and Src. In accordance to previous studies, we used SU6656 at a concentration of 10 
µM (Palmer, Zimmer et al. 2002; Georgakopoulos, Litterst et al. 2006). As a consequence of 
the treatment, Src phosphorylation remained essentially unchanged with only slight increase 
at the later time-points (lanes 5-7). Importantly, EphB4/Fc-induced ephrinB2 phosphorylation 
levels were also decreased and only started appearing after 30 minutes from stimulation (lane 
4). Total ephrinB2 expression levels only slightly decreased at the later time-points of 120 
and 240 minutes (lanes 6 and 7 respectively). 
Taken together, these results proved that ephrinB2 was functional and that EphB4/Fc 
stimulation triggered ligand phosphorylation via Src activation. We concluded that our 
MCF7-ephrinB2 cell line was a good model to use in our study. Additionally, we observed 
that the basal level of ephrinB2 phosphorylation was low in non-stimulated conditions, while 
the basal level of Src phosphorylation was relatively high (probably due to basal integrin-
dependent signalling). Furthermore, we noticed that the decrease in ephrinB2 total levels at 
the later time-points was less pronounced in the presence of the SU6656 inhibitor, suggesting 
that Src and/or ephrinB2 phosphorylation might increase ligand degradation.  
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A)         B) 
 
     
Figure 3.3: ephrinB2 phosphorylation is induced by soluble EphB4/Fc and is dependent on Src activation. 
EphrinB2 functionality was tested by stimulating cells with EphB4/Fc in the presence or absence of the Src 
family inhibitor SU6656 and detecting phospho and total levels of ephrinB2 and Src proteins by WB. MCF7-
ephrinB2 cells were starved in serum-free medium for 4 hours and then stimulated with 5 µg/ml of EphB4/Fc, 
pre-clustered with anti-Fc IgG, for 5, 15, 30, 60, 120 and 240 minutes (panel A). In panel B, the Src inhibitor 
SU6656 was added to the medium 1 hour prior to stimulation at a concentration of 10 µM and was left in 
medium throughout the stimulation time-course. Cells were lysed in Laemmli buffer and protein samples 
resolved on SDS-PAGE. Phospho and total levels of ephrinB2 and Src were detected using phospho-specific 
anti-ephrinB pAb (Tyr324/329), anti-ephrinB pAb, phospho-specific anti-Src family pAb (Tyr416) and anti-Src 
family pAb. β-actin was detected using anti- β-actin mAb as loading control. Note, in the presence of Src 
inhibitor SU6656 (panel B), both ephrinB2 and Src phosphorylation is strongly impaired. 
  
Results and Discussion 
~ 113 ~ 
 
3.1.2.3 Impact of ephrinB2 expression on 3D colony growth of MCF7 cells 
 
Culturing of cells in extracellular matrix (3D-ECM) provides valuable knowledge on 
how basic biological processes can impact higher-order tissue architecture. Some of the 
mammary epithelial cell lines grown in 3D-ECM are able to form spherical structures with a 
central lumen resembling breast acini. Thus, 3D-based systems are often used to identify 
proteins and signalling pathways that regulate mammary morphogenesis and cancer 
development. This type of cell culturing represents a more physiological-like setting, thus 
revealing protein functions which would not be necessarily detectable when cells are grown as 
a monolayer on plastic (Hebner, Weaver et al. 2008). MCF7 cells can be cultured in 3D 
collagen and Matrigel (MG), where they form round colonies (Kirshner, Chen et al. 2003). 
EphrinB2 reverse signalling plays an important role in cell segregation and cell polarity 
during mammary gland morphogenesis (Nikolova, Djonov et al. 1998; Munarini, Jager et al. 
2002); and induces angiogenesis and metastasis during breast tumour progression (Pasquale 
2010). Thus, growing MCF7-ephrinB2 cells in 3D cultures and stimulating them with 
EphB4/Fc should allow us to uncover physiologically and pathologically relevant functions of 
ephrinB2 reverse signalling which might have remained undetected under in vitro standard 
settings. 
 For these reasons, we carried out a preliminary experiment whereby we cultured MCF7 
parental cells and MCF7-ephrinB2 cells in either 3D collagen I or Matrigel in the presence or 
absence of the EphB4/Fc chimera. Cells were embedded in 3D-ECM and allowed to grow for 
12 days, during which EphB4/Fc pre-clustered with anti-Fc IgG was added to the growing 
medium every two days.  
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When we cultured cells in collagen, colonies formed by MCF7-ephrinB2 and MCF7 
parental cells grew as uniform compact spheres with no clearly detectable cell-to-cell 
boundaries (figure 3.4A). After 12 days of culturing, we were unable to observe any 
differences in morphology and only limited differences in size of the colonies formed by the 
control MCF7 and MCF7-ephrinB2 cells (Figure 3.4A, upper panels). Moreover, EphB4/Fc 
stimulation did not appear to affect either morphology or size of the colonies formed by 
control MCF7 and MCF7-ephrinB2 cells (Figure 3.4A, lower panels). In order to carry out a 
statistical analysis of colony size, we used Nikon software to calculate the surface area (in 
pixels) of the colony’s circumference, which was manually drawn around the widest point of 
the colony. 30 colonies per condition were analysed. The histogram and the table outlining the 
distribution of colony size highlighted a decrease in the quantity of MCF7-ephrinB2 colonies 
in the 20-25 size class compared to MCF7 colonies (figure 3.4B). Furthermore, there were no 
EphB4/Fc-stimulated MCF7 colonies in the <15 size class. However, as we detected MCF7-
ephrinB2 colonies in the 25-30 and >30 size classes and as the size distribution pattern of 
MCF7 colonies stimulated with EphB4/Fc was not particularly different to the pattern of 
MCF7 colonies in the other size classes, we concluded that these differences were probably 
due to variability within the experimental settings. Subsequent experiments conducted in the 
same conditions proved that this was indeed the case (data not shown).  
When cells were cultured in Matrigel, we observed considerable differences both in 
morphology and size between colonies formed by MCF7-ephrinB2 and MCF7 control cells. 
After 12 days of growth, colonies formed by control MCF7 cells appeared sphere-like and cell 
-cell boundaries were partially detectable at the periphery of the colonies (figure 3.4C). In 
comparison, the colonies formed by MCF7-ephrinB2 cells were considerably larger with less 
defined shape. The colony margins were not clearly defined, as the more peripheral cells 
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seemed to spread and/or migrate away from the main body of the colony. The size distribution 
analysis confirmed that MCF7-ephrinB2 colonies tended to be larger and more varied in size 
(figure 3.4D). More specifically, most MCF7 colonies fell in the 20-40 size class (56%) and 
the 40-60 class size (28%), while very few colonies were present in the higher size classes 
(8% in the 60-80 size class and 4% in the >80 size class). MCF7-ephrinB2 colonies were 
notably larger, with 20% measured in the 20-40 size class, 48% in the 40-60 size class, 28% 
in the 60-80 size class and 4% in the >80 size class. Surprisingly, EphB4/Fc stimulation only 
marginally increased colony size of MCF7-ephrinB2 colonies, while it did not affect the 
colony size of control MCF7 cells. Most of the MCF7 colonies stimulated with EphB4/Fc still 
fell in the 20-40 size class (68%) and the 40-60 size class (20%) with very few colonies in the 
60-80 size class (8%). EphB4/Fc stimulation only slightly increased MCF7-ephrinB2 colony 
size, with 4% of colonies in the 20-40 size class, 32% in the 40-60 size class, 44% in the 60-
80 size class and  20% in the >80 size class. As 3D culture experiments are subject to a 
certain degree of variability depending on the matrix used, we repeated the experiment twice 
and confirmed that the size distribution patterns for both cell lines and conditions were 
consistent (data not shown). Colony morphology remained unaffected by EphB4/Fc 
stimulation in both control MCF7 and MCF7-ephrinB2 colonies.  
These results suggest that only the Matrigel environment allows ephrinB2 to alter the 
morphology and size of MCF7 colonies. As the stimulation of ephrinB2 with the EphB4/Fc 
chimeric molecule only marginally increased MCF7 colony size, it is possible that the mere 
presence of ephrinB2 on the cell surface might be sufficient to induce the changes in colony 
size and morphology that we observed. Therefore, this effect might have been caused by 
ephrinB2-driven activation of the EphB4 receptor, rather than through ephrinB2 reverse 
signalling. Also, from these results it is unclear whether the increase in size of the MCF7-
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ephrinB2 colonies is caused by a different cell organization within the colony architecture or 
by increased cell growth. In order to address this issue, the colonies were fixed and Hoechst 
staining performed. We then analyzed the colonies by taking images of optical slices running 
through the middle of the structure. The images presented in figure 3.4E show a wide internal 
lumen within MCF7-ephrinB2 colonies. This suggests that the increase in MCF7-ephrinB2 
colony size might be aided by the formation of a lumen and might not be entirely caused by 
increased cell proliferation. This finding is intriguing, as reports in literature suggest that 
MCF7 colonies do not form a lumen in Matrigel 3D cultures (Kirshner, Chen et al. 2003). 
However, further analyses are needed to determine the contribution of lumen formation and 
cell proliferation to colony size. 
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Cell lines: <15 15-20 20-25 25-30 >30 
MCF7 25% 39% 29% 7% 0% 
MCF7 + EphB4/Fc 0% 57% 26% 13% 4% 
MCF7-ephrinB2 30% 45% 15% 1% 9% 
MCF7-ephrinB2 + EphB4/Fc 31% 46% 4% 11% 8% 
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E) 
 
   
 
Figure 3.4: ephrinB2 expression drives MCF7 colony growth in 3D Matrigel, but not 3D collagen I. 
MCF7 parental cells and MCF7-ephrinB2 cells were plated in 3D collagen I (panels A and B) or Matrigel (MG) 
(panels C and D) in the presence or absence of 5 µg/ml EphB4/Fc pre-clustered with anti-Fc IgG added every 2 
days for 12 days. A) Representative photographs of 30 colonies per condition grown in collagen. B) The surface 
area of the circumference drawn around each colony at its widest point was calculated using Nikon software and 
plotted on a histogram showing the percentage of analysed colonies categorized under a certain size class. 30 
colonies were analysed for each condition. The data is also presented as a table. C) Representative photographs 
of MG grown colonies. D) Quantification of MG colony size presented as histogram and table. E) Images of 
colonies grown in MG in the same conditions described in panel C, fixed to the glass bottom of the chamber 
slide and stained with Hoechst 33342. Images of optical slices positioned in the middle of the colony were taken 
using the confocal microscope.  
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3.1.3  Generation and characterization of tetracycline 
 inducible MCF7 cell lines expressing the wild type and 
 mutants of ephrinB2 
 
One of the main aims of our study was to characterize contribution of PDZ domain-
containing proteins to ephrinB2 signalling in breast cancer cells. Specifically, we were 
interested in proteins interacting with the PDZ binding motif of ephrinB2. Towards this goal 
we generated the ephrinB2/ΔV mutant with deletion of the C-terminal valine (Val333), 
which, according to previously published reports, does not bind to PDZ domain containing 
partners of ephrinB2 (Makinen, Adams et al. 2005). In another mutant, Val333 was 
substituted with Gly (ephrinB2/G) (figure 3.5). Based on the studies carried out in our 
laboratory (unpublished), the substitution of the last hydrophobic aminoacid in PDZ binding 
type I motifs had a less dramatic effect on the interaction with PDZ domain containing 
proteins. Hence, we expected ephrinB2/G to retain some of the interactions with PDZ-domain 
containing partners, thus allowing us to discriminate their contribution to ephrinB2 function. 
In particular, syntenin-1’s unique ability to bind all three types of PDZ binding motifs as well 
as degenerated PDZ binding sequences (Ivarsson 2012), lead us to believe that it might retain 
binding to the ephrinB2/G mutant. If this were the case and syntenin-1 was the only PDZ 
domain-containing protein to retain binding to ephrinB2/G, then we would be able to 
understand and pinpoint the specific role of syntenin-1 in ephrinB2 pathways using ephrinB2 
and ephrinB2/ΔV as positive and negative controls respectively. 
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Figure 3.5: diagram of the ephrinB2-Flag proteins used in our study.  
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3.1.3.1 Mutations of the ephrinB2 PDZ binding motif affect binding of  
  PDZ domain-containing proteins 
 
Before generating cell lines expressing the ephrinB2/G or ephrinB2/ΔV mutants, we 
tested their ability to bind all the PDZ domain-containing proteins known to interact with the 
PDZ binding motif of ephrinB2. These include syntenin-1, PICK1, PTPL1, PAR3, GRIP1 and 
GRIP2. In order to do so, we conducted pull down assays using biotin-conjugated peptides 
representing the C-terminal 14 amino acids of wild type and ephrinB2 mutants. Given that 
Dishevelled-2 is known to bind ephrinB2 in the same region through its DEP domain (section 
1.1.4.4 of the introduction), we decided to verify whether it too was able to bind the ephrinB2 
C-terminal peptides. This would give us additional information on whether non-PDZ domain-
containing proteins are able to compete with PDZ domain-containing proteins for the PDZ 
binding motif of ephrinB2. Apart from syntenin-1 and Dishevelled-2, the interaction with 
PDZ domain-containing proteins was examined using transiently transfected MCF7 cells.  
The blot in figure 3.6A clearly shows that syntenin-1 partially retained its ability to bind 
the ephrinB2/G peptide (lane 4), albeit to a lower extent than the ephrinB2 wild type peptide 
(lane 3). As expected, the interaction of syntenin-1 with the ephrinB2/∆V peptide was 
completely abolished (lane 5). We used an unrelated PDZ domain-containing protein CASK, 
which is endogenously expressed in MCF7 cells, as a negative control in order to ascertain 
that syntenin-1 binding to the peptides was specific. Dishevelled-2 and PICK1 were not able 
to bind the ephrinB2 wild type peptide and thus were not tested for ephrinB2/G and 
ephrinB2/∆V (figures 3.6B and 3.6C respectively). PTPL1, PAR3, GRIP1 and GRIP2 were 
all able to bind the ephrinB2 wild type peptide, but not the ephrinB2/G or the ephrinB2/∆V 
mutant peptides (figure 3.6, panels D, E, F and G respectively). 
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Taken together, these results revealed that the Val to Gly mutation at the C-terminus of 
ephrinB2/G abolished PDZ-mediated binding to all known PDZ domain-containing partners 
of ephrinB2, except syntenin-1. Thus, by using this mutant we would be able to discriminate 
the effects of the interaction between syntenin-1 and ephrinB2 from the effects of the other 
known interacting PDZ domain-containing partners. However, these results do not exclude 
the possibility that other yet unidentified proteins might be able to retain binding to the 
ephrinB2/G mutant in a PDZ-dependent or independent manner. 
 
  A) 
 
B)      C) 
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Figure 3.6: the C-terminal ephrinB2 peptide interacts with all known PDZ partners of ephrinB2 in MCF7 
cells, except PICK1. The /ΔV mutation completely impairs PDZ binding, while the /G mutation retains a 
discrete level of binding only to syntenin-1. 
Interaction of ephrinB2 PDZ domain-containing partners with ephrinB2 wild type, ephrinB2/G and ephrinB2/∆V 
C-terminal peptides assessed by pull down assay. The interaction with Dishevelled-2 and syntenin-1 was 
analysed using antibodies recognising endogenous proteins. The interaction with PICK1, PTPL1, PAR3, GRIP1 
and GRIP2 was analysed using MCF7 cells which were transiently transfected to express epitope-tagged 
proteins. Cells were lysed using 1% TritonX-100 buffer and pulled-down proteins (PD) were collected on 
peptides-conjugated NeutrAvidin-agarose beads and separated on SDS-PAGE. Whole lysates (Ly) samples were 
also resolved on SDS-PAGE as internal control. Proteins of interest which did not show any interaction with 
ephrinB2 wild type peptide were not tested for mutant peptides. Densitometry analysis was performed on pull 
down blots and optical densities (OD) shown for each lane. A) Endogenous syntenin-1 was detected using anti-
syntenin-1 mAb. The unrelated endogenous PDZ domain-containing protein CASK was also detected as internal 
negative control using anti-CASK mAb. Note, syntenin-1 was able to retain partial binding to the ephrinB2/G 
peptide. Densitometry analysis was performed only on syntenin-1 blot. B) Endogenous Dishevelled-2 was 
detected using anti-deshevelled-2 mAb. C) PICK1, F) GRIP1 and G) GRIP2 transfected proteins contained a c-
myc tag and were detected using anti-c-myc pAb. D) PTPL1 and E) PAR3 transfected proteins contained a flag 
tag and were detected using anti-flag pAb. Note, dishevelled-2 and PICK1 did not interact with the ephrinB2 
wild type peptide, while PTPL1, PAR3, GRIP1 and GRIP2 interacted with the wild type, but not mutant 
ephrinB2 peptides. 
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3.1.3.2 Generating and characterizing tetracycline inducible MCF7 cell 
  lines expressing ephrinB2, ephrinB2/G and ephrinB2/∆V 
 
In order to assess the biological activities of ephrinB2, ephrinB2/G or ephrinB2/ΔV, we 
needed the expression levels of the mutants to be comparable with that of the wild type 
protein. Therefore, we decided to generate tetracycline inducible MCF7 cell lines which 
expressed ephrinB2 wild type or the mutants only in the presence of the antibiotic tetracycline 
(or doxycycline). This system presented us with the opportunity of growing the newly 
generated MCF7 cell lines under standard conditions and actively regulating the expression of 
the proteins at our discretion. We decided to use the MCF7 TetOn cells (purchased from 
Clontech). According to the supplier’s manual, these cells are stably transfected with the 
pTet-On Advanced vector which encodes the Tet-On Advanced transcriptional activator. This 
engineered transcription factor consists of a mutant E. coli TetR protein (rTetR) fused to three 
minimal “F”-type activation domains derived from the herpes simplex virus (HSV) VP16 
protein. In the presence of doxycycline, Tet-On Advanced binds to the tetO sequences in the 
PTight inducible promoter on a different expression vector (in our case, the pBI vector) 
containing the gene of interest and induces gene expression. As PTight lacks binding sites for 
endogenous mammalian transcription factors, it is virtually silent in the absence of induction 
by doxycycline. Before generating our cell lines of interest, we established that the levels of 
endogenous EphB4 and syntenin-1 were comparable to those seen in our MCF7 cells. We 
also found that like MCF7 cells, MCF7 TetOn cells did not express ephrinB ligands (data not 
shown). We then stably transfected MCF7 TetOn cells with the tetracycline inducible pBI 
plasmid encoding either the wild type or the ephrinB2 mutants. Tetracycline-dependent 
expression was initially tested by flow cytometry (data not shown). Cells were subsequently 
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sorted by FACS using anti-Flag mAb for high expression of wild type or ephrinB2 mutants on 
the cell surface 48 hours after stimulation with doxycycline. We conducted FACS sorting 
twice in order to obtain a homogenous cell population expressing high levels of ephrinB2 
upon doxycycline stimulation. Newly generated cell lines were called MCF7 Tet-ephrinB2, 
MCF7 Tet-ephrinB2/G and MCF7 Tet-ephrinB2/∆V. We also generated a MCF7 Tet-
ephrinB2 cell line in which we depleted endogenous syntenin-1 using a lentiviral-based 
approach. After testing five different commercial shRNA lentiviral constructs targeting 
syntenin-1 in MCF7 TetOn cells (data not shown), we selected the most effective and used it 
to generate the MCF7 Tet-ephrinB2/shSyntenin-1 cell line. As shown in figure 3.7C, we 
managed to achieve ~75% knock down of endogenous syntenin-1 in these cells.  
In order to characterize the newly established tetracycline inducible cell lines, we 
performed flow cytometry analysis and immunofluorescence staining using anti-Flag mAb. 
We also verified expression levels of ephrinB2 and syntenin-1 by Western blotting. For all 
experiments, we analyzed cells before and after stimulation with doxycycline. In figure 3.7A, 
the histogram shows cell surface expression levels of ephrinB2 and mutants. These results are 
presented as percentages of ephrinB2 mean fluorescence intensity upon doxycycline 
stimulation (considered as 100%). These data are also presented in table format in figure 3.7B 
with negative and positive control values. Unstimulated cells expressed low levels of ephrinB 
protein on the cell surface (blue columns), which was expected, as inducible expression 
systems are subject to gene expression leakiness. Expression levels of ephrinB2/G and 
ephrinB2/ΔV after doxycycline stimulation (red columns), were ~20% lower than ephrinB2. 
However, in syntenin-1-depleted MCF7 Tet-ephrinB2 cells, ephrinB2 expression was ~30% 
higher. Interestingly, we noticed that cell surface expression of tetraspanin CD81 (ie the 
positive control) was also notably higher in syntenin-1-depleted cells. 
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The overall protein expression levels of ephrinB2/G and ephrinB2/∆V (lanes 4 and 6 
respectively) where slightly lower than ephrinB2 (lane 2) when measured by Western blotting 
(figure 3.7C). As expected, syntenin-1 levels were considerably lower in syntenin-1-depleted 
cells (lanes 7 and 8). β-actin levels were also measured and served as internal loading control. 
In order to obtain accurate values of overall expression levels, which we would be able to 
compare to flow cytometry values, we performed densitometric analysis of Western blots and 
presented the results as percentages of the expression level of ephrinB2 wild type upon 
stimulation with doxycycline (taken as 100%) (figure 3.7D). Our results show that the 
difference in cell surface expression observed for ephrinB2/G and ephrinB2/ΔV were 
probably caused by differences in overall expression, as the two mutants are expressed at 
~20% lower levels than ephrinB2. Interestingly, the total ephrinB2 expression level in the 
presence of syntenin-1 knock down was ~10% lower than that in non-depleted cells.  
Immunofluorescence staining of ephrinB2, ephrinB2/G and ephrinB2/∆V proteins using 
anti-Flag antibody confirmed that PDZ binding motif mutations and syntenin-1 depletion did 
not alter cell surface localization (figure 3.7E). As in the stable MCF7-ephrinB2 cell line, 
stronger staining was observed on the plasma membrane. However, in MCF7 Tet-
ephrinB2/shSyntenin-1 cells ephrinB2 staining appeared to be more diffuse.  
In summary, these experiments confirmed that the tetracycline-inducible system worked 
and that stimulation with 1 µg/ml doxycycline for 48 hours was sufficient to ensure high 
levels of protein expression in all four cell lines. More importantly, all cell lines expressed 
comparable levels of ephrinB2 proteins, albeit with minor differences.  
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A) 
 
 
 
B) 
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E) 
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Figure 3.7: doxycycline stimulation of tetracycline inducible MCF7 cell lines leads to strong and 
comparable ephrinB2, ephrinB2/G and ephrinB2/ΔV expression on the cell surface, although low levels of 
leaky expression are present in non-stimulated conditions. 
Characterization of MCF7 Tet-ephrinB2, MCF7 Tet-ephrinB2/G, MCF7 Tet-ephrinB2/ΔV and MCF7 Tet-
ephrinB2/shSyntenin-1 cell lines. A) The histogram illustrates the mean fluorescence intensities obtained by 
flow cytometry analysis of all four cell lines in normal conditions (control) or after 48 hours stimulation with 1 
µg/ml doxycycline using anti-Flag mAb. The results are presented as percentage values related to the mean 
fluorescence of ephrinB2 expressing cells upon doxycycline stimulation (considered as 100%). B) The table lists 
the percentage values shown in the histogram (A) alongside the negative and positive controls of the flow 
cytometry analysis for each cell line. Anti-PI4K mAb as negative control; anti-CD81 mAb was used to detect the 
endogenous membrane protein CD81 as positive control. C) The same samples presented in panel A were 
analyzed via WB. Cells were lysed in 1x Laemmli buffer and proteins were resolved on SDS-PAGE. EphrinB2 
total protein levels were detected with anti-ephrinB pAb. Syntenin-1 total levels were detected with anti-
syntenin-1 mAb and β-actin was detected with anti-β-actin mAb as internal loading control. D) The histogram 
shows densitometric values obtained with Odyssey software (Licor) from WB (C) and presented as percentages 
of ephrinB2 expression after doxycycline stimulation (considered as 100%). E) Immunofluorescence images of 
MCF7 tetracycline inducible cells 48 hours after stimulation with 1 µg/ml doxycycline. Cells were fixed with 
2% PFA and probed with anti-flag mAb. 
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3.1.3.3 EphrinB2 expression affects colony growth of MCF7 TetOn cells in 
  Matrigel based 3D cultures 
 
As already mentioned, 3D culture systems are commonly used to analyze protein 
functions in higher-order tissue architecture during mammary morphogenesis and cancer 
development (Hebner, Weaver et al. 2008). Having discovered that ephrinB2 expression in 
stably transfected MCF7 cells alters colony size and morphology in Matrigel based 3D 
cultures, we decided to evaluate the effect of ephrinB2, ephrinB2/G and ephrinB2/∆V 
expression in the MCF7 tetracycline inducible model. We first conducted a pilot experiment 
whereby MCF7 TetOn parental cells and MCF7 Tet-ephrinB2 cells were plated in 2% 
Matrigel and colonies allowed to grow for 12 days in the presence or absence of doxycycline. 
The cells which formed the colonies were then lysed and the protein extracts were analyzed 
by WB in order to detect ephrinB2 expression levels. By doing so, we were able to confirm 
that doxycycline stimulation induced ephrinB2 expression in 3D Matrigel (figure 3.8C). 
Figure 3.8A shows representative images of MCF7 TetOn (parental) and MCF7 Tet-
ephrinB2 colonies. In contrast to the MCF7 cells we used to generate the stable MCF7-
ephrinB2 cell line, MCF7 TetOn cells formed smaller colonies with well defined borders. 
MCF7 Tet-ephrinB2 cells formed relatively large and round colonies in the presence or 
absence of doxycycline stimulation. The morphology of these colonies differed from the one 
we observed in MCF7-ephrinB2 cells: the colonies were compact, had clear and defined 
borders and were not characterized by single cells escaping from the main body. We 
concluded that the MCF7 TetOn cell line behaved differently when grown in 2% Matrigel, as 
both the size of MCF7 TetOn colonies and the morphology of MCF7 Tet-ephrinB2 colonies 
was notably different from MCF7 and MCF7-ephrinB2 colonies. Moreover, doxycycline 
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stimulation did not seem to affect the size or shape of MCF7 Tet-ephrinB2 colonies. 
Quantification of these experiments (conducted as explained in section 3.1.2.3) is presented in 
figure 3.8B. All the MCF7 TetOn colonies fell in the lower <10 size class in the presence or 
absence of doxycycline stimulation. MCF7 Tet-ephrinB2 colonies were considerably larger, 
with 3% falling in the 10-20 size class, 53% in the 20-30 size class, 27% in the 30-40 size 
class and 17% in the >40 size class. As already mentioned, doxycycline did not alter colony 
distribution size of MCF7 Tet-ephrinB2 colonies, as 20% of measured colonies fell in the 10-
20 size class, 37% in the 20-30 size class, 17% in the 30-40 size class and 27% in the >40 size 
class. 
Taken together, these results suggest that even low levels of ephrinB2 expression are 
sufficient to drive colony growth in MCF7 TetOn cells when grown in 2% Matrigel. 
However, the morphology of the colonies seemed to remain unchanged. The small colonies 
formed by MCF7 TetOn cells suggest that colony growth is strongly impaired in this cell line 
when grown in Matrigel 3D cultures. Moreover, the fact that the size and shape of MCF7 Tet-
ephrinB2 colonies remained unaffected by doxycycline stimulation probably indicates that 
colony growth was not driven by ephrinB2 reverse signalling. More likely, it seems that small 
amounts of ephrinB2 were sufficient to activate endogenous EphB receptors or other cell 
surface communication systems on neighbouring cells which in turn increased colony growth. 
Data from previous experiments using EphB4/Fc stimulation in MCF7-ephrinB2 3D cultures, 
described in section 3.1.2.3, also seems to suggest that ephrinB2 reverse signaling did not 
play a role in 3D colony growth. If indeed activation of the reverse signalling pathway did not 
contribute to growth of MCF7 colonies in 3D cultures, then one would not expect the 
experiments using ephrinB2/G and ephrinB2/∆V expressing cells to yield any useful 
information. Moreover, the use of MCF7 Tet-ephrinB2 cells depleted of syntenin-1 via 
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shRNA knock down did not prove useful, as syntenin-1 depletion strongly inhibits MCF7 
colony growth in 2% Matrigel as ascertained in previously conducted pilot experiments (data 
not shown).  
To summarize, by culturing MCF7 Tet-ephrinB2 cells in Matrigel-based 3D cultures, 
we determined that small amounts of ephrinB2 expression were sufficient to drive colony 
growth of MCF7 TetOn cells. Thus, ephrinB2 reverse signalling does not seem to play a role 
in this process and for this reason we decided not to pursue this assay any further. 
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B)  
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C) 
 
 
Figure 3.8: low levels of ephrinB2 expression are sufficient to drive colony growth of tetracycline inducible 
MCF7 cells in 3D Matrigel, while doxycycline-induced over-expression of ephrinB2 does not show an 
added effect. 
A) representative photographs of MCF7 Tet-ephrinB2 and MCF7 TetOn parental cells grown in 2% Matrigel 
(MG) for 12 days in the presence or absence of 1 µg/ml doxycycline (added to the growth medium every 48 
hours). Photographs were taken at an inverted light microscope at 20x magnification. B) Statistical analysis of 
colony size was conducted as described in figure 3.4 and presented in the histogram and the table as percentage 
of measured colonies which fell under a pre-determined size class. C) After 30 colonies were photographed for 
each condition, MCF7 Tet-ephrinB2 cells were lysed in 1x Laemmli buffer and cell lysates were loaded on SDS-
PAGE. EphrinB2 was detected using anti-ephrinB pAb. β-actin was detected as internal loading control.  
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3.1.3.4 Assessing syntenin-1 binding to ephrinB2 and mutants in 
tetracycline inducible MCF7 cells 
 
When analyzing interactions between two proteins, pull down assays using short 
peptides are not always representative of the binding dynamics observed in cells. One of the 
reasons is that binding between full-length proteins can be affected by their tertiary structure. 
Another reason is that proteins in cells are compartmentalized differently. Therefore, it was 
important to verify the binding of syntenin-1 to wild type and ephrinB2 mutants expressed in 
tetracycline inducible MCF7 cells. After stimulating cells with doxycycline, we performed a 
co-immunoprecipitation (co-IP) assay using anti-Flag antibody conjugated to agarose beads 
followed by WB with anti-ephrinB pAb and anti-syntenin-1 pAb.  
Figure 3.8A shows the WB analysis of both co-IP and whole lysate samples. Similarly 
to the pull down assay, syntenin-1 binding to ephrinB2/G was strongly impaired but not 
abolished (lane 3). By contrast, binding of syntenin-1 to ephrinB2/ΔV was hardly detectable 
(lane 4). As expected, in MCF7 Tet-ephrinB2/shSyntenin-1 cells the residual level of binding 
of syntenin-1 to ephrinB2 reflected the incomplete level of syntenin-1 knock down (lanes 5). 
Because the amount of precipitated protein can slightly differ between samples in co-
immunoprecipitation experiments, we performed densitometric analysis on both ephrinB and 
syntenin-1 levels and calculated the ratio between them. The histogram in figure 3.8B 
illustrates the percentage of syntenin-1 binding in all cell lines with MCF7 Tet-ephrinB2 
considered to be 100%. By doing so, we observed that syntenin-1 binding to ephrinB2/G was 
20 fold lower when compared to the wild type ephrinB2. The binding ability of syntenin-1 to 
ephrinB2/ΔV was more than 70 fold lower. This experiment confirmed that ephrinB2/G still 
retains the ability to bind syntenin-1, albeit at a much lower level than ephrinB2. 
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To summarize, we proved that the tetracycline inducible cell lines that we generated 
worked according to expectations and that endogenous syntenin-1 binding to ephrinB2 and 
mutants yielded comparable results to the ones observed in pull down assays. 
 
 
 
  
Results and Discussion 
~ 140 ~ 
 
A) 
 
B) 
 
Figure 3.9: ephrinB2/G retains a discrete level of binding to syntenin-1, while ephrinB2/ΔV does not. 
EphrinB2, ephrinB2/G and ephrinB2/∆V interaction with syntenin-1 was assessed using co-immunoprecipitation 
(co-IP) assay. MCF7 TetOn and MCF7 Tet-ephrinB2/shSyntenin-1 cell lines were also tested. Cells were lysed 
in 1% TritonX-100 buffer and protein complexes were collected on anti-Flag antibody-conjugated agarose 
beads. Co-immunoprecipitated proteins (IP) were eluted from agarose beads and resolved on SDS-PAGE. Whole 
lysate samples (Ly) were also analysed as internal control. A) EphrinB2 was detected with anti-ephrinB pAb, 
while syntenin-1 was detected with anti-syntenin-1 pAb. Note, syntenin-1 retained partial binding to 
ephrinB2/G, but was unable to bind ephrinB2/∆V. B) Densitometry analysis was conducted on WB (A). Ratios 
between densitometry values of immunoprecipitated ephrinB2 proteins and co-immunoprecipitated syntenin-1 
was calculated for each sample and presented as percentage of the wild type ephrinB2/syntenin-1 ratio 
(considered as 100%) in the histogram.  
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3.1.4  Discussion 
 
In normal physiological conditions, ephrinB2 is expressed in luminal epithelial cells in 
the mammary gland, while EphB4 is expressed in the surrounding myoepithelial cells 
(Munarini, Jager et al. 2002). During mammary gland tumourigenesis, luminal epithelial cells 
gradually suppress ephrinB2 expression and induce EphB4 expression. At later stages of 
tumour development, EphB4 expression is also suppressed (Nikolova, Djonov et al. 1998). 
Therefore, ephrinB2 and EphB4 expression levels differ greatly between epithelial breast 
cancer cell lines (Berclaz, Flutsch et al. 2002; Andres and Ziemiecki 2003; Kumar, Singh et 
al. 2006; Noren, Foos et al. 2006).  
For these reasons, we analyzed endogenous expression levels of EphB4, ephrinB 
ligands and syntenin-1 in 21 breast cancer epithelial cell lines and 2 non-tumourigenic 
mammary epithelial cell lines in order to select an adequate cell line to use as a model system 
(figure 3.1). To our knowledge, this screening was the largest conducted to date and proved 
that EphB4 and ephrinB ligands expression varies considerably between these cell lines. 
Previous studies have either analysed mRNA levels of the EphB4 receptor alone (Berclaz, 
Andres et al. 1996) or have included fewer breast cancer cell lines in their screening (Wu, Suo 
et al. 2004; Kumar, Singh et al. 2006; Noren, Foos et al. 2006). Only one study conducted a 
methodical examination of mRNA levels of all Eph and ephrin proteins in representative cell 
lines of normal breast epithelium (MCF10A), non-invasive breast carcinoma (MCF7) and 
invasive breast carcinoma (MDA-MB-231) (Fox and Kandpal 2004). In our screening, most 
cell lines expressed medium to high levels of EphB4, but only 12 expressed appreciable levels 
of ephrinB ligands. For the purpose of our study, we selected the breast adenocarcinoma 
MCF7 cell line, as it did not express any ephrinB ligands and expressed minimal levels of 
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EphB4. Interestingly, a previous study has observed high levels of EphB4 and low levels of 
ephrinB2 expression in MCF7 cells (Kumar, Singh et al. 2006). Additionally, ephrinB2 
mRNA levels were found to be higher than EphB4 levels in the study by (Fox and Kandpal 
2004). Whilst the correlation between mRNA levels and protein levels is not direct and thus 
may account for some of these discrepancies, other factors may come into play, such as the 
expression levels of other proteins which induce protein expression (high ErbB2 levels induce 
EphB4 expression in MCF7 cells (Kumar, Singh et al. 2006)) or simply the source of cell 
lines used and slight variations in culturing conditions. By contrast, the ZR75.30, T47D and 
SKBR3 cell lines analysed in the study previously mentioned (Kumar, Singh et al. 2006) 
showed comparatively similar levels of EphB4 and ephrinB2 expression as detected in our 
study. 
 
We generated a MCF7 cell line stably expressing an ephrinB2 wild type protein tagged 
with a flag sequence on the extracellular portion at the N-terminus. As expected, Flag-
ephrinB2 was detected on the cell surface (figure 3.2A). Interestingly, we could detect low 
basal level of ligand phosphorylation (figure 3.2B). This phenomenon was also observed in 
previous studies focused on ephrinB ligands phosphorylation dynamics (Bruckner, Pasquale 
et al. 1997; Palmer, Zimmer et al. 2002). Various pathways could be involved in basal 
ephrinB2 phosphorylation. Firstly, endogenous EphB4 might induce ephrinB2 
phosphorylation via trans interaction. However, various reports have suggested that ephrinB 
ligands over-expression in cell lines cultured in vitro tend to lose EphB receptor expression, 
possibly through continuous ligand-induced internalization and degradation (Pasquale 2008). 
Secondly, ephrinB2 phosphorylation might be driven by FGF receptors-induced trans-
phosphorylation. Indeed, direct interaction of ephrinB1 with FGF receptors induced ligand 
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phosphorylation and Grb4-mediated reverse signalling in Xenopus embryos (Chong, Park et 
al. 2000; Bong, Park et al. 2004). Alternatively, trans activation of claudin-4 during cell-cell 
adhesion was shown to induce ephrinB1 phosphorylation through Src activation (Tanaka, 
Kamata et al. 2005). As the cytoplasmic tails of ephrinB1 and ephrinB2 are 95% identical 
with the C-terminal 33 amino acids sharing 100% homology, it is likely that ephrinB2 can be 
phosphorylated in the same manner as ephrinB1. Finally, ephrinB2 basal phosphorylation 
might also be caused by the presence of constitutively active Src kinases in MCF7 cells 
(Gonzalez, Agullo-Ortuno et al. 2006). In fact, our data suggests that Src kinases are directly 
responsible for ephrinB2 phosphorylation, as reported by previous studies (Palmer, Zimmer et 
al. 2002; Georgakopoulos, Litterst et al. 2006). Taken together, we conclude that many 
different pathways, related and unrelated to EphB receptors stimulation, might take part in 
ephrinB2 basal phosphorylation in MCF7 cells. 
 
To determine the functionality of our MCF7-ephrinB2 cell line, we analyzed ephrinB2 
phosphorylation dynamics upon EphB4/Fc stimulation by WB (figure 3.3A). In order to 
conduct a more comprehensive analysis of ephrinB2 phosphorylation, we included both early 
time-points (5, 15, 30 minutes) and late time-points (60, 120, 240 minutes) in our signalling 
experiments. Increase in ephrinB2 phosphorylation was first detected at 15 minutes after 
EphB4/Fc stimulation and peaked between 60 and 120 minutes before diminishing at 240 
minutes. These results somewhat differed from a previous study on ephrinB1 phosphorylation 
(Bruckner, Pasquale et al. 1997). In this study, ephrinB1 phosphorylation peaked at 10 
minutes after EphB2/Fc stimulation and gradually decreased at 20, 30 and 60 minutes. 
Notably, Bruckner and colleagues used 10 µg/ml of non-clustered EphB2/Fc to stimulate 
ephrinB1, which might explain the differences in phosphorylation dynamics. As ephrinB1 and 
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ephrinB2 share 95% homology in their cytoplasmic tail, it is possible to draw a parallel 
between the signalling data obtained from these two proteins. In the study by Bruckner and 
colleagues and in our study the decrease in ligand phosphorylation was accompanied by a 
decrease in total protein levels. These data are in accordance with previous reports suggesting 
that prolonged EphB4 stimulation eventually causes ephrinB2 internalization and degradation 
(Foo, Turner et al. 2006). Detection of increased Src phosphorylation after 5 minutes from 
EphB4/Fc stimulation, suggested that ephrinB2 phosphorylation was preceded and driven by 
Src activation (figure 3.3B), thus confirming literature reports on the importance of Src 
kinases in ephrinB2 reverse signalling (Palmer, Zimmer et al. 2002; Georgakopoulos, Litterst 
et al. 2006; Georgakopoulos, Xu et al. 2011). Inhibition of Src kinases with the SU6656 
inhibitor prior to EphB4/Fc stimulation considerably decreased ephrinB2 phosphorylation 
(figure 3.3B), as previously reported in literature (Palmer, Zimmer et al. 2002). Intriguingly, 
we also noticed that the decrease of ephrinB2 total levels at the later time-points was less 
sharp upon SU6656 treatment. This observation points to the possibility that ephrinB2 
phosphorylation status and/or Src activity are involved in the process of ligand degradation. 
This would imply, for the first time, that ephrinB degradation is not only driven by protein 
cleavage and EphB-induced ligand internalization, but also by ligand phosphorylation. This 
hypothesis is supported by the fact that prolonged stimulation with EphB receptors causes the 
complete degradation of ephrinB ligands (Foo, Turner et al. 2006). Therefore, we propose that 
ligand phosphorylation status might be responsible for a yet unreported mode of ephrinB 
degradation. 
 
One of the main research objectives of this study was to analyze the functional 
consequences of ephrinB2 – expression in breast cancer development. In order to address this 
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point, we employed the use of three-dimensional (3D) culture systems (figure 3.4), which are 
best suited to study how proteins influence breast cancer development in a more “in vivo-like” 
setting (Hebner, Weaver et al. 2008). We tested the ability of MCF7 and MCF7-ephrinB2 
cells to grow in collagen I (figure 3.4A,B) and Matrigel (figure 3.4C,D) based matrices with 
or without EphB4/Fc stimulation. In collagen, colonies grew as symmetrically shaped, 
compact spheres and were not affected by ephrinB2 expression or EphB4/Fc stimulation. In 
Matrigel, MCF7 cells formed compact sphere-like colonies, which grew as larger and 
irregularly shaped structures in the presence of ephrinB2 expression and independently of 
EphB4/Fc presence. Interestingly, the colonies formed by MCF7-ephrinB2 cells were 
characterized by a wide internal lumen (figure 3.4E), which is usually not present in typical 
MCF7 colonies grown in Matrigel (Kirshner, Chen et al. 2003; Krause, Maffini et al. 2010; 
Wang, Lacoche et al. 2013). The different colony growth patterns observed in collagen and 
Matrigel might be caused by the different components contained in the two matrices. For 
example, Matrigel contains laminin-1, collagen IV and entactin (Grant, Kleinman et al. 1985). 
Furthermore, collagen I and Matrigel matrices show different mechanotransduction 
properties, which are known to produce different effects on mammary architecture, metabolic 
function and differentiation in normal breast epithelium (Emerman and Pitelka 1977; 
Emerman, Bartley et al. 1980).  Matrigel also contains various growth factors, such as FGF, 
EGF, TGF-β and PDGF (Benton, Kleinman et al. 2011). In this respect, various studies have 
reported that FGF receptor activity induces ephrinB1 phosphorylation (Chong, Park et al. 
2000; Bong, Park et al. 2004), thus suggesting that the FGFR – ephrinB2 axis might be 
involved in the faster colony growth of MCF7-ephrinB2 cells. EphrinB2 might also be able to 
affect MCF7 colony growth through its association with β-integrins, which are known to 
increase cell proliferation and alter morphology of breast cancer cell colonies in 3D cultures 
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(Weaver, Petersen et al. 1997). Previous studies have shown that ephrinB2 – β1-integrin 
association induced cell migration in B16 melanoma cultures (Meyer, Hafner et al. 2005) and 
that ephrinB2 modulated αVβ1 integrin clustering at sites of cell-driven fibronectin assembly 
in Matrigel based 3D cultures (Julich, Mould et al. 2009). Interestingly, there are no reports 
on ephrinB association with β4-integrin, which interacts specifically with laminin and is 
responsible for cell-ECM adhesion through the formation of hemidesmosomes (Borradori and 
Sonnenberg 1999). β4-integrin also plays an important role in breast carcinoma progression 
(Mercurio, Rabinovitz et al. 2001). Specifically, α6β4-integrin is associated with ErbB2-
induced mammary tumourigenesis, as reported in the study by (Guo, Pylayeva et al. 2006). 
Here, the authors found that ErbB2 induced phosphorylation of the signalling domain of 
α6β4-integrin through activation of Src kinases. Intriguingly, ephrinB1 is also phosphorylated 
as a result of ErbB2 activation and both proteins have been found to associate at sites of cell-
cell junctions (Vermeer, Bell et al. 2012). Therefore, it is possible that ephrinB2 activation by 
EphB receptors, FGF receptors or ErbB2 might drive colony growth through α6β4-integrin 
activity upon interaction with laminin-1 in 3D Matrigel.  
Although we did not conduct a detailed analysis on the effect of ephrinB2 over-
expression on MCF7 cell proliferation in Matrigel 3D cultures, it appears that ephrinB2 is 
able to alter the cellular organization of MCF7 colonies by driving cells to spread at the 
periphery of the structures (figure 3.4C). This “pro-migratory” phenotype is consistent with 
the role of ephrinB2 in driving angiogenesis and metastasis in breast tumours described in 
literature (Kumar, Singh et al. 2006; Salvucci, Maric et al. 2009), although it remains unclear 
whether it is caused by ephrinB2 reverse signalling or EphB forward signalling. Nevertheless, 
ephrinB/EphB signalling-induced cell repulsion is likely to contribute to the “pro-migratory” 
phenotype observed in 3D Matrigel-grown colonies. Syntenin-1 might also be responsible for 
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this phenotype, as it promotes breast cancer cell migration by up-regulating β1-integrin 
expression (Yang, Hong et al. 2013). Furthermore, the role of syntenin-1 in FAK and Src 
activation upon integrin-mediated binding to fibronectin and collagen is important for 
anchorage-independent growth and migration (Boukerche, Su et al. 2008; Sarkar, Boukerche 
et al. 2008; Hwangbo, Kim et al. 2010), which would facilitate cell spreading to the periphery 
of the colony. Taking into consideration the role of Src in ephrinB2 phosphorylation and the 
ability of syntenin-1 to bind ephrinB ligands, it is possible that the ephrinB2 – syntenin-1 axis 
contributes to the “pro-migratory” phenotype of MCF7-ephrinB2 cells in 3D Matrigel-grown 
colonies. 
Another interesting characteristic of MCF7-ephrinB2 colonies is the presence of a wide 
internal lumen (figure 3.3E). Matrigel-grown MCF7 colonies typically do not form a lumen, 
as their cells are not polarized (Kirshner, Chen et al. 2003; Krause, Maffini et al. 2010; Wang, 
Lacoche et al. 2013). Given the ability of ephrinB2 to interact with PAR3, it is possible that 
this interaction affects cell polarity and promotes lumen formation in MCF7-ephrinB2 
colonies. In mammalian polarized epithelial cells, PAR3 localizes at the apical/lateral 
boundary of polarized cells where it recruits PAR6 and aPKC to form the PAR3 – PAR6 – 
aPKC PAR polarity complex, thus contributing to the formation of a correctly orientated 
microtubule spindle (Hebner, Weaver et al. 2008; McCaffrey and Macara 2011; Chen and 
Zhang 2013). Knock down of PAR3 in MCF10A cells disrupts cell polarity and lumen 
formation in colonies grown in 3D Matrigel (Wang, Lacoche et al. 2013). Moreover, PAR3 
takes part in tight junction formation between epithelial cells (Ohno 2001; Chen and Zhang 
2013) and its association with PAR6 and aPKC can be disrupted by the physical interaction of 
ErbB2 with PAR6 in MCF10A cells grown in 3D cultures (Aranda, Haire et al. 2006). Given 
the ability of ephrinB ligands to bind PAR3 via PDZ-mediated interaction (Cowan and 
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Henkemeyer 2002) and to cross-talk with ErbB2 signalling at sites of cell-cell junctions 
(Vermeer, Bell et al. 2012), it is possible that ephrinB2 modulates PAR3 and ErbB2 activity 
during junction formation. As ephrinB2 over-expression appeared to induce lumen formation 
in MCF7 colonies, it is possible that ephrinB2 is able to restore a certain level of cell polarity 
through interaction with PAR3 by countering the disrupting effect of ErbB2 on the PAR 
polarity complex. In support of this hypothesis, a study by (Kaenel, Antonijevic et al. 2012) 
has found that deletion of the cytoplasmic tail of ephrinB2 in luminal epithelial cells causes 
aberrant cell polarization in vivo. However, the role of ephrinB2 in this context might not be 
so simple, as studies have shown that ephrinB2 over-expression or knock out in mouse 
models is associated with aberrant lumen formation and deregulated proliferation/apoptosis 
ratios of normal mammary epithelial cells (Weiler, Rohrbach et al. 2009). Interestingly, this 
effect has been closely linked to ephrinB2 cross-talk with E-cadherin (Haldimann, Custer et 
al. 2009), which has been identified as a major player in the formation of MCF7 spheroid 
structures in 3D cultures (Ivascu and Kubbies 2007).   
Therefore, ephrinB2 expression seems to play a pivotal role in driving both structure 
and lumen formation in epithelial mammary colonies through the possible cross-talk with 
integrins, E-cadherin, syntenin-1 and PAR3. Further study might reveal new connections 
between ephrinB ligands and other adhesion molecules involved in these processes. A 
possible candidate is, for example, CEACAM1, which is involved in driving lumen formation 
in mammary epithelial colonies (Kirshner, Hardy et al. 2004). All considered, the Matrigel 
based 3D cell culturing technique seemed to possess the potential for uncovering functional 
aspects of the ephrinB2 ligand in the context of breast cancer epithelial cells, which would 
have otherwise remained hidden in standard in vitro cultures.  
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After establishing the functionality of our MCF7 model system, we generated ephrinB2 
mutants with a disrupted PDZ binding motif: ephrinB2/G and ephrinB2/ΔV (figure 3.5). 
Surprisingly, whilst assessing the interaction of wild type and ephrinB2 mutants with known 
PDZ domain-containing partners, we found that the ephrinB2 peptide does not bind 
Dishevelled-2 and PICK1 (figures 3.6B and 3.6C respectively). Dishevelled-2 was initially 
found to bind the cytoplasmic tail of Xenopus ephrinB1 in co-immunoprecipitation assays 
performed with recombinant GST-ephrinB1 (aa 264-346) (Tanaka, Kamo et al. 2003). The 
authors also stated that Xenopus ephrinB1 phosphorylation upon EphB2 stimulation did not 
affect binding affinity. Later studies reported that the DEP domain of Dishevelled-2 was 
essential for binding to Xenopus ephrinB1 and that deletion of the 6 C-terminal amino acids 
of ephrinB1 abolished the interaction with Dishevelled-2 (Lee, Bong et al. 2006; Lee, Mood 
et al. 2009). Interestingly, Lee and colleagues also reported that phosphorylation of Tyr326 
and/or Tyr327 of Xenopus ephrinB1 (which correspond to Tyr330 and Tyr331 of human 
ephrinB2) strongly impairs binding to Dishevelled-2, thus contradicting the previous report by 
Tanaka and colleagues. As the 14 C-terminal amino acids of human, chicken and Xenopus 
ephrinB1 are 100% identical to human ephrinB2, our data suggests that this C-terminal 
sequence is not sufficient for ephrinB1 and ephrinB2 binding to Dishevelled-2.  
PICK1 was found to interact with ephrinB1 through PDZ-mediated interaction in a 
yeast two-hybrid system using a 92 aminoacid long bait formed by the C-terminus sequence 
of ephrinB1 (Torres, Firestein et al. 1998). The interaction was also confirmed via co-
immunoprecipitation in the same study. Since then, only one study has investigated the 
binding properties of the PICK1 – ephrinB1 interaction by using bioinformatics and 
biophysical docking simulations (Bolia, Gerek et al. 2012). Therefore, it is possible that the 
14 C-terminal amino acids of ephrinB ligands are not sufficient to allow PICK1 binding. 
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In co-immunoprecipitation experiments conducted early on in our study (data not 
shown), we were also unable to detect PDZ-RGS3 binding to ephrinB2. PDZ-RGS3 was 
initially discovered as an ephrinB1 interacting protein via yeast two-hybrid screening using a 
bait formed by the whole cytoplasmic tail of ephrinB1 (Lu, Sun et al. 2001). The authors 
confirmed the existence of the interaction via pull down assays using a recombinant GST-
ephrinB1 protein containing the 33 amino acids long C-terminal sequence of ephrinB1 (which 
is 100% identical to ephrinB2). Through the use of mutants, they also determined that the 
PDZ-RGS3 – ephrinB1 interaction was mediated by the PDZ domain of PDZ-RGS3 in co-
immunoprecipitation assays performed in COS cells. As Lu and colleagues used our same 
detergent conditions for cell lysis, it is unlikely that the experimental conditions are to blame 
for this discrepancy. However, it is possible that ephrinB2 and PDZ-RGS3 are diversely 
compartmentalized in MCF7 cells, which would not allow us to detect the ephrinB2 – PDZ-
RGS3 interaction by co-immunoprecipitation. 
As expected, the ephrinB2/ΔV peptide was unable to pull down any of the PDZ 
domain-containing proteins, while the ephrinB2/G peptide retained partial binding only to 
syntenin-1, albeit at a considerably lower level than ephrinB2 wild type (figure 3.6). This 
phenomenon is probably due to the versatility of syntenin-1 PDZ-mediated binding and its 
ability to bind degenerated PDZ binding motif sequences (Beekman and Coffer 2008). 
Therefore, by generating MCF7 cell lines expressing ephrinB2, ephrinB2/G and ephrinB2/∆V 
we would be able, for the first time, to distinguish the role of syntenin-1, during its interaction 
with ephrinB2, from all the other known PDZ partners that we have tested in this study. 
Nevertheless, one has to keep into account the possibility that ephrinB2/G might also retain 
binding to other yet unknown PDZ binding partners of ephrinB2, leading to a more cautious 
interpretation of the ephrinB2/G phenotype.  
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Although a small level of leakiness in protein expression was observed, our tetracycline 
inducible MCF7 cell lines worked as expected. Cell surface and total protein expression levels 
of ephrinB2, ephrinB2/G and ephrinB2/∆V were comparable, with minor differences of ~20% 
less expression of ephrinB2/G and ephrinB2/∆V compared to ephrinB2 (figure 3.7). These 
results were expected, as previous reports suggested that the PDZ binding motif is not 
involved in ephrinB delivery to the cell surface (Makinen, Adams et al. 2005). In MCF7 Tet-
ephrinB2/shSyntenin-1 cells, ephrinB2 cell surface expression was higher than the total 
expression when compared to the other cell lines (figure 3.7A,B). However, this effect is 
probably indirect and not caused by the lack of ephrinB2 – syntenin-1 interaction, as both 
ephrinB2/G and ephrinB2/ΔV did not show similar discrepancies in their expression levels. 
Additionally, cell surface expression of tetraspanin CD81, which we used as a positive 
control, was also higher in syntenin-1 depleted cells. Indeed, syntenin-1 is involved in many 
trafficking pathways and its depletion might have widespread repercussions on cell trafficking 
(Beekman and Coffer 2008). For example, syntenin-1 knock down would affect syndecan 
recycling to the cell surface via interaction with PI(4,5)P2 (Zimmermann, Zhang et al. 2005) 
and the formation of tripartite complexes with syndecans and Alix in connection with cargo 
recruitment to exosomal compartments (Baietti, Zhang et al. 2012). Furthermore, syntenin-1 
is involved in CD63 endocytosis (Latysheva, Muratov et al. 2006) and is responsible for 
proTGFα delivery to the cell surface (Fernandez-Larrea, Merlos-Suarez et al. 1999). 
Therefore, the overall effect of syntenin-1 knock down on cell trafficking might have caused 
the slight increase in ephrinB2 cell surface expression.  
Protein localization observed using immunofluorescence confirmed that ephrinB2 and 
mutants are expressed and localized on the cell surface of MCF7 tetracycline inducible cells 
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(figure 3.7E). Moreover, binding motif mutations did not seem to affect ligand localization, as 
has already been reported in literature (Makinen, Adams et al. 2005).  
3D culture experiments on MCF7 TetOn parental cells and MCF7 Tet-ephrinB2 cells 
grown in Matrigel under doxycycline stimulated or non-stimulated conditions revealed that 
low ephrinB2 expression levels were sufficient to cause a notable increase in colony size, but 
no difference in colony morphology (figure 3.8). Surprisingly, MCF7 TetOn colonies were 
much smaller than MCF7 colonies analysed in our previous experiment (section 3.1.2.3). 
Although we did not investigate these differences further, it is possible that lower integrin 
expression levels in MCF7 TetOn cells were responsible for the colony phenotype that we 
observed. In fact, laminin-induced integrin activation increases colony growth in 3D Matrigel 
(Kirshner, Hardy et al. 2004; Cagnet, Faraldo et al. 2013). More specifically, high expression 
levels of β1-integrin and β4-integrin were found to increase cell proliferation and alter 
morphology of T4-2 breast cancer cell colonies in Matrigel based 3D cultures (Weaver, 
Petersen et al. 1997). The same group also reported that the role of β1-integrin in this context 
was tightly linked with EGFR activity. Down-regulation of either β1-integrin or EGFR 
resulted in impaired T4-2 colony growth in Matrigel based 3D cultures. Moreover, inhibition 
of EGFR signalling normalized β1-integrin expression levels in 3D cultures, but not in 2D 
monolayer cultures (Wang, Moorer-Hickman et al. 1998). This might explain why we 
detected a different phenotype between MCF7 TetOn and MCF7 cells in 3D cultures and not 
in 2D monolayers.  
The similar morphology between control and ephrinB2 expressing cells might also be 
explained by the possibility that these cells express low integrin levels. Given the ability of 
ephrinB2 to induce cell migration in B16 melanoma cells by associating with β1-integrin 
(Meyer, Hafner et al. 2005) and the role of ephrinB2 in modulating αVβ1-integrin clustering 
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at sites of cell-driven fibronectin assembly in Matrigel based 3D cultures (Julich, Mould et al. 
2009), it is possible that lower integrin levels in MCF7 TetOn cells prevented the 
development of the ephrinB2-induced morphological phenotype that we observed in MCF7-
ephrinB2 colonies. Furthermore, low integrin levels would also impair the pro-migratory 
stimuli generated by syntenin-1-driven FAK-Src activation upon β1-integrin binding to 
fibronectin and collagen (Boukerche, Su et al. 2008). Interestingly, the increase in size of 
MCF7 Tet-ephrinB2 colonies appears to require low levels of ephrinB2 expression and thus is 
probably caused by ephrinB2-induced activation of endogenous EphB receptors and not by 
ligand reverse signalling.  
Taken together, these results suggest that ephrinB2 expression in breast cancer epithelial 
cells might increase tumour progression by inducing cell proliferation via activation of EphB 
forward signalling and by increasing cell migration via cross-talk with integrins. However, 
more experimental data is needed to confirm this hypothesis. Unfortunately, these findings 
also inferred that the use of ephrinB2/G and ephrinB2/ΔV mutants would probably prove 
unhelpful in analysing the effects of disrupting the ephrinB2 – syntenin-1 axis in 3D cultures. 
Furthermore, the modulation of ephrinB2 expression through the tetracycline inducible 
system did not alter the outcome of the experiment, thus rendering this system unuseful in 3D 
Matrigel settings. The use of syntenin-1 depleted MCF7 Tet-ephrinB2 cells also proved 
unhelpful, as syntenin-1 knock down greatly impaired colony growth of MCF7 cells in 
Matrigel based 3D cultures (data not shown). This outcome is not surprising, as syntenin-1 is 
essential for cell proliferation and is involved in numerous cell signalling and trafficking 
pathways (Beekman and Coffer 2008). Furthermore, syntenin-1 is necessary for the correct 
assembly of focal adhesion complexes through activation of FAK (Hwangbo, Kim et al. 
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2010), which plays a pivotal role during cell-ECM interaction and consequent increase in cell 
proliferation (Hebner, Weaver et al. 2008). 
Finally, using co-immunoprecipitation we confirmed that full length wild type and 
ephrinB2 mutants retained the same binding characteristics to endogenous syntenin-1, when 
expressed in tetracycline inducible MCF7 cells (figure 3.9), as previously observed in pull 
down assays on MCF7 cell lysates.  
 
To summarize, we identified MCF7 cells to be the most suited cell line in which to 
study ephrinB2 pathways in the context of breast cancer and developed a flexible and 
functional model system based on tetracycline inducible cell lines, which enabled us to study 
signalling and trafficking pathways in ephrinB2, ephrinB2/G and ephrinB2/∆V expressing 
cells. Importantly, we were able to generate the ephrinB2/G mutant, which has the unique 
ability to retain partial binding to syntenin-1 and to abolish binding to all other PDZ domain-
containing partners of ephrinB2. For the first time, it was possible to selectively study the 
effects of the ephrinB2 – syntenin-1 interaction. Finally, we also found that ephrinB2 
expression drives MCF7 colony growth in 3D Matrigel independently of EphB4/Fc 
stimulation. 
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3.2  The role of syntenin-1 in ephrinB2 signalling and 
  trafficking pathways 
 
Syntenin-1 interacts directly with the PDZ binding motif of ephrinB ligands, which led 
us to hypothesize that it could actively modulate ephrinB2 signalling and/or trafficking 
pathways. Therefore, we studied the phosphorylation dynamics of ephrinB2 and mutants in 
our newly established tetracycline inducible cell lines in order to determine whether syntenin-
1 was involved in this process. We also analyzed trafficking dynamics of the wild type and 
ephrinB2 mutants.  
 
 
3.2.1  Syntenin-1 does not play a role in EphB4-induced 
  phosphorylation of ephrinB2 
 
Before analyzing the phosphorylation dynamics of ephrinB2, ephrinB2/G and 
ephrinB2/∆V, we tested EphB4/Fc stimulation on MCF7 Tet-ephrinB2 cells using WB 
analysis (described in section 3.1.2.2) (data not shown). However, ephrinB2 phosphorylation 
levels were barely detectable, possibly due to lower amounts of ephrinB2 protein on the cell 
surface compared to the stable MCF7-ephrinB2 cell line. To overcome this issue we 
performed immunoprecipitation (IP) using anti-Flag mAb prior to WB analysis. 
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3.2.1.1 EphrinB2, ephrinB2/G and ephrinB2/∆V phosphorylation dynamics 
 
MCF7 tetracycline inducible cell lines were stimulated with doxycycline for 48 hours in 
order to achieve maximum cell surface expression levels prior to EphB4/Fc stimulation for 0, 
15, 30, 60, 120 and 240 minutes. Flag-tagged ephrinB2, ephrinB2/G and ephrinB2/∆V were 
immunoprecipitated from cell lysates and analyzed by WB using phospho- and total-ephrinB 
antibodies. As illustrated in figure 3.10A, phosphorylation dynamics of ephrinB2 wild type in 
MCF7 tetracycline inducible cells was different compared to the MCF7-ephrinB2 stable cell 
line (figure 3.3A, section 3.1.2.2). Specifically, in MCF7 tetracycline inducible cells, the basal 
phosphorylation level of ephrinB2 under non-stimulated conditions was relatively high (lane 
1) and only modestly increased upon EphB4/Fc stimulation, peaking at 30 minutes (lane 3) 
and sharply decreasing at 240 minutes (lane 6). Syntenin-1 depletion in ephrinB2 expressing 
cells did not seem to alter dynamics of phosphorylation (figure 3.10B). By contrast, 
ephrinB2/G and ephrinB2/∆V mutants showed a different phosphorylation pattern (figure 
3.10A and 3.10B respectively), with hardly any increase in phosphorylation detected 
throughout the time-course of EphB4/Fc stimulation. However, the sharp decrease in 
ephrinB2 phosphorylation at 240 minutes (lane 6, panel A) was also observed for ephrinB2/G 
(lane 12, panel A) and ephrinB2/∆V (lane 6, panel B). The corresponding decrease in 
ephrinB2, ephrinB2/G and ephrinB2/∆V total expression levels suggests that protein 
degradation is responsible for the decrease of phosphorylation. Furthermore, we noticed that 
the decrease in ephrinB2/G (lane 12, panel A) and ephrinB2/ ΔV (lane 6, panel B) total levels 
at 240 minutes seemed more pronounced when compared to the wild type, possibly indicating 
increased protein degradation. Interestingly, the highly glycosylated form of ephrinB2 
(identified as the higher molecular weight band in ephrinB2 blots) showed a different pattern 
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of phosphorylation, which increased steadily throughout the time-course of EphB4/Fc 
stimulation and up to the final 240 minutes time-point. The corresponding highly glycosylated 
forms of ephrinB2/G and ephrinB2/∆V showed a lower increase in phosphorylation 
throughout the time-course compared to the wild type. It is possible that highly glycosylated 
forms of ephrinB2 are more resistant to de-phosphorylation and degradation following 
prolonged periods of EphB4/Fc stimulation. Moreover, the effect of PDZ binding motif 
mutations on the phosphorylation of the glycosylated form of the ligand seemed less 
pronounced compared to the non-glycosylated form. Syntenin-1 depletion had no effect. 
Densitometry analysis on both phospho and total ephrinB2 levels of three independent 
WB experiments conducted on each cell line allowed us to perform a quantitative analysis of 
ephrinB2, ephrinB2/G and ephrinB2/∆V phosphorylation dynamics. Within each cell line, we 
calculated the ratios of phospho/total levels for each time-point and presented the data in a 
histogram as fold increase of phosphorylation (figure 3.10C). Thus presented, these results 
clearly indicate that ephrinB2 phosphorylation upon EphB4/Fc stimulation increased over 
time and that syntenin-1 depletion did not affect this process. On the other hand, ephrinB2/G 
and ephrinB2/∆V phosphorylation remained mostly unaltered throughout the time-course of 
stimulation. At the 240 minute time-point, the difference between ephrinB2 and ephrinB2/G, 
ephrinB2/ΔV phosphorylation levels becomes statistically significant. This suggests that 
syntenin-1 is not directly involved in ephrinB2 phosphorylation, which is affected by 
mutations in the PDZ binding-motif. Yet, our results indicate that a PDZ domain-containing 
partner/s of ephrinB2 is/are involved in EphB4-induced ligand phosphorylation. Additionally, 
densitometry analysis revealed that ephrinB2 phosphorylation kept increasing over time up to 
the last time-point, instead of peaking at 30 minutes and then decreasing as previously 
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observed in WB analysis. This discrepancy is probably due to ephrinB2 internalization and 
degradation, which is triggered in order to terminate signalling. 
 
A)   
 
B) 
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C) 
 
Figure 3.10: EphB4/Fc-induced phosphorylation of ephrinB2 is impaired in the presence of /G and /ΔV 
mutations, but not when syntenin-1 is knocked down. 
Phosphorylation dynamics of ephrinB2, ephrinB2/G and ephrinB2/∆V upon EphB4/Fc stimulation in MCF7 Tet-
ephrinB2 (panel A, left), MCF7 Tet-ephrinB2/G (panel A, right), MCF7 Tet-ephrinB2/∆V (panel B, left) and 
MCF7 Tet-ephrinB2/shSyntenin-1 (panel B, right) were analysed by immunoprecipitation followed by WB. 
Cells were stimulated with 1 µg/ml doxycycline for 48 hours prior to EphB4/Fc stimulation. Cells were then 
starved in serum free medium for 4 hours and subsequently stimulated with 5 µg/ml EphB4/Fc (pre-clustered for 
1 hour with anti-Fc Ab) for 15, 30, 60, 120 and 240 minutes. Cells were lysed in 1% TritonX-100 buffer and 
lysates were incubated with anti-Flag antibody-conjugated agarose beads. Immunoprecipitated proteins (IP) were 
resolved on SDS-PAGE and phospho and total levels of ephrinB2 were detected with phospho-specific anti-
ephrinB (Tyr325/329) pAb and anti-ephrinB pAb, respectively. C) The histogram shows the quantitative 
analysis performed on the densitometry data obtained from the blots of three independent experiments for each 
cell line. The ratio between densitometry values of phospho and total blots was calculated for every time-point 
and presented in relation to the non-stimulated control (0 minute time-point) as fold increase in ligand 
phosphorylation. Mean values and standard deviations of fold increase were then calculated and plotted on the 
histogram. Statistical significance was determined by the two-way ANOVA multiple comparison test with the 
Tukey-Kramer post-test, using GraphPad Prism software, whereby significance was set at 0.05 (** P<0.01; *** 
P<0.001). Note: densitometry measurements of phospho bands include both glycosylated and non-glycosylated 
forms of ephrinB2 proteins. 
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3.2.1.2 EphrinB2, ephrinB2/G and ephrinB2/∆V basal levels of   
  phosphorylation 
 
The quantitative analysis of the fold increase in ligand phosphorylation previously 
described does not take into account the possibility of different basal phosphorylation levels 
between the wild type and ephrinB2 mutants in non-stimulated conditions (see figure 3.10). 
Having noticed that the basal levels of ligand phosphorylation seemed higher in MCF7 
tetracycline inducible cell lines (figure 3.10A,B) compared to stable MCF-ephrinB2 cells 
(figure 3.3A), we wondered whether differences in basal phosphorylation were also present 
between wild type and ephrinB2 mutants.  
We analyzed the basal phosphorylation levels of ephrinB2, ephrinB2/G and 
ephrinB2/∆V in all four MCF7 tetracycline inducible cell lines in parallel under non-
stimulated conditions, following the same procedure described in the previous section. The 
quantitative analysis conducted on densitometry values revealed that the basal 
phosphorylation levels of ephrinB2 and ephrinB2/G were similar, while the levels of 
ephrinB2/ΔV and ephrinB2 in syntenin-1-depleted cells were significantly lower by ~30% 
(figure 3.11). Intriguingly, these results seem to suggest that syntenin-1 plays a role in 
modulating the ephrinB2 basal phosphorylation status in non-stimulated conditions, although 
the mechanism behind this regulation remains unclear.  
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Figure 3.11: basal phosphorylation levels of ephrinB2 are lower in the presence of the /ΔV mutation and 
syntenin-1 knock down. 
Basal phosphorylation levels of ephrinB2, ephrinB2/G and ephrinB2/∆V in non-stimulated conditions was 
assessed as described in figure 3.10. Densitometric analysis was conducted on WB data and the ratio between 
densitometry values of phospho and total blots was calculated. Means and standard deviations were calculated 
and presented in the histogram. Statistical significance was determined by the one-way ANOVA multiple 
comparison test with the Tukey-Kramer post-test, using GraphPad Prism software, whereby significance was set 
at 0.05 (* P<0.05). 
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3.2.2  Syntenin-1 is involved in ephrinB2 turnover 
 
Syntenin-1 is known to be responsible for biosynthetic trafficking, recycling and 
internalization of various cell surface proteins. Thus, it is possible that syntenin-1 is also 
involved in regulation of ephrinB2 trafficking. Therefore, we analyzed whether syntenin-1 
plays a role in ephrinB2 trafficking to or from the cell surface.  
 
 
3.2.2.1 Syntenin-1 is not involved in ephrinB2 trafficking to the cell surface 
 
We used flow cytometry to analyze dynamics of cell surface levels of ephrinB2, 
ephrinB2/G and ephrinB2/∆V in MCF7 tetracycline inducible cell lines after 0, 4, 8, 12 and 
24 hours of doxycycline stimulation. The data are presented as fold increase in means of 
fluorescence intensities and compiled in a histogram and table shown in figure 3.12.  
The results clearly indicate that protein delivery to the cell surface was not notably 
affected by the disruption of the PDZ binding sequence of ephrinB2 or depletion of syntenin-
1, thus suggesting that neither syntenin-1 nor any other PDZ domain-containing proteins are 
involved in ephrinB2 biosynthetic trafficking. The slightly higher values of ephrinB2/G and 
ephrinB2/∆V observed at the 24 hour time-point were likely due to their lower basal gene 
expression levels. 
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Figure 3.12: biosynthetic trafficking of ephrinB2 to the cell surface is unaffected by the /G and /ΔV PDZ 
mutations as well as syntenin-1 knock down. 
Flow cytometry analysis on cell surface expression levels of ephrinB2, ephrinB2/G and ephrinB2/∆V in MCF7 
tetracycline inducible cell lines stimulated for 0, 4, 8, 12 and 24 hours with 1 µg/ml doxycycline. In the 
histogram, mean fluorescence values of each time-point was related to the 0 hours value within each individual 
cell line and presented as fold increase in cell surface expression. 
  
0 h 4 h 8 h 12 h 24 h 
ephrinB2 1.00 2.00 2.55 4.37 4.96 
ephrinB2/G 1.00 1.90 2.79 4.82 6.69 
ephrinB2/∆V 1.00 1.98 3.23 5.69 6.74 
ephrinB2/shSyn1 1.00 1.90 2.96 4.30 4.82 
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3.2.2.2 Syntenin-1 modulates ephrinB2 internalization 
 
To analyze ephrinB2 internalization, we performed biotinylation assay. We decided to 
perform the experiments in the presence or absence of EphB4/Fc stimulation, as the latter 
leads to ephrinB2 internalization and degradation (see section 1.1.4.7 of the Introduction). 
The biotinylation experiment is used to determine the percentage of internalized cell surface 
protein compared to the overall amount at any given time-point (figure 3.13A). Hence, we 
stimulated cells with 5 µg/ml of EphB4/Fc or anti-Fc (as a control) to maintain the same 
experimental settings used in the signalling experiments. However, we did not serum starve 
cells prior to stimulation to avoid indirect effects on ligand internalization. In these 
experiments we stimulated cells for 15 and 60 minutes. The earlier time-point allowed us to 
analyse changes in EphB4-driven ligand internalization, while the later time-point was chosen 
to correlate ligand phosphorylation and ephrinB2 internalization.  
The WB data in figure 3.13A show the levels of total biotinylated ephrinB2 (lanes 1-4) 
and of internalized biotinylated ephrinB2 (lanes 5-8) after EphB4/Fc or anti-Fc stimulation. 
As expected, EphB4/Fc stimulation in MCF7 Tet-ephrinB2 cells increased the internalization 
levels of ephrinB2 (lanes 7 and8) compared to non-stimulated conditions (lanes 5 and 6). 
Surprisingly, ephrinB2/G internalization levels were not affected by EphB4/Fc stimulation 
(lanes 7 and 8) and remained unchanged when compared to non-stimulated condition (lanes 5 
and 6). EphrinB2/∆V internalization levels appeared similar to ephrinB2 under non-
stimulated conditions (lanes 5 and 6), but did not notably increase after EphB4/Fc stimulation 
(lanes 7 and 8). Interestingly, in syntenin-1 depleted cells, ephrinB2 internalization levels 
appeared higher in both non-stimulated (lanes 5 and 6) and EphB4/Fc stimulated conditions 
(lanes 7 and 8). The histogram in figure 3.13B illustrates the WB densitometric analysis 
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presented as percentage of internalized relative to total protein. In control samples, we noticed 
that ligand internalization occurred at a slow speed. At 15 minutes, ephrinB2 internalization 
was 2% and barely increased to 3% after 60 minutes. Similarly, ephrinB2/G internalization 
was 1% at 15 minutes and less than 2% at 60 minutes. Interestingly, internalization levels of 
both ephrinB2/ΔV and ephrinB2 expressed in syntenin-1 depleted cells were slightly higher 
under non-stimulated conditions, reaching 3% after 15 minutes and over 4% after 60 minutes. 
Overall, these results on control samples suggest that wild type and ephrinB2 mutants remain 
stable on the cell surface and do not undergo rapid internalization under non-stimulated 
conditions. As expected, EphB4/Fc stimulation notably increased ephrinB2 internalization, 
which reached 4% at 15 minutes and 8% at 60 minutes. Surprisingly, ephrinB2/G 
internalization was not affected by EphB4/Fc stimulation, as internalization levels remained 
significantly lower, compared to ephrinB2, at 1% after 15 minutes and 2% after 60 minutes. 
In MCF7 Tet-ephrinB2/shSyntenin-1 cells, EphB4/Fc stimulation increased ephrinB2 
internalization to only 4% after 15 minutes, but more than 10% after 60 minutes. 
EphrinB2/ΔV internalization was mostly unaffected by EphB4/Fc stimulation, as 
internalization levels remained at 3% after 15 minutes and barely rose over 5% after 60 
minutes, thus remaining significant lower compared to ephrinB2.  Summarizing, ephrinB2 
internalization doubled at 15 minutes and nearly quadrupled at 60 minutes upon EphB4/Fc 
stimulation, while ephrinB2/G internalization remained unchanged. In MCF7 Tet-
ephrinB2/shSyntenin-1 cells, ephrinB2 internalization barely rose after 15 minutes of 
EphB4/Fc stimulation, but increased 2.5 fold after 60 minutes. Following a similar pattern, 
ephrinB2/ΔV internalization remained unchanged after 15 minutes of EphB4/Fc stimulation, 
but rose nearly 1.5 fold after 60 minutes.  
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Taken together, these results suggest that syntenin-1 modulates ephrinB2 
internalization, especially upon EphB4 interaction. In particular, the pattern of ephrinB2 
internalization in syntenin-1 depleted cells and the absent EphB4/Fc induced internalization of 
ephrinB2/G seemed to suggest that syntenin-1 might be involved in stabilizing ephrinB2 on 
the cell surface by binding to its PDZ binding motif and preventing internalization. Moreover, 
this effect was significantly observed at 60 minutes after EphB4/Fc stimulation. Additionally, 
disruption of the PDZ binding motif impairs ephrinB2 internalization, thus suggesting that 
other PDZ domain-containing partners might be involved in this process. However, the 
mechanism behind this regulation remains unclear.  
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A)   
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B) 
 
Figure 3.13: EphB4/Fc-induced internalization of ephrinB2 is strongly impaired by the /G PDZ mutation; 
mildly impaired by the /ΔV PDZ mutation; and slightly increased in the presence of syntenin-1 knock 
down.  
Analysis of internalization levels of wild type and ephrinB2 mutants under basal or EphB4/Fc stimulated 
conditions measured using biotinylation assay. MCF7 Tet-ephrinB2, MCF7 Tet-ephrinB2/G, MCF7 Tet-
ephrinB2/ΔV and MCF7 Tet-ephrinB2/shSyntenin-1 cells were stimulated with 1 µg/ml doxycycline for 48 
hours and subsequently labelled with sulfo-NHS-SS-biotin for 1 hour and stimulated with EphB4/Fc or anti-Fc 
antibody for 15 and 60 minutes at 37ºC. The experiment was conducted in duplicate: in the control set of 
samples, cells were lysed after stimulation and lysates were incubated with NeutrAvidin-conjugated agarose 
beads to pull down all biotinylated proteins; in the other set of samples (internalized) cells were treated with 
MESNA to remove biotin from cell surface proteins and lysates were incubated with NeutrAvidin-conjugated 
agarose beads to pull down internalized biotinylated proteins. A) Pulled-down proteins from both set of samples 
were separated on SDS-PAGE and ephrinB2 was detected with anti-ephrinB pAb. B) Densitometric analysis was 
conducted on blots of three independent experiments for each cell line and the ratio between control and 
MESNA-treated samples was calculated. Mean values and standard deviations of ratios were calculated and 
presented as percentage of internalized ephrinB2 (MESNA-treated) compared to overall biotinylated ephrinB2 
(control) in the histogram. Statistical significance was determined by the two-way ANOVA multiple comparison 
test with the Tukey-Kramer post-test, using GraphPad Prism software, whereby significance was set at 0.05 (* 
P<0.05; **** P<0.0001). 
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3.2.3  Discussion 
 
In our signalling experiments on MCF7 tetracycline inducible cell lines, we observed 
that the phosphorylation pattern of ephrinB2/G and ephrinB2/ΔV differed from ephrinB2 by 
showing lower phosphorylation levels upon EphB4/Fc stimulation (figure 3.10). This suggests 
that the interaction of a PDZ domain-containing protein with the PDZ binding motif of 
ephrinB ligands is required for the correct phosphorylation of the latter upon EphB 
stimulation. However, syntenin-1, one of the well characterized PDZ domain-containing 
partners of ephrinB ligands, did not seem to affect ephrinB2 phosphorylation levels and 
dynamics upon EphB4/Fc stimulation. Nevertheless, this finding supports the hypothesis that 
PDZ-mediated interactions with PDZ domain-containing proteins modulate ephrinB ligands 
phosphorylation upon EphB stimulation and thus SH2 mediated signalling, a theory which 
has been often disregarded due to the ability of PDZ and SH2 mediated signalling to occur 
simultaneously (Su, Xu et al. 2004). 
The ephrinB2 reverse signalling pathway can be triggered in multiple ways, which can 
lead to different biological outcomes. As described in section 1.1.4.1 of the Introduction, 
EphB receptor interaction with ephrinB ligands triggers Src family kinases activation which 
in turn is responsible for ephrinB phosphorylation (Palmer, Zimmer et al. 2002; 
Georgakopoulos, Litterst et al. 2006). However, ephrinB reverse signalling can also be 
triggered by direct interaction of the ligand with activated membrane receptor kinases such as 
FGF, VEGF, PDGF and ErbB receptors (Arvanitis and Davy 2008; Pitulescu and Adams 
2010; Vermeer, Colbert et al. 2013). Although reports in literature suggest that ephrinB 
phosphorylation and PDZ-mediated signalling remain independent of each other (Su, Xu et al. 
2004), there are very few studies which have analysed ephrinB phosphorylation dynamics in 
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detail (Holland, Gale et al. 1996; Bruckner, Pasquale et al. 1997) and none in the context of 
impaired PDZ interaction. Research by (Bruckner, Pasquale et al. 1997) focused on ephrinB 
phosphorylation at early time points while other studies analysed post-activation dynamics of 
PTPL1 de-phosphorylation (Palmer, Zimmer et al. 2002) and ligand degradation upon 
protracted EphB stimulation (Foo, Turner et al. 2006). Therefore, our data suggests, for the 
first time, that a functional PDZ binding motif is required for EphB-induced phosphorylation 
of ephrinB ligands. 
Further analysis on ephrinB2, ephrinB2/G and ephrinB2/∆V basal phosphorylation 
under non-stimulated conditions revealed ~30% lower phosphorylation levels in MCF7 Tet-
ephrinB2/∆V and MCF7 Tet-ephrinB2/shSyntenin-1 cells when compared to ephrinB2 and 
ephrinB2/G expressing cells (figure 3.11). This finding suggests that syntenin-1 interaction 
with ephrinB2 is able to modulate the ligand’s basal phosphorylation level. Possibly, 
syntenin-1 might be involved in aiding ephrinB ligands phosphorylation induced by other 
receptor tyrosine kinases in cis (Pitulescu and Adams 2010). This process could involve the 
reported ability of syntenin-1 to form signalling complexes by acting as a scaffolding protein: 
at sites of integrin-mediated cell adhesion with fibronectin, syntenin-1 recruits and holds into 
complex FAK, Src and aPKC to allow aPKC to phosphorylate and activate FAK and Src 
(Hwangbo, Kim et al. 2010; Hwangbo, Park et al. 2011).  Alternatively, syntenin-1 might be 
indirectly affecting ephrinB2 phosphorylation by modulating ligand internalization and 
preventing its degradation. 
 
According to previous reports, the cytoplasmic tail of ephrinB ligands is necessary for 
protein trafficking to the cell surface. Deletion of the cytoplasmic tail causes ephrinB ligands 
to remain trapped in the Golgi network and subsequently degraded (Makinen, Adams et al. 
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2005). However, this effect does not seem to be related to SH2 or PDZ mediated signalling, 
as mutating the five tyrosines on the cytoplasmic tail and/or the PDZ binding motif of 
ephrinB1 does not cause ligand depletion from the cell surface (Makinen, Adams et al. 2005). 
We analysed the dynamics of ephrinB2, ephrinB2/G and ephrinB2/∆V trafficking to the cell 
surface in order to determine whether syntenin-1 and other PDZ domain-containing proteins 
played a part in this process (figure 3.12). By using flow cytometry analysis on MCF7 
tetracycline inducible cell lines, we determined that neither syntenin-1 nor other PDZ domain-
containing proteins affected ephrinB2 trafficking to the cell surface. Our results corroborate 
previous reports suggesting that PDZ-mediated binding is not required for ephrinB ligands 
delivery to the cell surface (Makinen, Adams et al. 2005). 
By measuring protein internalization using biotinylation assay (figure 3.13), we 
observed that ephrinB2 internalization is clearly enhanced upon interaction with EphB4/Fc, as 
previously reported in literature (Marston, Dickinson et al. 2003; Zimmer, Palmer et al. 2003). 
Moreover, the relatively slow speed of ligand internalization observed in our assay seems to 
confirm previous studies suggesting that ephrinB2 endocytosis is not clathrin-dependent 
(Marston, Dickinson et al. 2003; Zimmer, Palmer et al. 2003). Importantly, our data seems to 
indicate that syntenin-1 is directly involved in ephrinB2 internalization upon EphB4/Fc 
stimulation. In this regard, previous study has shown that neither tyrosine phosphorylation nor 
PDZ mediated signalling seem to be required during this process (Zimmer, Palmer et al. 
2003). In contrast to the wild type protein, ephrinB2/G internalization did not increase upon 
EphB4/Fc stimulation. Furthermore, ephrinB2 internalization was noticeably higher in cells 
depleted of syntenin-1. When taken together, these results seem to suggest that syntenin-1 is 
able to prevent ephrinB2 internalization. Interestingly, this effect was more pronounced after 
60 minutes of EphB4/Fc stimulation, which is when the highest level of ephrinB2 
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internalization was observed in syntenin-1 depleted cells. Therefore, syntenin-1-induced 
impairment of ephrinB2 internalization seems to occur alongside with increased ephrinB2 
phosphorylation. The mechanism underlying this process is still unclear and open to 
speculation. One possibility is that syntenin-1 stabilizes the phosphorylated ligand on the cell 
surface, thus prolonging reverse signalling and preventing PTPL1-driven de-phosphorylation. 
Additionally, the strong impairment of ephrinB2/G internalization caused by syntenin-1 might 
also be enhanced by the lack of competition from other PDZ domain-containing proteins. 
Indeed, syntenin-1 PDZ-mediated binding to the C-terminus of the Notch-associated Delta1 
ligand has been found to prevent its internalization from the plasma membrane (Estrach, Legg 
et al. 2007). Similarly, our group has found that syntenin-1 PDZ-mediated interaction with 
tetraspanin CD63 impairs clathrin-mediated internalization of the protein (Latysheva, 
Muratov et al. 2006). Specifically, the authors found that the NTD of syntenin-1 was 
responsible for shifting CD63 clathrin-dependent endocytosis to a slower internalization 
pathway, probably by competing with the clathrin-associated Adaptor Protein 2 (AP2). In 
support of this claim, a study by (Janvier and Bonifacino 2005) proposed the existence of an 
AP2-independent sorting pathway for proteins containing the AP2 consensus sequence YXXɸ 
at the C-terminus. Therefore, syntenin-1 might be modulating ephrinB2 internalization in a 
similar manner to CD63. Additionally, syntenin-1 might induce or prevent 
compartmentalization of phosphorylated ephrinB2 to a different membrane microdomain. 
However, this possibility is unlikely according to a recent study by (Xu, Sun et al. 2011), 
where the authors showed that EphB-induced phosphorylation of ephrinB1 in Jurkat cells was 
specifically mediated by Lck (a member of the Src family kinases) and induced ephrinB1 
relocation to lipid rafts. Importantly, this process was specifically induced by ligand 
phosphorylation on Tyr residues and not by PDZ-mediated interactions.  
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Intriguingly, ephrinB2/∆V internalization was overall higher than ephrinB2/G in both 
stimulated and non-stimulated conditions, but it did not increase significantly upon EphB4/Fc 
stimulation. This result suggests that other proteins may be responsible for ligand 
internalization. Although the identity of this protein remains to be established, we can 
speculate on two possible candidates. One of these is the previously mentioned clathrin-
associated sorting adaptor AP2. (Parker, Roberts et al. 2004) suggested that AP2 might be 
responsible for clathrin-dependent endocytosis of ephrinB1, as they observed co-localization 
of EphB1/ephrinB1-containing vesicles with the early endosome marker EEA1 and caveolin. 
In support of this observation, the cytoplasmic tails of ephrinB ligands contain three YXXɸ 
consensus sequences, which might act as binding motifs for AP2 (Traub 2003; Edeling, Smith 
et al. 2006). In human ephrinB2, these sequences are located between amino acids 304-307 
(YEKV), 311-314 (YGHP) and 330-333 (YYKV). Although AP2 is unlikely to bind the C-
terminal YYKV sequence in ephrinB2/∆V, it might be able to bind one or both of the other 
two YXXɸ sequences. Therefore, AP2 might be responsible for clathrin-dependent 
endocytosis of ephrinB ligands. However, the speed of ephrinB2 internalization measured in 
our assays is not consistent with clathrin-dependent endocytosis, which usually induces fast 
internalization of its cargo. Additionally, previous studies have not been able to co-localize 
EphB/ephrinB-containing vesicles with known endocytic markers (e.g. EEA1) (Marston, 
Dickinson et al. 2003; Zimmer, Palmer et al. 2003). Nevertheless, it is possible that different 
endocytic pathways might be triggered by different EphB and ephrinB family members or by 
different levels of EphB – ephrinB multimerization. Furthermore, clathrin-dependent 
endocytosis might be required during internalization of phosphorylated-ephrinB ligands 
which are not in complex with EphB receptors. However, further study is needed to assess the 
possible role of AP2-induced endocytosis of ephrinB ligands.  
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Another candidate is PAR6, a component of the PAR polarity complex (formed by 
PAR3-PAR6-aPKC) (Chen and Zhang 2013) which has been implicated in clathrin-
independent recycling and clathrin-dependent uptake of various cell membrane proteins, 
including MHC-I and transferrin receptor (Balklava, Pant et al. 2007). PAR6 associates with 
ephrinB1 in a PDZ-independent manner which does not involve the 15 C-terminal amino 
acids of ephrinB1 (Lee, Nishanian et al. 2008). Interestingly, PAR6 has been found to play a 
role in Dynamin-dependent endocytosis at sites of adherens junctions by activating WASp 
and the Arp2/3 complex via interaction with Cdc42 (Georgiou, Marinari et al. 2008). 
Therefore, PAR6 might be involved in ephrinB2/∆V internalization. However, the fact that 
EphB or FGFR-induced phosphorylation of ephrinB1 causes PAR6 dissociation from the 
ligand (Lee, Nishanian et al. 2008), suggests that this endocytic pathway may not be involved 
in internalization of phosphorylated ephrinB2.  
Additionally, the PAR polarity protein PAR3, which binds to ephrinB ligands via its 
second and third PDZ domains (Cowan and Henkemeyer 2002), has also been implicated in 
endocytosis (Balklava, Pant et al. 2007; Nishimura and Kaibuchi 2007). A recent study by 
(Nakayama, Nakayama et al. 2013) has found that PAR3 interaction with ephrinB2 induces 
the recruitment of the clathrin-associated sorting adaptor Dab2 to ephrinB2 – VEGFR2,3 
complexes during ephrinB2-driven internalization of VEGF receptors. However, PAR3-
mediated internalization may only affect the ephrinB2 wild type protein and not the PDZ 
binding mutants ephrinB2/G and ephrinB2/∆V. 
Interestingly, a recent study has found that SH2-mediated binding of Grb4 (Nck2) to 
phosphorylated CEACAM3 mediated bacterial phagocytosis through WAVE2 activation 
(Pils, Kopp et al. 2012). As Grb4 is a main component of ephrinB reverse signalling (Cowan 
and Henkemeyer 2001), this newly described internalization mechanism might be involved in 
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the internalization of phosphorylated ephrinB2 and would not be hindered by mutations in the 
PDZ-binding motif. Taken together, these speculations suggest that more than one 
internalization pathway might be employed in ephrinB2 endocytosis. Intriguingly, these 
pathways might be specifically triggered depending on the phosphorylation status of ephrinB2 
 
To conclude, in this chapter we analysed the ability of syntenin-1 to modulate ephrinB2 
signalling and protein trafficking. We discovered that syntenin-1 does not affect ephrinB2 
phosphorylation levels and dynamics, but that a functional PDZ binding motif is necessary for 
EphB4-induced ligand phosphorylation. However, lack of syntenin-1 interaction with 
ephrinB2 lowered the levels of basal phosphorylation of the ligand. In ephrinB2 trafficking, 
syntenin-1 does not modulate protein delivery to the cell surface, but negatively regulates 
ephrinB2 internalization upon EphB4/Fc stimulation.  
  
Results and Discussion 
~ 176 ~ 
 
3.3  EphrinB2 phosphorylation alters PDZ-mediated 
  binding characteristics 
 
Given the PDZ domain-dependent differences in phosphorylation of ephrinB2, it was 
important to investigate further how tyrosine phosphorylation affected interaction of ephrinB2 
with its known PDZ domain-containing partners. While an early study by (Lin, Gish et al. 
1999) reported that tyrosine phosphorylation at position -2, but not -3, of ephrinB1 decreases 
syntenin-1 binding, but does not affect PTPL1 binding, a later study by (Su, Xu et al. 2004) 
observed that phosphorylation of C-terminal tyrosines did not influence PDZ-mediated 
binding of PDZ-RGS3 to ephrinB2. These findings suggest that phosphorylation may 
differentially affect binding of PDZ domain-containing proteins to ephrinB ligands.  
 
 
3.3.1  Phosphorylation of Tyr330 on ephrinB2 and   
  ephrinB2/G increases syntenin-1 binding 
 
In the ephrinB2 ligand, the interaction with EphB4 induces the phosphorylation of 
tyrosines in position 311, 316 and 330 (Kalo, Yu et al. 2001), with Tyr330 being the 
predominant site of phosphorylation in vivo (Su, Xu et al. 2004). Thus, we compared 
syntenin-1 binding to ephrinB2 and phospho-ephrinB2(Tyr330) peptides, as well as 
ephrinB2/G and phopho-ephrinB2/G(Tyr330), using pull down assay.  
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3.3.1.1 Syntenin-1 binding to phospho-peptides in pull down   
  experiments 
 
The PDZ binding motif of ephrinB2 binds with stronger affinity to the PDZ2 domain of 
syntenin-1, rather than the PDZ1. However, the two PDZ domains work together to ensure 
high affinity binding to ephrinB2 (Grembecka, Cierpicki et al. 2006; Beekman and Coffer 
2008). Therefore, in our initial experiments we used a recombinant GST-PDZ1,2 protein. 
Lane 3 in figure 3.14A shows that the recombinant GST-PDZ1,2 protein strongly binds the 
ephrinB2 wild type peptide, while not binding the ephrinB2/G or ephrinB2/∆V peptides 
(lanes 4 and 5 respectively). Interestingly, binding of both the phospho-ephrinB2 and 
phospho-ephrinB2/G peptides increased (lanes 6 and 7 respectively), proving that PDZ 
mediated binding is affected by the tyrosine phosphorylation at position -3. 
We also performed a similar analysis using full-length recombinant syntenin-1. 
Surprisingly, we observed that binding of syntenin-1 to the ephrinB2/G peptide was only 
slightly less effective than to the ephrinB2 wild type peptide (figure 3.14B, lane 4). Although 
tyrosine phosphorylation at position -3 causes an increase in syntenin-1 binding (lanes 6 and 7 
respectively), the increase was modest and only observed for ephrinB2/G. Finally, we carried 
out a pull down assay on MCF7 cell lysates and detected the levels of endogenous syntenin-1 
that bound to the peptides (figure 3.14C). In this case, syntenin-1 bound to the ephrinB2/G 
peptide (lane 5) to a lesser degree when compared to the ephrinB2 wild type peptide (lane 3). 
However, tyrosine phosphorylation at position -3 notably increased syntenin-1 binding to the 
ephrinB2/G peptide (lane 6), while only slightly increasing binding to the wild type peptide 
(lane 4). 
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These data suggest that the C-terminal and N-terminal domains of syntenin-1 are able to 
modulate PDZ binding dynamics to the ephrinB2 PDZ binding motif. Furthermore, syntenin-
1 binding to the ephrinB2/G peptide might be negatively affected by the presence of other 
PDZ domain-containing partners of ephrinB2 which compete for the same PDZ binding 
motif. Taken together, pull down assays demonstrated that phosphorylation of Tyr330 
facilitated binding of syntenin-1 to the PDZ binding motif of ephrinB2. 
 
 
 
A)   
 
 
B) 
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C) 
 
Figure 3.14: phosphorylation of Tyr330 increases binding of recombinant GST-PDZ1,2 and syntenin-1 to 
ephrinB2 and ephrinB2/G peptides, but not ephrinB2/ΔV. 
Pull down assays of recombinant GST-PDZ1,2 (panel A), recombinant full-length syntenin-1 (panel B) and 
endogenous syntenin-1 from MCF7 cells (panel C) using various ephrinB2 C-terminal peptides. The following 
peptides were used: ephrinB2 wild type (wt), ephrinB2/G (/G), ephrinB2/∆V (/∆V), ephrinB2 wild type and 
ephrinB2/G with phosphorylated Tyr330 at -3 position (wt-pY and /G-pY respectively). In panels A and B, equal 
amounts of recombinant protein were incubated with peptide-conjugated NeutrAvidin agarose beads in 1% 
TritonX-100 buffer. In panel C, the same buffer was used to produce MCF7 cell lysates, which were 
subsequently incubated with peptide-conjugated NeutrAvidin agarose beads. Pulled-down proteins were eluted 
from beads and separated on SDS-PAGE. Anti-GST mAb was used to detect recombinant GST-PDZ1,2 (panel 
A), while anti-syntenin-1 mAb was used to detect full-length recombinant and endogenous syntenin-1 (panels B 
and C respectively).  
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3.3.1.2 Label-free interaction analysis of syntenin-1 binding affinity to  
  ephrinB2 and ephrinB2/G peptides 
 
In order to quantify the levels of syntenin-1 binding to non-phosphorylated and 
phosphorylated peptides, we used a Biacore3000 which measures the protein binding to an 
immobilized ligand. This system uses chips on which biotin-conjugated peptides can be 
immobilized. A constant flow of buffer containing the protein of interest is then applied over 
the chip to analyse binding to the peptide. The increase in molecular weight of bound protein 
during the association phase is measured by the instrument via Surface Plasmon Resonance 
(SPR), which is displayed as Response Units (RU). The binding is measured as increased 
response in the “sensorgram” which increases as the protein interacts with the peptide until it 
reaches a plateau, saturating the binding sites. At this point, the flow of protein-containing 
buffer is interrupted and a constant flow of buffer is applied to the chip. Consequentially, the 
protein starts to dissociate from the peptide during the dissociation phase and the sensorgram 
displays a decrease in RU. The slope of the sensorgram curve during the association and 
dissociation phases are indicative of the protein-ligand binding affinity, while the value 
measured at plateau level represents the relative binding capacity. 
We used this approach to analyze the binding of full-length recombinant syntenin-1 to 
non-phosphorylated and phosphorylated ephrinB2 and ephrinB2/G peptides. Figure 3.15 
illustrates the sensorgram representing the binding of syntenin-1 to each peptide. As a 
negative control, we used the NET5/Tspan9 peptide consisting of the C-terminal 13 amino 
acids of Tspan9 (FQHIHRTGKKYDA). This peptide is unable to bind PDZ domains and has 
already been used as a negative control by our group (Latysheva, Muratov et al. 2006). The 
figure shows that the binding capacity of syntenin-1 to the phosphorylated ephrinB2 peptide 
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(blue) increased ~20% compared to the non-phosphorylated peptide (red). Interestingly, the 
binding capacity to the phosphorylated ephrinB2/G peptide (green) compared to the non-
phosphorylated peptide (pink) was considerably higher (~90%). Finally, the binding capacity 
of syntenin-1 to the wild type ephrinB2 peptide (red) was ~140% higher than the ephrinB2/G 
peptide (pink). With regards to binding affinity, we noticed that syntenin-1 bound to both the 
ephrinB2 peptides with higher affinity than the ephrinB2/G peptides during the association 
phase. However, syntenin-1’s binding affinity to the non-phosphorylated peptides was lower 
in the dissociation phase compared to the phosphorylated peptides. For the purpose of this 
study, we did not measure the Kd (dissociation constant) values of binding affinity and thus 
these observations are based entirely on the normalization of the response units for all 
peptides and the comparison of their sensorgrams. This data confirms that syntenin-1’s 
binding capacity to ephrinB2 increases upon Tyr330 phosphorylation. Moreover, this effect is 
more pronounced in the ephrinB2/G mutant than in the wild type. Interestingly, the binding 
affinity is higher for the ephrinB2 peptides during the association phase and for 
phosphorylated peptides in the dissociation phase, suggesting that that the Val to Gly 
mutation affects peptide association to syntenin-1, while phosphorylation affects dissociation 
from syntenin-1. 
 To summarize, these results prove that syntenin-1 binding to ephrinB2 is enhanced 
upon phosphorylation of Tyr330. This novel discovery has important implications in our 
study on the role of syntenin-1 in ephrinB2 biology, as it reveals a new mode of interaction 
between the proteins. 
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Figure 3.15: phosphorylation at Tyr330 increases syntenin-1 binding capacity to ephrinB2 and 
ephrinB2/G peptides. 
Sensorgrams of recombinant full-length syntenin-1 binding to the phosphorylated and non-phosphorylated 
ephrinB2 and ephrinB2/G C-terminal peptides assessed by label-free interaction analysis. The experiment was 
carried out using a Biacore3000. The biotin-conjugated peptides were immobilized on a CM5 sensor chip 
previously coated with streptavidin. NET5 peptide was used as a negative control. The response units (RU) 
shown in the graph are indicative of the amount of syntenin-1 binding to the peptides.  
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3.3.1.3 Phosphorylation of Tyr330 alters ephrinB2 and ephrinB2/G  
  interaction with syntenin-1 as seen by NMR analysis 
 
Having demonstrated that Tyr phosphorylation at position -3 increases binding of 
syntenin-1 to ephrinB2 wt and ephrinB2/G peptides, we decided to further investigate this 
interaction in more detail. Through collaboration with Dr Rajesh Sundaresan, we used nuclear 
magnetic resonance (NMR) experiments to characterise the binding of syntenin-1 PDZ1,2 
domains with 8 amino acids long C-terminal phosphorylated and non-phosphorylated peptides 
of ephrinB2 or ephrinB2/G. The method used was published in the studies by (Latysheva, 
Muratov et al. 2006) and (Rajesh, Bago et al. 2011) and provides detailed structural 
information on the role of individual amino acids of syntenin-1 upon peptide binding. The 
decrease in signal intensity for each aminoacid of syntenin-1 upon interaction with ephrinB2 
peptides was calculated and mapped onto the crystal structure of the syntenin-1 PDZ1,2 
monomer (1N99.pdb) published by (Kang, Cooper et al. 2003) (see figure 3.16). We used a 
colour code to represent the calculated values: yellow represents a 50-60% decrease in signal 
intensity; orange a 60-80% decrease; and red represents more than 80% decrease. The degree 
of decrease in NMR signal intensity roughly translates into a closer proximity of the relevant 
aminoacid with the interacting target peptide.  
Figure 3.16 illustrates the NMR results mapped onto the crystal structure of syntenin-1 
PDZ1,2 for each interaction analysed, including the relevant amino acids of syntenin-1 which 
interact with the peptide and the percentage of signal decrease measured in NMR. As 
expected, the ephrinB2 wt peptide engages only syntenin-1 PDZ1,2 amino acids in the PDZ2 
domain, as was reported in literature (Lin, Gish et al. 1999; Grembecka, Cierpicki et al. 2006). 
From the NMR results, the region between amino acids 199-204, 210-220, 251-258 and 265-
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268 in the PDZ2 domain are closely engaged in ephrinB2 wt binding. Interestingly, the 
binding of the phosphorylated form of the ephrinB2 wt peptide extended the contact region in 
the PDZ2 domain and, in addition, engaged amino acids between positions 125-127 in the 
PDZ1 domain. These results suggest that phosphorylation of Tyr330 in ephrinB2 increases 
the avidity of interaction with the PDZ2 domain of syntenin-1 through the recruitment of 
PDZ1 domain. However, from our NMR data it remains unclear whether the phosphorylated 
ephrinB2 wt peptide interacts with both PDZ domains on the same syntenin-1 PDZ1,2 
monomer or on the neighbouring homo-dimerized syntenin-1 PDZ1,2 molecule (crystal 
structure of syntenin-1 PDZ1,2 is seen as a homodimer).  
The ephrinB2/G peptide engages a notably smaller patch on the PDZ2 domain 
compared to ephrinB2 wt when interacting with the syntenin-1 PDZ1,2 monomer. In fact, it 
primarily engages amino acids in a single region between positions 208-216 of the PDZ2 
domain of syntenin-1 PDZ1,2, with additional secondary interactions with amino acids in 
position 235 and 262. Phosphorylation of Tyr at the -3 position of the ephrinB2/G peptide 
results in the engagement of a wider set of an extended patch within the PDZ2 domain of 
syntenin-1 PDZ1,2. More specifically, the phospho-ephrinB2/G peptide closely engages 
amino acids in the region of 199-203, 208-219, 235-239 and 255-256 of the PDZ2 domain of 
syntenin-1 PDZ1,2, which closely resemble the regions engaged by the ephrinB2 wt peptide. 
However, amino acids in the PDZ1 domain of syntenin-1 PDZ1,2 were not engaged. 
The NMR data corroborates our pull down and label-free interaction analysis data and 
further demonstrates that phosphorylation of Tyr330 in ephrinB2 increases binding to 
syntenin-1. Additionally, NMR analysis provided us with the structural insight on how 
Tyr330 phosphorylation increases ephrinB2 and ephrinB2/G proximity to the PDZ2 domain 
of syntenin-1 and induces a previously un-reported interaction of ephrinB2 with amino acids 
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in the PDZ1 domain of syntenin-1. These structural differences support the hypothesis that 
syntenin-1 might preferentially play a role in ephrinB2 pathways subsequent to ligand 
phosphorylation. 
 
Syntenin-1 – ephrinB2 wt       Syntenin-1 – ephrinB2 phospho-wt 
     
 
Syntenin-1 – ephrinB2/G         Syntenin-1 – ephrinB2/G phospho 
     
 
Figure 3.16: phosphorylation at Tyr330 induces a tighter interaction between ephrinB2, ephrinB2/G 
peptides and syntenin-1. 
Phosphorylation of ephrinB2 wt and ephrinB2/G on Tyr330 alters PDZ-mediated syntenin-1 interaction. The 
perturbation of syntenin-1 PDZ1,2 NMR signals upon interaction with phosphorylated and non-phosphorylated 
peptides of ephrinB2 wt or ephrinB2/G, was mapped onto the crystal structure of the syntenin-1 PDZ1,2 
(1N99.pdb) monomer resolved by (Kang, Cooper et al. 2003).  The decrease in signal intensity for every 
aminoacid of syntenin-1 PDZ1,2 monomer upon interaction with the peptides was calculated and represented 
using the following colour code: yellow represents a decrease in signal intensity of 50-60%; orange represents a 
decrease of 60-80%; and red a decrease of more than 80%. The degree of decrease in signal indicates proximity 
between the relevant aminoacid of syntenin-1 with the target peptide.  
= 50%-60% decrease = 60%-80% decrease = >80% decrease 
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3.3.2  Binding to the phospho-ephrinB2 peptide is enhanced 
  with PAR3 but not PTPL1 
 
As described in the previous paragraphs, we discovered that binding of syntenin-1 to the 
ephrinB2 wild type and ephrinB2/G peptides increased in the presence of a phospho-tyrosine 
at position -3. Our data disagrees with the study by (Lin, Gish et al. 1999), which suggested 
that tyrosine phosphorylation at position -3 did not affect syntenin-1 binding to the ephrinB1 
ligand, while phosphorylation at position -2 was inhibitory. The same study also described 
that PTPL1 binding to ephrinB1 was not affected by phosphorylation of tyrosines within the 
PDZ binding motif. We decided to perform two more pull down assays using all our peptides 
on PTPL1 and PAR3, as these two proteins are very relevant to breast cancer.  
We transiently transfected MCF7 cells with plasmids encoding flag-tagged PTPL1 or 
PAR3 and subsequently performed pull down assays using normal and phospho-peptides. As 
shown in figure 3.17A, PTPL1 binding to the phospho-ephrinB2 peptide (lane 5) remained 
unchanged when compared to the ephrinB2 peptide (lane 3), while no binding was detected 
for the phospho-ephrinB2/G peptide (lane 6). These results confirm previously published data 
by (Lin, Gish et al. 1999). By contrast, PAR3 binding to the phospho-ephrinB2 peptide was 
greatly enhanced (lane 5) when compared to the ephrinB2 peptide (lane3), while binding to 
the phospho-ephrinB2/G peptide (lane 6) remained undetectable (figure 3.17B). 
These findings prove that PDZ mediated binding to the PDZ binding motif of ephrinB 
ligands can be influenced by phosphorylation on Tyr330. Moreover, different types of PDZ 
domains may be variably affected by this phosphorylation event. The fact that the tyrosine at 
position -3 of ephrinB ligands is the most prominently phosphorylated upon EphB receptor 
interaction in vitro (Kalo, Yu et al. 2001) and in vivo (Su, Xu et al. 2004) suggests that it 
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could function as a regulator for interaction of some of the PDZ domain-containing partners 
of ephrinB ligands. 
 
A)   
 
 
B) 
 
Figure 3.17: phosphorylation at Tyr330 increases binding of the ephrinB2 peptide (but not ephrinB2/G) to 
PAR3, but not PTPL1. 
Binding ability of PTPL1 and PAR3 to various ephrinB2 peptides assessed by pull down assay. The following 
peptides were used: ephrinB2 wild type (wt), ephrinB2/G (/G), ephrinB2 wild type and ephrinB2/G with 
phosphorylated Tyr330 at -3 position (wt-pY and /G-pY respectively). MCF7 cells were transiently transfected 
with PTPL1-Flag (panel A) or PAR3-Flag (panel B) and lysed in 1% TritonX-100 buffer. Cell lysates were 
incubated with peptide-conjugated NeutrAvidin agarose beads and pulled-down proteins were resolved on SDS-
PAGE. Controls include transfected MCF7 cell lysates incubated with NeutrAvidin agarose beads (lane 1) and 
non-transfected cells lysates incubated with ephrinB2 peptide-conjugated NeutrAvidin agarose beads (lane 2). 
PTPL1-Flag (A) and PAR3-Flag (B) were detected with anti-Flag mAb.  
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3.3.3  Discussion 
 
It has been previously reported that PDZ-mediated interactions can be modulated by 
phosphorylation of Ser, Thr or Tyr residues within PDZ binding sequences or in close 
proximity to them (Ivarsson 2012). Phosphorylation at these sites can increase or decrease the 
binding affinity with PDZ domain-containing proteins. For example, phosphorylation of 
Ser411 at -2 position of β2-adrenergic receptors disrupts the interaction with NHERF1 (Cao, 
Deacon et al. 1999); and phosphorylation of Tyr at position -1 of syndecan-1 impairs 
syntenin-1 binding (Sulka, Lortat-Jacob et al. 2009). Instead, phosphorylation of Tyr at 
position -2 and -3 of ephrinB ligands did not affect binding to GRIP proteins (Essmann, 
Martinez et al. 2008) and FAP1/PTPL1 (Lin, Gish et al. 1999). 
A study by (Lin, Gish et al. 1999) reported that phosphorylation of the Tyr residue at -3 
position of ephrinB1 did not affect syntenin-1 binding, while phosphorylation of the Tyr at -2 
position inhibited binding. However, our data on ephrinB2 – syntenin-1 interaction is in 
disagreement with this earlier study. By using ephrinB2 and ephrinB2/G phosphorylated C-
terminal peptides to pull down recombinant GST-PDZ1,2, recombinant full-length syntenin-1 
or cell-derived syntenin-1, we demonstrated that syntenin-1 binding to both ephrinB2 and 
ephrinB2/G peptides increased upon phosphorylation on Tyr at position -3 (figure 3.14). 
Furthermore, by comparing binding to GST-PDZ1,2 tandem and the full length protein we 
established that the NTD and/or CTD of syntenin-1 are able to modulate the interaction with 
both phosphorylated and non-phosphorylated peptides, as previously reported by other studies 
(Latysheva, Muratov et al. 2006; Ivarsson 2012). Additionally, competition from other 
proteins might have caused the lower levels of cell-derived syntenin-1 binding to the 
ephrinB2/G peptide, when compared to the recombinant full-length protein. These results 
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were further confirmed by label-free interaction analysis, using the same peptides and full-
length recombinant syntenin-1; and NMR analysis, using recombinant syntenin-1 PDZ1,2 
monomer and 8-aminoacid-long C-terminal peptides of ephrinB2 and ephrinB2/G 
phosphorylated and non-phosphorylated on Tyr at position -3. Label-free interaction analysis 
also proved that binding of syntenin-1 to ephrinB2 and ephrinB2/G peptides are enhanced 
upon phosphorylation (figure 3.15), while NMR analysis revealed that the phospho group at 
the -3 position causes a tightening of the interaction between the ephrinB2 PDZ binding motif 
and the PDZ2 domain of syntenin-1 (figure 3.16). Intriguingly, the phosphorylated ephrinB2 
peptide was also able to engage amino acids within the PDZ1 domain of the syntenin-1 
PDZ1,2 molecule, suggesting that interaction of syntenin-1 with phosphorylated ephrinB2 
involves engagement of both PDZ domains simultaneously. These findings seem to support 
recent reports which suggest that phosphorylation of Tyr/Thr/Ser residues within the PDZ 
binding motif of certain proteins is able to modulate PDZ interaction by inducing a switch in 
preferential binding from one PDZ domain to another (Akiva, Friedlander et al. 2012; 
Ivarsson 2012). For example, phosphorylation on Ser1542 at position -3 of the Multidrug 
Resistence Protein (MRP) 2 strongly enhances PDZ-mediated binding to the Intestinal and 
Kidney Enriched PDZ Protein (IKEPP) and to the ERM (Ezrin/Radixin/Moesin) Binding 
Phosphoprotein (EBP) 50 in epithelial cells (Hegedus, Sessler et al. 2003). However, rather 
than a switch in preferential binding, our results suggest that ephrinB2 phosphorylation on 
Tyr330 enhances binding to the PDZ2 domain of syntenin-1 and additionally engages the 
PDZ1 domain, thus strengthening the interaction between the two proteins.  
The different results obtained by (Lin, Gish et al. 1999), which showed that 
phosphorylation of Tyr at the -3 position of ephrinB1 does not affect PDZ-mediated binding 
to syntenin-1, might be explained by the different experimental settings used. In their study, 
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Lin and colleagues used fluorescence polarization analysis to measure binding of recombinant 
GST-syntenin-1 to fluorescein-labelled probes containing the phosphorylated or non-
phosphorylated 6 C-terminal amino acids of ephrinB ligands. In our study we used 14 amino 
acids long peptides to measure binding of full length recombinant syntenin-1 by label-free 
interaction analysis, which is less likely to disturb protein interactions to short peptides. 
Moreover, our NMR analysis was conducted with non-tagged 8 amino acids long peptides 
and non-tagged recombinant syntenin-1 PDZ1,2 molecule. Therefore, it is possible that the 
more “invasive” experimental settings used in the study by Lin and colleagues were 
responsible for the discrepancy between their data and ours. 
Our findings that Tyr330 phosphorylation is able to modulate PDZ-mediated 
interactions prompted us to investigate whether binding of other PDZ domain-containing 
partners of ephrinB2 may be affected by this modification. Hence, we used phosphorylated 
and non-phosphorylated ephrinB2 and ephrinB2/G peptides to pull down PAR3 and PTPL1 
(figure 3.17). Intriguingly, we discovered that phosphorylation of Tyr at the -3 position of the 
ephrinB2 peptide strongly increased PAR3 binding. On the other hand, PTPL1 binding 
remained unaffected from phosphorylation, thus confirming the data from (Lin, Gish et al. 
1999). Moreover, no binding of either PTPL1 or PAR3 to the phosphorylated ephrinB2/G 
peptide was detected. Increased binding of PAR3 to phosphorylated ephrinB2 (after EphB4-
induced ligand phosphorylation) may explain the effects of ephrinB2 over-expression in 
MCF7 3D cultures (see section 3.1.2.3). Furthermore, these results identify PAR3 as a strong 
competitor of syntenin-1 in binding to phosphorylated ephrinB2. As previous studies have 
reported that PAR3 and the PAR3-PAR6-aPKC complex are involved in clathrin-independent 
recycling and clathrin-dependent endocytosis (Balklava, Pant et al. 2007; Nishimura and 
Kaibuchi 2007), it is possible that an equilibrium between binding of syntenin-1, PAR3 and 
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PTPL1 to phosphorylated ephrinB2 modulates the dynamics of reverse signalling termination 
induced by ligand de-phosphorylation or internalization. However, further study on the 
different affinity levels of the PDZ domains of these proteins for phosphorylated ephrinB2 
would be necessary to determine a hierarchy of interaction. 
To summarize, we have discovered that phosphorylation of Tyr330 on ephrinB2 
enhances PDZ-mediated binding of syntenin-1. The same phosphorylation also greatly 
increased ephrinB2 binding to PAR3, while not affecting PTPL1 binding. Taken together, 
these data suggest that both syntenin-1 and PAR3 preferentially interact with phosphorylated 
ephrinB2 and might be directly involved in modulating ligand reverse signalling and 
processing following EphB4-induced phosphorylation.  
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3.4 EphrinB2 – syntenin-1 interaction may play a 
role in cell-cell boundary formation 
 
One of the main physiological roles of ephrinB ligands and EphB receptors is the 
formation of spatial boundaries between different tissues. The gap-closure assay allowed us to 
analyse how ephrinB2 may contribute to collective cell migration and assess the role of the 
protein in responses of ephrinB2-expressing cells upon contact with EphB4-expressing cells. 
In this assay, cells were plated in two small adjacent wells of a silicon chamber glued to the 
glass bottom of a 35 mm dish. Once the cells had grown to confluency, the chamber was 
removed, allowing the cells to grow and migrate towards one another and eventually meet. 
This technique allowed us to analyse the gross migration speed and boundary formation 
characteristics of two different cell lines. To this end, we plated MCF7 TetOn cells on one 
side of the dual-well chamber and T47D cells on the other (see section 2.3.5 of materials and 
methods). We chose T47D cells as they express high levels of EphB4 and do not express any 
ephrinB ligands.  
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3.4.1.1 Gap-closure assay control experiment using MCF7 tetracycline 
  inducible cells 
 
Before performing the gap closure assay with T47D cells, we carried out a control 
experiment in which we plated the same MCF7 tetracycline inducible cells in both sides of the 
dual-well silicon chamber. We will refer to this type of experiment as homologous gap-
closure assay. The next day, cells were stimulated with doxycycline to induce ephrinB2, 
ephrinB2/G or ephrinB2/ΔV expression and 24 hours later the silicon chamber was removed 
in order to allow cells to close the gap. By observing gap-closure for all four cell lines in 
parallel, we assessed whether the mere expression of ephrinB2, ephrinB2/G or ephrinB2/ΔV 
altered cell migration. Figure 3.18 illustrates the closure of the gap after 1, 3 and 5 days from 
removing the silicon chamber. The migration for all cell lines was relatively slow. By day 3, 
all cell lines presented minimal distance between the opposing cell populations, while at day 5 
the gap was entirely closed. As expected, we could not observe any distinct boundary between 
the opposing cell populations, which merged together in a homogenous manner. These results 
suggested that the expression of ephrinB2, ephrinB2/G or ephrinB2/ΔV did not affect motility 
of MCF7 TetOn cells. 
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Figure 3.18: ephrinB2, ephrinB2/G or ephrinB2/ΔV expression in tetracycline inducible MCF7 cells does 
not affect cell motility or induce the formation of boundaries between contacting MCF7 cells. 
Gap-closure assay control experiments with MCF7 tetracycline inducible cell lines. The same MCF7 tetracycline 
inducible cells were plated in both left and right chambers of the gap closure assay 35 mm glass-bottom dish for 
all four cell lines including MCF7 TetOn parental, MCF7 Tet-ephrinB2, MCF7 Tet-ephrinB2/G and MCF7 Tet-
ephrinB2/ΔV cells. The next day, all cells were stimulated with 1 µg/ml doxycycline and 24 hours later, when 
cells reached confluency, the silicon chamber was removed. Cells were photographed after 1, 3 and 5 days from 
the removal of the chamber.  
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3.4.1.2 Gap-closure assay using MCF7 tetracycline inducible cells and 
T47D cells 
 
In heterologous gap-closure assays, we plated MCF7 tetracycline inducible cells in one 
well of the silicon chamber and T47D cells in the other and treated cells with doxycycline as 
explained in the previous section. Figure 3.19A shows photographs at 1, 4 and 8 days after 
removing the silicon chamber. Similarly to the control experiment, we did not detect 
considerable differences in migration speed, although the gap was not entirely closed even 
after 4 days. This effect may be caused by the lower migratory speed of T47D cells compared 
to MCF7 cells. Upon contact between the two cell populations, a clearly defined and 
relatively straight boundary was observed in all conditions apart for MCF7 Tet-ephrinB2/ΔV 
cells. In this case, even after 8 days from removing the silicon chamber, we could not detect 
the formation of a “boundary line” between MCF7 Tet-ephrinB2/ΔV cells and T47D cells. To 
examine this phenomenon in more detail, we generated MCF7 tetracycline inducible cells 
expressing the red fluorescent protein (RFP) and T47D cells expressing the freen fluorescent 
protein (GFP). This allowed us to distinguish the populations of MCF7 and T47D cells in 
heterologous gap closure assays and analyse their behaviour upon contacts made between the 
two opposing cell monolayers. Specifically, we examined the areas of contacts between T47D 
and MCF7 cell sheets 8 days after the onset of the gap-closure experiment. The photographs 
shown in figure 3.19B confirm that MCF7 TetOn, MCF7 Tet-ephrinB2 and MCF7 Tet-
ephrinB2/G cells form a clearly defined boundary with T47D cells and no cell penetration 
was detected from either side. By contrast, MCF7 Tet-ephrinB2/ΔV cells did not form a 
uniform “boundary line” with T47D cells, as invaginations within the sheet of GFP 
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expressing cells was observed. However, there was no clear indication of single-cell 
penetration of one cell line in the epithelial sheet of the other. 
Taken together, these results suggest that the interaction between ephrinB2 and 
syntenin-1 may be important for correct boundary formation between ephrinB2 and EphB4 
expressing cells. Indeed, MCF7 cells expressing ephrinB2/G, which retains syntenin-1 
binding, were able to form a boundary with T47D cells, while ephrinB2/ΔV expressing cells 
were not. However, as we have previously mentioned in section 3.1.3.1, it is also possible that 
yet undiscovered PDZ partners of ephrinB2 might be able to retain binding to ephrinB2/G and 
thus play a role in this context. It is also unclear how MCF7 TetOn cells were able to form a 
boundary with T47D cells in the absence of ephrinB2 – EphB4 interaction. Possibly, the 
expression of ephrinB2/ΔV displays a “dominant-negative” activity on boundary formation 
with EphB expressing cells. Furthermore, the mechanism by which ephrinB2 – syntenin-1 
interaction drives boundary formation between ephrinB2 and EphB4 expressing cells remains 
unknown. 
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A) 
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B) 
 
 
Figure 3.19: tetracycline inducible MCF7 cells form a clear boundary with contacting T47D cells both in 
the absence and presence of ephrinB2 or ephrinB2/G, while ephrinB2/ΔV-expressing MCF7 cells are 
unable to form a boundary with T47D cells. 
Gap-closure assay with MCF7 tetracycline inducible cell lines and T47D cells. A) MCF7 tetracycline inducible 
cells were plated in the left chamber of the gap-closure assay 35 mm glass-bottom dish, while T47D cells were 
plated in the right chamber. The next day all cells were stimulated with 1 µg/ml doxycycline and 24 hours later, 
when cells reached confluency, the silicon chamber was removed. Cells were photographed at an inverted light 
microscope at 10x magnification after 1, 4 and 8 days from the removal of the chamber. B) The same experiment 
was conducted with MCF7 tetracycline cell lines expressing the Red Fluorescent Protein (RFP) and T47D cells 
expressing the Green Fluorescent Protein (GFP). At 8 days after the removal of the chamber, cells were 
photographed under an inverted fluorescence microscope at 10x magnification.  
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3.4.2  Discussion 
 
The homologous gap-closure assays were conducted to observe the effect of ephrinB2 
expression on migration of MCF7 TetOn cells in 2D cultures and to determine whether PDZ-
mediated interactions were involved (figure 3.18). We did not observe any differences in the 
speed at which MCF7 tetracycline inducible cell lines closed the gap and thus concluded that 
ephrinB2 expression does not promote cell migration in this experimental setting. Eph/ephrin 
signalling promotes cell motility and migration in physiological and pathological conditions 
by inducing activation of the Rho family of GTPases (Poliakov, Cotrina et al. 2004; Pasquale 
2008; Klein 2012). In the case of ephrinB reverse signalling, STAT3 activation has also been 
found to induce cell migration (Bong, Lee et al. 2007). Although the main body of evidence 
suggests that Eph – ephrin interaction is required to induce migration, some studies have also 
found that ephrinB ligands can promote cell motility independently from EphB stimuli 
(Bochenek, Dickinson et al. 2010). In this study, Bochenek and colleagues demonstrated that 
ephrinB2 over-expression induced repeated cycles of cell contraction and spreading in the 
absence of EphB stimulation in HUVEC cells, but not in NIH3T3 or MDCK cells. 
Interestingly, they also found that PDZ-RGS3 binding to ephrinB2 is required for this 
process, confirming a previous report by (Makinen, Adams et al. 2005) which suggested that 
PDZ-RGS3 is involved in modulating ephrinB2-driven cell migration during remodelling of 
lymphatic vessels. Therefore, it is possible that we were unable to detect ephrinB2-driven 
increase in migration of MCF7 TetOn cells due to the missing ephrinB2 – PDZ-RGS3 
interaction, which we did not detect in our experimental settings. Moreover, in the previously 
mentioned studies, ephrinB2 over-expression induced random cell migration of individual 
cells, which might not be detectable by gap-closure assay. Additionally, it is possible that 
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MCF7 TetOn cells endogenously express EphA and/or ephrinA proteins, which are also 
known to induce cell migration (Poliakov, Cotrina et al. 2004). Indeed, a study by (Fox and 
Kandpal 2004) has found high mRNA levels of various EphA and ephrinA proteins in MCF7 
cells, thus suggesting that EphA/ephrinA signalling might also be involved in MCF7 TetOn 
migration. 
 
One of the main functions of Eph/ephrin signalling involves the formation and 
maintenance of spatial boundaries between different tissues and cell types. In the breast, 
Eph/ephrin signalling maintains cell borders between EphB4 expressing myoepithelial cells, 
which surround ducts and alveoli, and the neighbouring ephrinB2 expressing epithelial 
luminal cells. During cancer development, epithelial luminal cells gradually gain EphB4 
expression while losing ephrinB2 expression. This switch precedes tumour cell migration and 
metastasis by allowing cells to escape spatial boundary constrictions (Nikolova, Djonov et al. 
1998). By using gap-closure assays, we aimed to observe the behaviour of ephrinB2 
expressing cells when contacting EphB4 expressing cells (heterologous gap-closure assay) 
and analyze the effects of disrupting the ephrinB2 – syntenin-1 axis within this setting. We 
found that MCF7 TetOn, MCF7 Tet-ephrinB2 and MCF7 Tet-ephrinB2/G cells formed a 
clear and defined boundary upon contact with T47D cells (which express high endogenous 
levels of EphB4), while MCF7 Tet-ephrinB2/∆V cells did not (figure 3.19A). Analysis of the 
area of contact between RFP expressing MCF7 cell lines and GFP expressing T47D cells in 
heterologous gap-closure assays confirmed these results (figure 3.19B). Additionally, we 
noticed that MCF7 Tet-ephrinB2/∆V cells were able to form invaginations within the T47D 
monolayer, thus displaying a lack of spatial boundary constrictions. However, we could not 
detect infiltrating cells from either cell line within the opposite monolayer, thus suggesting 
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that ephrinB2-EphB4 signalling did not cause cells to display an invasive phenotype. These 
results suggest that syntenin-1 PDZ-mediated interaction with ephrinB2 may be important for 
boundary formation between ephrinB2 and EphB4 expressing cells. More specifically, the 
inability of ephrinB2/∆V to bind syntenin-1 might produce an effect by which MCF7 cells 
were unable to retract from T47D cells. However, other yet unknown PDZ partners of 
ephrinB2 which might retain binding to ephrinB2/G but not ephrinB2/ΔV, might also be 
involved in this process. The fact that MCF7 TetOn parental cells were also able to form a 
border with contacting T47D cells also suggests that other proteins might be involved in this 
process. If this were the case, then these proteins would probably be affected by ephrinB2-
EphB4 signalling. E-cadherin, for example, is affected by ephrinB/EphB signalling during 
cell adhesion (Cortina, Palomo-Ponce et al. 2007; Solanas, Cortina et al. 2011). In a recent 
study by (Fagotto, Rohani et al. 2013), ephrinB2/EphB4 signalling between the EphB4 
expressing presomitic mesoderm and the ephrinB2 expressing notochord in Xenopus laevis 
embryos disrupted E-cadherin clustering at sites of heterotypic cell contacts, thus inhibiting 
cell adhesion and inducing segregation between the two cell populations. Interestingly, earlier 
studies had reported that EphB3 activation induces E-cadherin-mediated cell adhesion 
between homotypic cell populations (Cortina, Palomo-Ponce et al. 2007). Hence, 
ephrinB/EphB signalling is able to modulate cell adhesion between homotypic cells and 
segregation between heterotypic cells by regulating E-cadherin localization and clustering. 
Considering our gap-closure assay data, it is possible that syntenin-1 interaction with 
ephrinB2 is required during ephrinB2/EphB4 signalling to inhibit E-cadherin clustering at 
sites of heterotypic cell contacts. The lack of cell intermingling between MCF7 Tet-
ephrinB2/∆V and T47D cells suggests that a certain level of cell segregation is maintained, 
albeit in the absence of a proper boundary between the two cell populations. Indeed, recent 
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studies have suggested that EphB forward signalling alone is sufficient to maintain a certain 
level of cell segregation between heterotypic cell populations (Rohani, Canty et al. 2011), 
although previous studies have reported that both ephrinB reverse signalling and EphB 
forward signalling are required during this process (Mellitzer, Xu et al. 1999; Xu, Mellitzer et 
al. 2000). However, to determine whether EphB forward signalling is sufficient to drive cell 
segregation, these early studies used truncated versions of ephrinB ligands lacking the whole 
cytoplasmic domain, which were later found to be unviable as they were not expressed on the 
cell surface (Makinen, Adams et al. 2005). Therefore, syntenin-1 might play an important role 
during cell segregation and border formation induced by ephrinB2/EphB4 signalling.  
The effect of ephrinB2/ΔV over-expression on boundary formation between MCF7 
TetOn and T47D cells might also be explained by a “dominant-negative” effect exerted by the 
mutant. The fact that MCF7 TetOn cells are able to form a boundary in heterologous gap 
closure assays suggests that these cells express other membrane proteins capable of inducing 
boundary formation. EphA and ephrinA proteins, for example, are expressed in MCF7 cells 
(Fox and Kandpal 2004) and have been shown to trigger cell repulsion between contacting 
cells (Astin, Batson et al. 2010). Moreover, the study by (Astin, Batson et al. 2010) describes 
a model in which EphA2 and EphA4 activation by ephrinAs halts migration of PC3 cells at 
homotypic contacts, while ephrinB2/EphB4 signalling increases cell migration at heterotypic 
contacts with fibroblasts. However, the same group had previously found that 
ephrinB2/EphB4 signalling produced cell repulsion (Marston, Dickinson et al. 2003). 
Therefore, concomitant EphA/ephrinA and EphB/ephrinB signalling might produce similar or 
opposite effects at heterotypic contacts. In our heterologous gap closure assays, it is possible 
that EphA/ephrinA signalling might be responsible for boundary formation between MCF7 
TetOn and T47D cells. EphrinB2/EphB4 signalling might also produce the same effect in 
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ephrinB2 and ephrinB2/G expressing cells. However, ephrinB2/ΔV might have exerted a 
“dominant-negative” effect on boundary formation by promoting EphB4 forward signalling in 
T47D cells and being unable to trigger PDZ-dependent reverse signalling. Intriguingly, 
syntenin-1 is likely to play a role in this type of reverse signalling, as the ephrinB2/G mutant 
did not induce this phenotype.  
To conclude, we report that gap-closure assays might prove to be a viable tool for the 
study of ephrinB2/EphB4-induced boundary formation between contacting heterologous cell 
populations. Furthermore, we discovered that the ephrinB2 – sytenin-1 axis might play an 
important role in the process of boundary formation between ephrinB2 and EphB4 expressing 
cells.  
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4 General discussion and future work 
 
The aim of our study was to determine the role of PDZ domain-containing proteins in 
modulating ephrinB2 signalling and trafficking pathways in the context of epithelial breast 
cancer cells, with a specific focus on the scaffolding protein syntenin-1. We also endeavoured 
to determine whether the ephrinB2 – syntenin-1 axis affects breast cancer tumourigenesis. 
Our findings demonstrate, for the first time, that syntenin-1 modulates ephrinB2 
internalization upon ligand stimulation and that this affects reverse signalling. Furthermore, 
we found that EphB4-induced ephrinB2 phosphorylation increases ligand binding to syntenin-
1 and PAR3, a component of the PAR polarity complex. Finally, we report that ephrinB2 
drives MCF7 colony growth in 3D cultures and that syntenin-1 is involved in boundary 
formation between ephrinB2 expressing cells and EphB4 expressing cells. These findings 
describe, for the first time, the role of syntenin-1 in ephrinB2 reverse signalling and the 
functional relevance of the ephrinB2 – syntenin-1 axis in epithelial breast cancer pathways. 
They also warrant further study to uncover the specific molecular mechanisms underlying 
ephrinB2 biological pathways. 
 
Our initial screening of endogenous levels of ephrinB ligands, EphB4 and syntenin-1 in 
a panel of 21 breast cancer cell lines uncovered a wide range of expression patterns (figure 
3.1). As these proteins have been identified as independent prognostic factors in many 
epithelial tumours (Brantley-Sieders 2012; Yang, Hong et al. 2013), further analysis of their 
protein levels in breast cancer might uncover expression patterns which correlate with stage 
and grade of the tumour. Screening for co-expression of ErbB2 (HER-2) together with 
ephrinB ligands, EphB receptors and syntenin-1 might also help to better characterize breast 
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cancer types and behaviours, as ephrinB1, ErbB2 and syntenin-1 have all been implicated in 
driving cell proliferation and/or migration through Src-mediated activation of integrins 
(Meyer, Hafner et al. 2005; Guo, Pylayeva et al. 2006; Hwangbo, Kim et al. 2010). A recent 
study by (Vermeer, Colbert et al. 2013) has also found that ephrinB1 associates with ErbB1 
and ErbB2 through transmembrane domain interactions. These associations induce ephrinB1 
phosphorylation and trigger ERK1/2 activation, thus promoting cell proliferation and survival. 
Furthermore, treatment of HNSCC cells co-expressing ephrinB1 and ErbB2 or ErbB1 with 
monoclonal antibodies Herceptin and Certuzimab, which are used in the treatment of HER-2 
and HER-1 positive cancers, did not inhibit ERK1/2 phosphorylation, thus suggesting that 
blockage of ErbB receptors does not prevent signalling through the ErbB-ephrinB1 complex. 
Therefore, further analysis on the effect of ErbB inhibitors (e.g. Herceptin, Lapatinib, 
Certuzimab) on breast cancer cell lines which co-express ErbB receptors and ephrinB ligands 
might reveal new pathways involved in tumour resistance to anti-HER therapies. 
 
By generating the ephrinB2/G and ephrinB2/ΔV mutants and using them to establish 
tetracycline inducible MCF7 cell lines, we developed a new and innovative model system in 
which to study the effects of disrupting the ephrinB2 – syntenin-1 axis. Our data on ephrinB2 
phosphorylation dynamics revealed that mutations in the PDZ binding motif impair receptor-
induced ligand phosphorylation (figure 3.10). This novel finding denotes the existence of a 
direct link between SH2 and PDZ mediated reverse signalling. As we were unable to detect 
any interaction between ephrinB2 and PICK1 or Dishevelled-2 via pull down assay; and 
between ephrinB2 and PDZ-RGS3 via co-immunoprecipitation; and given that PTPL1 is 
involved in ligand de-phosphorylation (Palmer, Zimmer et al. 2002), we suggest that GRIP1, 
GRIP2 or PAR3 might be required for receptor-induced ligand phosphorylation. Further 
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studies using knock down approaches or PDZ-binding mutants in the context of EphB-
induced ligand phosphorylation might help identify the PDZ domain-containing protein/s 
involved in receptor-induced phosphorylation of ephrinB ligands. These findings would 
reveal new connections between SH2- and PDZ-mediated reverse signalling which would 
have major implications in the field of EphB/ephrinB biology. Alternatively, other proteins 
capable of PDZ-dependent or -independent binding to the cytoplasmic tail of ephrinB ligands 
might also be involved in EphB-driven ligand phosphorylation.  In this respect, the use of 
mass spectrometry to identify new proteins which are co-immunoprecipitated by ephrinB 
ligands subjected to increasing intervals of EphB receptors stimulation would prove useful.  
Although syntenin-1 is not involved in EphB-induced ligand phosphorylation, we 
observed that it affects basal phosphorylation of ephrinB2 in non-stimulated conditions 
(3.11). Therefore, syntenin-1 might mediate ligand phosphorylation induced by cross-talk 
with other tyrosine kinase receptors (e.g. FGFR, ErbB2) and/or adhesion molecules (e.g. 
claudin-4). Alternatively, syntenin-1 might mediate ephrinB-induced phosphorylation of other 
cell membrane receptors. In a recent study, syntenin-1 was found to interact with the EGF 
receptor in a PDZ-independent manner and to induce EGFR phosphorylation through Src-
activation (Dasgupta, Menezes et al. 2013). Therefore, syntenin-1 might be able to link 
ephrinB ligands with EGFRs, resulting in receptor phosphorylation by ephrinB-induced Src 
activity. This possibility is supported by various studies which describe the role of syntenin-1 
in forming FAK-Src signalling complexes at sites of focal adhesion (Hwangbo, Kim et al. 
2010; Hwangbo, Park et al. 2011). Furthermore, syntenin-1 might be involved in regulating 
ephrinB2 compartmentalization into specific membrane microdomains, possibly through the 
interaction with tetraspanins CD63 (Latysheva, Muratov et al. 2006) or Tspan6 (unpublished). 
In this respect, tetraspanins are known to selectively recruit signalling molecules (e.g. β1-
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integrins, PKC, PI4K) in specific Tetraspanin Enriched Microdomains (TERMs), placing 
them in close proximity with other cell membrane receptors (e.g. FGFR, EGFR, ErbB2) 
(Yunta and Lazo 2003; Hemler 2005; Lazo 2007; Zoller 2009). Indeed, ephrinB1 association 
with ErbB receptors 1 and 2 (Vermeer, Colbert et al. 2013) would benefit from ephrinB 
recruitment to TERMs. Further study might reveal whether ephrinB reverse signalling can be 
modulated by syntenin-1-mediated compartmentalization in TERMs. Co-localization 
experiments in the context of disrupted ephrinB – syntenin-1 interaction might provide novel 
insight on the role of syntenin-1 in driving the formation of ephrinB signalling complexes in 
specific membrane microdomains.  
 
In this study we have proven that phosphorylation of Tyr330 in ephrinB2 increases 
PDZ-mediated binding of syntenin-1 and PAR3. Our data supports recent reports suggesting 
that phosphorylation of Tyr/Thr/Ser within the PDZ binding motif can either increase or 
decrease binding to various PDZ domain-containing proteins (Akiva, Friedlander et al. 2012; 
Ivarsson 2012). More importantly, these findings strongly suggest that EphB-induced 
phosphorylation of ephrinB ligands modulates PDZ mediated signalling by affecting the 
binding properties of certain PDZ domain-containing proteins, such as syntenin-1 and PAR3. 
However, further study is warranted to establish how phosphorylation-induced binding of 
these proteins affects ephrinB reverse signalling. In this respect, it would be useful to 
determine the hierarchy of binding affinity between phosphorylated and non-phosphorylated 
ephrinB ligands and their PDZ domain-containing partners. Label-free interaction analysis 
and similar methods might prove useful in reaching this purpose. Additionally, quantitative 
phospho-proteomics analysis by SILAC mass spectrometry would allow us to better 
understand which sites of ephrinB ligands are phosphorylated and to what extent, in response 
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to different stimulating partners (e.g. EphB, FGF, ErbB and VEGF receptors). Such studies 
would shed light on which ephrinB reverse signalling pathways are triggered in response to 
specific stimulating or PDZ-interacting proteins.  
Previous studies have reported that ephrinB ligands recruit GRIP proteins to lipid rafts 
via PDZ-mediated interactions (Bruckner, Pablo Labrador et al. 1999). Furthermore, EphB2-
induced phosphorylation of ephrinB2 on Ser325 enhances binding of GRIP1 and GRIP2 
(Essmann, Martinez et al. 2008). Intriguingly, a recent study has found that EphB-induced 
phosphorylation of ephrinB1 causes ligand relocation to lipid rafts in a manner specifically 
dependent on phospho-Tyr (Xu, Sun et al. 2011). Therefore, we can speculate that PDZ 
domain-containing proteins which show increased binding to phosphorylated ephrinB ligands 
(ie syntenin-1, PAR3, GRIP1, GRIP2) might be recruited to specific lipid rafts or membrane 
microdomains (e.g. TERMs through binding with syntenin-1) upon EphB stimulation. Further 
study aimed at proving the veracity of this proposed recruitment mechanism might uncover 
new characteristics of ephrinB reverse signalling. Specifically, it might shed light on ephrinB 
signalling at sites of focal adhesions (Kullander and Klein 2002; Segura, Essmann et al. 
2007), tight junctions (Tanaka, Kamata et al. 2005; Lee, Nishanian et al. 2008) and synapses 
formation (McClelland, Sheffler-Collins et al. 2009; Xu, Sun et al. 2011). 
 
In our study, we found that syntenin-1 seems to prevent ephrinB2 internalization 
preferentially upon EphB4/Fc stimulation (figure 3.13). The increase in syntenin-1 binding to 
phosphorylated ephrinB2 further supports these data. Our findings fit well with previous 
reports on the role of syntenin-1 in preventing Delta1 internalization from the cell surface 
(Estrach, Legg et al. 2007) and impairing CD63 endocytosis (Latysheva, Muratov et al. 2006). 
More specifically, Latysheva and colleagues suggested that syntenin-1 induces a switch in 
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CD63 endocytosis from the fast clathrin-dependent pathway to a slower non-canonical 
pathway. This mechanism might also apply to ephrinB ligands internalization upon EphB-
induced phosphorylation. 
Complete disruption of the PDZ binding motif also impairs internalization, thus 
supporting the existence of a yet unidentified protein capable of inducing ephrinB2 
internalization in the absence of PDZ-mediated interactions. In this study we have discussed 
the possibility that AP2, PAR6, and Grb4 might be involved in ephrinB2 internalization by 
binding to the cytoplasmic tail of the ligand in a PDZ-independent manner. Furthermore, our 
results on PAR3 binding to ephrinB proteins phosphorylated on Tyr330, together with the 
recent study implicating PAR3 in ephrinB2-induced internalization of VEGFR2 and VEGFR3 
(Nakayama, Nakayama et al. 2013), strongly suggest that PAR3 might induce ephrinB 
internalization upon EphB-induced ligand phosphorylation. Therefore, ephrinB internalization 
might involve more endocytic pathways than was previously thought (Marston, Dickinson et 
al. 2003; Zimmer, Palmer et al. 2003; Parker, Roberts et al. 2004; Groeger and Nobes 2007). 
Importantly, we also suggest that certain internalization pathways (e.g. involving syntenin-1, 
PAR3 and Grb4) might be triggered preferentially upon EphB-induced phosphorylation of 
ephrinB ligands. Further research on ephrinB internalization mechanisms might uncover 
specific roles for individual endocytosis pathways which might induce different effects in 
ephrinB reverse signalling. Importantly, future studies should focus on determining ephrinB 
endocytosis in the context of cell-cell contact between ephrinB and EphB expressing cells, as 
previous studies have shown that both EphB forward and ephrinB reverse signalling pathways 
are involved in this process (Marston, Dickinson et al. 2003; Zimmer, Palmer et al. 2003).  
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Our data on 3D cultures suggests that low expression levels of ephrinB2 in MCF7 cells 
are sufficient to drive colony growth in 3D Matrigel in a manner which seems independent of 
reverse signalling (figure 3.8). Intriguingly, we also found that ephrinB2 expression does not 
affect MCF7 colony growth in 3D collagen I (figure 3.4). Therefore, we have speculated on 
the possibility that ephrinB2-driven colony growth might require the presence of biological 
components found in Matrigel and not in collagen (e.g. laminin-1, growth factors). An 
interesting possibility which warrants further study is the potential role of ephrinB2 in 
modulating α6β4-integrin activity upon interaction with laminin-1 through Src activation. In 
this respect, a similar regulatory mechanism has already been reported for ErbB2 (Guo, 
Pylayeva et al. 2006). As ephrinB ligands have already been implicated in β1-integrin activity 
(Meyer, Hafner et al. 2005; Julich, Mould et al. 2009), it is possible that ephrinB proteins 
might also associate with β4-integrins and modulate laminin-1-driven cell migration. 
In culturing cells in 3D Matrigel, we also found that MCF7 TetOn cells form much 
smaller colonies than MCF7 cells used to generate the stable MCF7-ephrinB2 cell line. 
Moreover, ephrinB2 expression in tetracycline inducible cells did not alter colony 
morphology as seen in MCF7-ephrinB2 colonies. Although we did not investigate this effect 
any further, we speculated on the possibility that MCF7 TetOn cells develop smaller colonies 
in 3D cultures because they express lower levels of integrins. Intriguingly, both syntenin-1 
and ephrinB ligands induce cell migration through association with β1-integrins (Meyer, 
Hafner et al. 2005; Hwangbo, Kim et al. 2010; Pasquale 2010; Yang, Hong et al. 2013) and 
induce Src and FAK activation (Cowan and Henkemeyer 2001; Segura, Essmann et al. 2007; 
Sarkar, Boukerche et al. 2008; Hwangbo, Kim et al. 2010). Therefore, further study might 
reveal a link between syntenin-1 and ephrinB pathways in modulating Src and FAK activation 
in the context of β1-integrin activity at sites of focal adhesion. 
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Another interesting characteristic of MCF7-ephrinB2 colonies grown in 3D Matrigel is 
the presence of a wide internal lumen (figure 3.4E), which is not found in typical MCF7 
colonies (Kirshner, Chen et al. 2003; Krause, Maffini et al. 2010; Wang, Lacoche et al. 2013). 
Therefore, we discussed the possibility that ephrinB2 expression might restore a certain level 
of cell polarity in 3D Matrigel-grown MCF7 colonies through the interaction with PAR3. Our 
pull down data on PAR3 binding to phosphorylated ephrinB ligands and recent studies on the 
role of ephrinB2 in maintaining cell polarity (Kaenel, Antonijevic et al. 2012), suggest that 
ephrinB2 might be involved in maintaining epithelial cell polarity by recruiting PAR3 at sites 
of ephrinB2 – EphB4 interaction. Furthermore, given the role of ErbB2 in disrupting cell 
polarization by associating with PAR6 (Aranda, Haire et al. 2006) and the ability of ephrinB1 
to interact with ErbB2 (Vermeer, Colbert et al. 2013), it is possible that ephrinB ligands and 
ErbB receptors are tightly involved in modulating cell polarity through the PAR polarity 
complex. Further study using knock down and interaction-deficient mutants in 3D Matrigel 
cell cultures might prove useful in understanding the role of ephrinB ligands in maintaining 
cell polarity.  
 
In our heterologous gap closure assays with ephrinB2 and EphB4 expressing cells we 
found that syntenin-1 interaction with ephrinB2 might be required for boundary formation 
between the two cell populations (figure 3.19). In this respect, various studies have found that 
ephrinB2/EphB4 signalling drives boundary formation at heterotypic contacts by modulating 
E-cadherin clustering (Fagotto, Rohani et al. 2013) or extracellular cleavage (Solanas, Cortina 
et al. 2011). Therefore, we have speculated on the possibility that the ephrinB2 – syntenin-1 
axis might be responsible for inhibiting E-cadherin clustering on the cell membrane or for 
ADAM10-mediated cleavage of E-cadherin. Future work involving the use of MMP 
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inhibitors and immunofluorescence following gap-closure experiments in the context of 
disrupted ephrinB2 – syntenin-1 axis, might determine the veracity of this assumption and the 
molecular mechanisms involved. Alternatively, we have speculated on the possibility that 
ephrinA ligands and EphA receptors might be responsible for boundary formation between 
MCF7 TetOn and T47D cells, as the MCF7 cell line has been found to produce high mRNA 
levels of ephrinA and EphA proteins (Fox and Kandpal 2004). Hence, we have suggested that 
ephrinB2/EphB4 signalling might be inducing a similar effect to that of ephrinA/EphA 
signalling in boundary formation at heterotypic contacts. Moreover, ephrinB2/ΔV expression 
might be disrupting boundary formation through a “dominant-negative” effect by activating 
EphB forward signalling in T47D cells and at the same time being unable to induce syntenin-
1-mediated reverse signalling in MCF7 TetOn cells. However, further study is needed to 
assess the validity of this hypothesis. The use of selective knock down of ephrin and Eph 
proteins in the context of boundary formation might reveal specific roles for ephrinA/EphA 
and ephrinB/EphB signalling, as has been suggested in the study by (Astin, Batson et al. 
2010). Additionally, PDZ binding mutants (such as the ephrinB2/G and ephrinB2/ΔV mutants 
used in our study) and the use of EphB forward signalling inhibitors might shed light on the 
role of syntenin-1-driven reverse signalling in boundary formation. 
To conclude, our study has provided insight into the role of syntenin-1 in modulating 
ephrinB2 reverse signalling and trafficking. Furthermore, we have discovered new properties 
of syntenin-1 and PAR3 binding to ephrinB ligands that point to the existence of unreported 
links between EphB-induced ligand phosphorylation and PDZ-mediated reverse signalling. 
Our data also supports the existence of alternative trafficking pathways involved in ephrinB 
internalization that might be diversely triggered depending on the ligand’s phosphorylation 
status, as summarised in figure 3.20. Lastly, we have proven that Matrigel 3D cultures and 
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gap closure assays are viable tools to study the role of ephrinB2 in breast cancer progression, 
opening the possibility of further research on the role of ephrinB ligands in cancer 
progression. 
 
 
Figure 3.20: proposed role of syntenin-1 in EphB4-induced ephrinB2 internalization. 
Upon interaction with the EphB4 receptor, the C-terminal tail of the ephrinB2 ligand is cleaved by the γ-
secretase/PS1 complex to release a C-terminal fragment (CTF) (1). The CTF mediates CSK inactivation, which 
in turn leads to Src activation (2). Activated Src directly phosphorylates ephrinB2 ligands, which have not made 
contact with EphB4, on tyrosines 311,316 and 330. Phosphate groups are later removed by PTPL1, which binds 
to ephrinB2 via PDZ-mediated interaction (3). In this study, we hypothesize that PTPL1, syntenin-1 and a yet 
unidentified protein compete for the PDZ binding motif (or the C-terminus region) of phosphorylated ephrinB2 
(4). Our model suggests that de-phosphorylation of ephrinB2 by PTPL1 is hindered by syntenin-1 binding to the 
ligand, which is increased upon phosphorylation of Tyr330. Prolonged ephrinB2 phosphorylation would 
ultimately cause ligand internalization via the interaction with a yet unidentified protein in order to terminate 
phospho-dependent reverse signalling. 
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Appendix 
 
 
5.1  Appendix 1: cell culture medium and supplements 
 
MCF7:  DMEM 
  10% heat inactivated FCS 
  50 U/ml Penicillin / 50 μg/ml Streptomycin 
  ± 1 µg/ml Puromycin 
 
MCF7 TetOn: DMEM 
  10% heat inactivated FCS (tetracycline free) 
  50 U/ml Penicillin / 50 μg/ml Streptomycin 
  100 µg/ml Geneticin 
  ± 100 µg/ml Zeocin 
  ± 1 µg/ml Puromycin 
 
HEK293T: DMEM 
  10% heat inactivated FCS 
  50 U/ml Penicillin / 50 μg/ml Streptomycin 
 
T47D:  RPMI 1640 
  10% heat inactivated FCS 
  50 U/ml Penicillin / 50 μg/ml Streptomycin 
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5.2  Appendix 2: list of primers, shRNA and peptide sequences 
 
 
Primers: 
Name Sequence (5’ to 3’) 
EphrinB2/PstI (forward) 
5’ – GTGAGCCTGCAGTCATGGCTGTGAGAA 
GGGACTCC – 3’ 
EphrinB2/SalI (reverse) 
5’ – GTGAGCGTCGACTCTCAGACCTTGTAGTA 
AATGTTCG – 3’ 
pBI MCS2 (forward) 5’ – GGTTTGTCCAAACTCATCAATG – 3’ 
EphrinB2 internal (forward) 5’ – TCTTGGTCTGGTTTGGCACAG – 3’ 
EphrinB2/∆V mutagenesis (forward) 
5’– GCGAACATTTACTACAAGTAGTGAGAGTCGACC 
TAGTCTAG – 3’ 
EphrinB2/∆V mutagenesis (reverse) 
5’– CTAGACTAGGTCGACTCTCACTACTTGTAGTAA 
ATGTTCGC – 3’ 
EphrinB2/G mutagenesis (forward) 
5’– GCGAACATTTACTACAAGGGCTGAGAGTCGACC 
TAGTCTAG – 3’ 
EphrinB2/G mutagenesis (reverse) 
5’ – CTAGACTAGGTCGACTCTCAGCCCTTGTAGTAA 
ATGTTCGC – 3’ 
 
 
 
ShRNA sequences targeting syntenin-1 (purchased by Sigma): 
Name Product number Sequence (5’ to 3’) 
shRNA (1) TRC0000029158 
5’ – CCGGCGGAACATAACATCTGTGAAACTCGAGTTTCA 
CAGATGTTATGTTCCGTTTTT – 3’ 
shRNA (2) TRC0000029157 
5’ – CCGGGTACTTCAGATCAATGGTGAACTCGAGTTCACC 
ATTGATCTGAAGTACTTTTT – 3’ 
shRNA (3) TRC0000029156 
5’ – CCGGGCAGAAATTAAGCAAGGGATTCTCGAGAATCC 
CTTGCTTAATTTCTGCTTTTT – 3’ 
shRNA (4) TRC0000029154 
5’ – CCGGCCTATCCCTCACGATGGAAATCTCGAGATTTCC 
ATCGTGAGGGATAGGTTTTT – 3’ 
shRNA (5) TRC0000029155 
5’ – CCGGGAGAAGATTACCATGACCATTCTCGAGAATGG 
TCATGGTAATCTTCTCTTTTT – 3’ 
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Peptides: 
Name Sequence (N-terminus to C-terminus) 
EphrinB2  biotin – EMPPQSPANIYYKV 
EphrinB2/G  biotin – EMPPQSPANIYYKG 
EphrinB2/∆V  biotin – EMPPQSPANIYYK 
Phospho-ephrinB2 (pTyr330)  biotin – EMPPQSPANI(pY)YKV 
Phospho-ephrinB2/G (pTyr330)  biotin – EMPPQSPANI(pY)YKG 
NET5  biotin – FQHIHRTGKKYDA 
EphrinB2 (NMR)  KANIYYKV 
EphrinB2/G (NMR)  KANIYYKG 
Phospho-ephrinB2 (pTyr330) (NMR)  KANI(pY)YKV 
Phospho-ephrinB2/G (pTyr330) (NMR)  KANI(pY)YKG 
 
 
 
5.3  Appendix 3: solutions and WB gel recipes 
 
1% TritonX-100 buffer (pH 7.4): 50 mM Tris-HCl  
     150 mM NaCl  
     1% TritonX-100 (v/v) 
 
1% TritonX-100 lysis buffer:  1% TritonX-100 buffer (pH 7.4) 
     10 mM tetrasodium pyrophosphate (Na2P2O7) 
     100 µM sodium orthovanadate  
     5 mM sodium fluoride (NaF) 
     2 mM phenylmethylsulfonyl fluoride (PMSF) 
     20 µg/ml Aprotinin  
     20 µg/ml Leupeptin 
 
1x Laemmli buffer:   1.5% sodium dodecyl sulfate (v/v)  
     8% glycerol (v/v) 
     250 mM Tris-HCl 
     small amount of Bromophenol Blue 
 
4x Laemmli buffer:   6% sodium dodecyl sulfate (v/v)  
     32% glycerol (v/v) 
     1 M Tris-HCl 
     small amount of Bromophenol Blue 
 
1x TBS:    10 mM Tris-HCl 
     150 mM NaCl 
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2-3% PFA/PBS:   2-3% paraformaldehyde (w/v) 
     0.5 mM CaCl2  
     1 mM MgCl2  
     100 mM sucrose  
 
Blocking solution/PBS:  20% goat serum 
     0.02% sodium azide (NaN3) (w/v) 
 
Freezing medium:   90% heat inactivated FCS 
     10% DMSO 
 
Laemmli lysis buffer:   1x Laemmli buffer (without Bromophenol Blue) 
     10 mM tetrasodium pyrophosphate (Na2P2O7) 
     100 µM sodium orthovanadate  
     5 mM sodium fluoride (NaF) 
     2 mM phenylmethylsulfonyl fluoride (PMSF) 
     20 µg/ml Aprotinin  
     20 µg/ml Leupeptin 
 
MESNA:    50 mM sodium 2-mercaptoethanesulfonate (ie MESNA)  
     50 mM Tris/HCl  
     100 mM NaCl 
     2.5 mM CaCl2  
 
PBS*:      1 mM MgCl2  
     0.5 mM CaCl2 
 
PBS**:     0.33 mM MgCl2  
     0.9 mM CaCl2 
 
TAE:     40 mM Tris-HCl 
     1 mM EDTA 
     0.12% acetic acid (v/v) 
 
 
Recipes for a single mini SDS-PAGE gel: 
% Gel 
Volumes (µl) 
30% acrylamide 1.5 M Tris-HCl pH 8.8 10% SDS 10% APS TEMED H2O 
8% 1300 1300 50 50 6 2300 
10% 1700 1300 50 50 6 1900 
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5.4  Appendix 4: materials used in this study 
 
Product Supplier Catalogue number 
0.5% (10x) Trypsin-EDTA Invitrogen 15400-054 
1 Kb DNA size marker New England Biolabs P7708L 
35mm µ-Dish culture insert Ibidi 80206 
5-alpha I
q
 competent E. coli cells New England Biolabs C2992H 
10x SDS/Tris/Glycine Geneflow B9-0032 
10x Tris/Glycine Geneflow B9-0056 
2-β-mercaptoethanol Sigma M7522 
Acetic acid Fisher Scientific A/0406/pb08 
Agar Sigma A5054 
Agarose Gibco 16500500 
Amersham Hyperfilm
TM
 MP GE Healthcare 28-9068-46 
Ammonium persulfate Sigma A6761 
Ampicillin Sigma A9518 
Anti-Flag (M2) conjugated agarose beads Sigma A2220 
Aprotinin Sigma M7522 
BD Matrigel BD Biosciences 354230 
Biacore sensor CM5 chip GE Healthcare BR-1003-99 
Bio-Rad Dc protein assay reagent A Bio-Rad Laboratories 500-0113 
Bio-Rad Dc protein assay reagent B Bio-Rad Laboratories 500-0114 
Bio-Rad Dc protein assay reagent S Bio-Rad Laboratories 500-0115 
BioTrace
TM
 pure nitrocellulose blotting membrane VWR International 732-3031 
Bovine serum albumin (BSA) Sigma A4503 
Bromophenol blue Fisher Scientific B/4630/44 
Buffer H (10x) Roche 11417991001 
Calcium chloride (dihydrate) Sigma C5080 
Cell dissociation buffer Invitrogen 13151-014 
CellTrics
® 
disposable filters PARTEC 04-0042327 
Collagen, Type I Sigma C7661 
Dimethyl sulphoxide (DMSO) Sigma D2650 
DNA gel loading dye Qiagen 239901 
dNTP mix New England Biolabs N0446S 
Doxycycline Sigma D9891 
DPN1 New England Biolabs R0176S 
Dulbecco’s Modified Eagle’s Medium (DMEM) Sigma D6429 
EDC/NHS, Ethanolamine kit GE Healthcare BR100050 
EDTA Fisher Chemicals BPE118-500 
Enhanced Chemiluminescence Substrate (ECL Plus) Perkinelmer NEL105 
Ethanol Fisher Scientific E/0650DF/P17 
EZ link NHS-SS-Biotin Thermo Scientific 21331 
Fetal bovine serum (FBS) PAA Laboratories A15-101 
Fetal bovine serum (FBS) (tetracycline free) Clontech 631106 
Fluorescent mounting medium Dako S3023 
FuGene
®
 6 Roche 11814 443001 
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Gel extraction kit Qiagen 28704 
Geneticin Gibco 10131027 
Glycerol Fisher Scientific G/0650/08 
Glycine Sigma G8898 
HBS-EP GE Healthcare BR100188 
High Fidelity TAQ Polymerase Roche 11732641001 
Hoechst 33342 Invitrogen H3570 
Iodoacetamide Sigma I1149 
Lab-TekTM chambered coverglass (8-wells) Nunc 155411 
Leupeptin Sigma L2023 
Lysogeny broth (LB) Gibco 12780-052 
Magnesium chloride Fisher Scientific M/0600/53 
Maxi-prep DNA purification kit Qiagen 12163 
Methanol Sigma 24229 
Mini-prep DNA purification kit Qiagen 27106 
NeutrAvidin
TM
-conjugated agarose beads Thermo Scientific 29201 
Paraformaldehyde powder (PFA) Park Scientific 30525-89-4 
Penicillin/Streptomycin Invitrogen 15070-063 
Pfu polymerase Fermentas EP0501 
Phenylmethanesulfonyl fluoride (PMSF) Sigma P7626 
Polybrene Sigma Al-118 
PageRuler Prestained protein ladder  Fermentas 26617 
ProtoGel
®
 Acrylamide Geneflow EC-890 
PstI endonuclease Roche 10621633001  
Puromycin dihydrochloride Sigma P8833 
rmEphB4/Fc R&D 446-B4 
RPMI-1640 Sigma R8758 
SalI endonuclease Roche 10567663001 
Sodium 2-mercaptoethanesulfonate (MESNA) Sigma M1511 
Sodium azide Fisher Scientific S/2380/48 
Sodium chloride BDH 10241AP 
Sodium dodecyl sulphate BDH 444464T 
Sodium fluoride Sigma S7920 
Sodium hydroxide Sigma S8045 
Sodium orthovanadate Sigma S6508 
Streptavidin Thermo Scientific 21122 
SU6656 Calbiochem 572636 
Sucrose Sigma S0389 
Syber Safe DNA dye Invitrogen S33102 
T4 ligase New England Biolabs M0202L 
Tetramethylethylenediamine (TEMED) Sigma T2,250-0 
Tetrasodium pyrophosphate  Sigma 221368 
Tris(hydroxymethyl)methylamine BDH 271195Y 
Triton X-100 Sigma T9284 
Tween
®
 80 Sigma P1754 
Zeocin Invitrogen P/N 46-0509 
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